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Abstract 
Autoimmunities are extremely difficult to treat and involved in their pathogenesis are pro-
inflammatory immune responses redirected against one’s own tissues. Studies in our lab 
have shown macrophages that are induced to become type II macrophages protect 
against an animal model of MS, experimental autoimmune encephalomyelitis (EAE), with 
protection due to immune deviation. Another way to deviate immune responses away from 
inflammation is by infection with the parasitic helminth Schistosoma mansoni, which also 
protects against EAE. The contribution of type II macrophages in this protection is 
unknown, as are the mechanisms involved in promoting the phenotype induced by type II 
activation. This project investigates key mechanisms involved in type II activation, while 
also elucidating the possible effect of schistosome exposure on the induction of this 
activation state. 
Using a validated model of type II activation in vitro, we compared the effects of 
schistosome immune complexes on various macrophage properties such as cytokine, 
surface marker and enzymatic profiles. This thesis identified that exposure to schistosome 
complexes induces a macrophage state with characteristics of two distinct activation 
states (type II and alternative activation), as well as completely novel characteristics. This 
activation state shows many phenotypic properties associated with immune regulation, 
and may have important consequences for understanding mechanisms involved in 
protection against inflammatory illnesses. 
We also investigated key mechanisms involved in the anti-inflammatory responses 
induced by type II activation. Cytokine, chemokine and surface marker profiles of 
macrophages were assessed in response to type II activation in vitro, with the main 
emphasis on determining the effects of IL-10 and CD40 on the type II activation 
phenotype and function. This investigation found that type II activated macrophages 
depend on low levels of CD40/CD40L signalling to polarise Th2 development, as the 
expression of receptors for Th2-inducing cytokines are significantly impaired in the 
absence of this interaction. This suggests an important role for the low but maintained 
levels of CD40 on type II activated macrophages, in aiding the deviation of immune 
responses, while maintaining Th2 polarization. We also suggest a suppressive role of 
CD40/CD40L in IL-10 production, which is a novel find. 
The requirement of new treatments for MS is escalating as more people are affected each 
year. The impact of MS on the quality of life is severe and long lasting. Having a greater 
understanding of the mechanisms involved in deviating pro-inflammatory or anti-
inflammatory responses will enable the development of much more effective treatments 
and therapies in the future. 
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Chapter 1: Introduction 
1.1 Innate and adaptive immune responses 
Adequate protection against pathogens requires an efficient innate and adaptive immune 
response (Abbas et al., 1996; Bowdish et al., 2007; Janeway et al., 2002). The innate arm 
of the immune response is the first to recognise pathogens, create an initial defense, and 
alert the adaptive arm of the immune response when extra help is required. Cells involved 
in innate immune responses include macrophages (MØ), dendritic cells (DC), mast cells, 
basophils, neutrophils and natural killer (NK) cells (Janeway et al., 2002). Innate immune 
cells express a repertoire of germ-line encoded receptors. Upon recognition of general 
pathogen associated molecular patterns (PAMPs), innate cells elicit rapid responses such 
as the phagocytosis of bacteria, uptake of cellular debris and secretion of reactive oxygen 
species. Innate responses also interact with cells of the adaptive immune system through 
the presentation of antigen and production of cytokines and mediators which influence the 
adaptive responses (Vyas et al., 2008). Unlike the innate system, cells of the adaptive 
immune response elicit more targeted responses against a single antigen to which their 
assembled receptors are specific (Janeway et al., 2002). Cells of the adaptive immune 
system include CD4 T cells, NK.T cells, Regulatory T cells, and B cells. Although the 
responses of the adaptive immune system is slower than that of the innate arm, the cells 
of the adaptive system can elicit memory responses such that upon re-exposure to the 
same antigen, a much faster, more effective and stronger response can occur. The innate 
and adaptive immune systems work together to provide host protection, with each system 
aiding the other for optimal anti-pathogenic responses (Campbell et al., 1996; Stenger et 
al., 1996).   
1.2 Macrophages 
1.2.1 Derivation 
Macrophages are innate immune cells, and are the first line of defense against invading 
pathogens (Dunn et al., 1985). They are derived from haemopoietic cells that develop into 
monocytes, which upon entering tissues from the blood, differentiate into macrophages 
(Brem-Exner et al., 2008; Gordon et al., 2005; Mosser et al., 2008). Macrophages are 
distributed in essentially every tissue such as the lungs, liver, bone, brain, connective 
tissue, intestines and skin. Depending on the tissue environment, they are capable of 
eliciting different physiological functions (Stout et al., 2004) . These functions can include 
host defence, wound repair, or immune regulation (Albina et al., 1990; Anderson et al., 
2002b; MacMicking et al., 1997). Macrophages are extremely heterogeneous and exhibit 
a variety of functions including homeostatic  mechanisms such as the recycling of red 
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blood cells (RBCs) and removal of debris, as well as functions involving the activation of 
immune responses against pathogens (Mosser et al., 2008). Much of their immune 
responses are derived by the recognition of conserved molecular patterns on pathogens, 
which are detected by pathogen recognition receptors (PRRs) such as scavenger 
receptors and toll-like receptors (TLR) (Janssens et al., 2003; Pluddemann et al., 2007). 
There are also receptors such as FcγRs and complement receptors which are involved in 
recognising opsonised particles (Gordon, 2007). Upon recognition of pathogens, 
macrophages can elicit a variety of functions depending on the receptors involved in the 
particular response. Receptors such as FcγRs, scavenger receptors and complement 
receptors can elicit phagocytosis (Aderem et al., 1999). In contrast, TLR signalling alters 
the production of inflammatory mediators involved in immune activation, which in the 
context of antigen presentation, can initiate appropriate T cell responses. These only 
represent some functions of macrophages, and each function often crosses over into the 
other, as seen by the ability of phagocytosis to sometimes induce the production of 
inflammatory mediators or enhance T cell proliferation (Barker et al., 2002; Janeway et al., 
2002). 
1.2.2 Function 
1.2.2.1 Phagocytosis 
Phagocytosis is an ancient function of macrophages (Sanjuan et al., 2007), and involves 
the recognition of pathogen associated molecular patterns (PAMPs) through the 
expression of PRRs (Akira et al., 2004). These PRRs enable macrophages to recognize 
and phagocytose particles or pathogens, and include a wide array of different receptors 
such as scavenger receptors, mannose receptors, Fcγ receptors and complement 
receptors (Aderem et al., 1999; Janeway et al., 2002). In addition to taking up and killing 
pathogens, macrophages also use phagocytosis for homeostatic mechanisms like the 
clearance of erythrocytes and apoptotic or necrotic debris (Barker et al., 2002; Mosser et 
al., 2008). Involved in the degradation of pathogens upon cellular uptake into the 
phagosome, are processes involved in phagosome maturation, phagosome-lysosome 
fusion and acidification. Although TLRs are non-phagocytic receptors, they contribute to 
the phagocytic process through alterations of macrophage responses, and are important 
in the maturation of phagosomes (Sanjuan et al., 2007). As well as clearing pathogens by 
uptake and degradation, the phagocytic process can often result in the production of 
inflammatory mediators, and enhanced expression of co-stimulatory molecules associated 
with T cell activation (Barker et al., 2002). This is seen by the ligation of mannose 
receptors and Fcγ receptors (Aderem et al., 1999), which either alone or in conjunction 
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with TLR signalling can activate the transcription factor NFκB  and result in the production 
of inflammatory mediators (Gordon, 2007). 
1.2.2.2 Pathogen/danger recognition  
The ability of macrophages to respond to microbial infection lies in the wide array of PRRs 
capable of recognising different PAMPs, thus enabling responses to numerous pathogens 
such as  bacteria, fungi and viruses (Creagh et al., 2006). PAMPs are conserved 
molecular motifs that are present on bacteria and helminths, as well as host cells, and 
enable immune cells to distinguish non-self (pathogen) from self (host cells) (Janssens et 
al., 2003). These PRRs include TLRs, lectin receptors, scavenger receptors and 
complement receptors (Pluddemann et al., 2007). Some of these PRRs are involved in 
the homeostatic mechanisms (e.g scavenger receptors), while others are involved in the 
activation of macrophages (e.g. TLR) through the production of inflammatory mediators 
(Janeway et al., 2002; Mukherjee et al., 2009). To date, 13 TLRs have been identified in 
mice and 11 in humans (Zhang et al., 2008). Different responses can be elicited by the 
downstream signalling of various TLRs, and some TLRs can co-operate with each other. 
An example of this is TLR2 co-operating with either TLR1 or 6 to significantly enhance 
inflammatory cytokine production (Ozinsky et al., 2000). In response to TLR signalling, 
macrophages produce a vast array of inflammatory mediators (Akira et al., 2004; Janeway 
et al., 2002).  
The most well characterised TLR is TLR4, which is stimulated by bacterial components 
such as lipopolysaccharide (LPS) from the outer membrane of gram negative bacteria 
(Akira et al., 2004). TLR4 signalling leads to NFκB activation and results in increased 
expression of MHC II, the co-stimulatory molecule CD40, as well as the production of pro-
inflammatory cytokines such as IL-6, TNFα and IL-12 (Chow et al., 1999; Gordon, 2007). 
The production of TNFα in concert with IFNγ increases the anti-microbial functions of 
macrophages by enhancing the production of superoxide anions and nitric oxide (Chow et 
al., 1999; Hoshino et al., 1999; Modolell et al., 1995). The multitude of cytokines produced 
can elicit a variety of responses ranging from activation to inhibition of immune responses, 
depending on the cytokine repertoire induced (Gerber et al., 2001; Janeway et al., 2002; 
O'Shea et al., 2008; Rahim et al., 2005). 
1.2.2.3 Other functions  
Macrophages are extremely plastic and multi-functional (Mosser, 2003; Stout et al., 2004). 
Macrophages are capable of a wide variety of different functions, some of which include 
tissue remodelling and antigen presentation. In the presence of helminths for example, 
macrophages alter their functions to produce cytokines and mediators involved in tissue 
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remodelling and repair, as opposed to exhibiting anti-microbial functions (Corraliza et al., 
1995; Kane et al., 2008; Pesce et al., 2009b). Macrophages involved in wound repair and 
tissue remodelling express enzymes diametrically opposed to those produced by 
macrophages involved in responses to danger signals (Modolell et al., 1995). One such 
enzyme is arginase1, which converts the substrate for nitric oxide production, into 
precursors for collagen and polyamines that are involved in the deposition of the 
extracellular matrix (Corraliza et al., 1995; Modolell et al., 1995).  
Another important function of macrophages is the presentation of antigen to T cells in the 
context of major histocompatability complexes (MHC), to evoke responses of T cells 
carrying T cell receptors (TCR) specific for recognising the particular antigen (Russell et 
al., 2009). Dendritic cells are highly specialised at antigen presentation, however 
macrophages also contribute to this process. Pathogens are taken up, processed, and 
presented on the cell surface in the context of MHC I (for intracellular-derived pathogens) , 
or MHC II (for extracellular constituents) (Smith-Garvin et al., 2009). TLR signalling plays 
an important role in the activation of APCs, resulting in the high levels of expression of 
MHC molecules, as well as co-stimulatory molecules on APCs, required for the full 
activation of T cells (Banchereau et al., 1994; Vyas et al., 2008).  
Macrophages are highly plastic, and are able to significantly deviate T cell responses 
depending on the environmental signals (e.g cytokines and chemokines), which are 
predominantly produced by macrophages (Attwood et al., 1999; Barker et al., 2002; 
Curtsinger et al., 1999). Macrophages in an inflammatory state are able to present antigen 
and  induce the development of CD4 T cell subsets of an inflammatory phenotype 
(Th1,Th17) (Schulz et al., 2009; Seder et al., 1996). Macrophages involved in immune 
regulation elicit an environment dominated by anti-inflammatory cytokines/mediators 
which results in more polarized Th2 responses (Anderson et al., 2002a; Gerber et al., 
2001). Therefore, macrophages have important roles in directing not only innate 
responses, but also adaptive immune responses, through the different immune 
environments elicited by the various macrophage phenotypes. 
1.2.3 Production of immune mediators 
1.2.3.1 IL-12 
IL-12 is a pro-inflammatory cytokine most prominently produced by APCs. IL-12 consists 
of a heterodimer of p40 and p35, which together form IL-12p70 (Oppmann et al., 2000), 
and is produced by multiple cell types although the major source appears to be from 
dendritic cells and macrophages (DeKruyff et al., 1997; Kelsall et al., 1996). IL-12 is 
required for the ability of macrophages to protect the host from intracellular pathogens 
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such as Leishmania major, and Mycobacterium avium (Campbell et al., 1996; Florido et 
al., 2004; Li et al., 1997), with the addition of recombinant murine IL-12 shown to cure 
such infections (Heinzel et al., 1993). This protection occurs primarily through the 
induction of Th1 cells producing IFNγ (Seder et al., 1993). In concert with CD40 ligation, 
this induces the activation of macrophages resulting in the production of nitro oxide (NO) 
and superoxide anions required for parasite killing (Campbell et al., 1996).  
1.2.3.2 IL-10 
IL-10 is secreted by many different cell types including Th1 cells (Abbas et al., 1996), Th2 
cells (Sornasse et al., 1996), Tregs (Groux et al., 1997), and innate cells such as 
macrophages (Anderson et al., 2002a). Although IL-10 was first thought to suppress 
immune responses as seen in its suppressive effect on macrophages (Bogdan et al., 
1991), it soon became evident that its functions extended beyond simple inhibition. IL-10 
has been shown to suppress Th1-associated responses by inhibiting pro-inflammatory 
cytokines such as IL-6, TNFα, IL-1β and IL-12p40 (Anderson et al., 2004; de Waal Malefyt 
et al., 1991; Howard et al., 1993). Additionally it is also able to promote the development 
of regulatory T cell subsets (Tregs). Furthermore, an essential role for IL-10 in Th2 
induction was demonstrated by Groux et al 1997, where IL-10 deficient mice suffered from 
severe morbidity during helminth infection due to the absence of a protective Th2 
response. IL-10 induces the expression of IL-4Rα on macrophages (Lang et al., 2002), 
which are essential in mediating the protective effects of Th2-derived IL-4 during 
schistosomiasis. In the context of pro-inflammatory diseases such as endotoxemia and 
EAE, macrophage-produced IL-10 has been shown to be essential in conferring protection 
or increasing recovery (Gerber et al., 2001; Howard et al., 1993; Kennedy et al., 1992). 
1.2.3.3 TNFα 
Tumor necrosis factor alpha (TNFα) is a pro-inflammatory cytokine produced most 
predominantly by macrophages (Ma, 2001). TNFα production is produced early in 
response to inflammatory stimuli such as IFNγ or LPS (Crume et al., 2007; Vila-del Sol et 
al., 2007). The autocrine production of TNFα is essential for the activation of 
macrophages, as seen by the inability of macrophages to elicit anti-microbial functions in 
the absence of TNFα (Vila-del Sol et al., 2007). This is due, in part, to the  activation of 
transcription factors such as NFκB, which are required for the production of inflammatory 
mediators (e.g iNOS), cytokines, and chemokines involved in the recruitment of 
leukocytes (Ciesielski et al., 2002; Vila-del Sol et al., 2007). Some of the inflammatory 
consequences of TNFα production include its involvement in septic shock, tumoricidal 
functions, as well as the pathogenesis of autoimmunities including MS, where high levels 
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of TNFα production are seen at the peak of disease (Abu-Amer et al., 1994; Begolka et 
al., 1998).  
In addition to initiating inflammatory responses, TNFα also exhibits regulatory functions. 
This is seen by the suppressive effects on inflammatory mediators such as IL-12 (Ma, 
2001), which are significantly enhanced in the absence of TNFα. The functions of TNFα 
vary, dependant on the environmental setting, the location, as well as the differential 
signalling pathways elicited through the receptors TNFRI or TNFRII.    
1.2.3.4 IL-6  
IL-6 is a pleiotropic cytokine that is produced by a variety of cells including T cells, 
dendritic cells, macrophages, and astrocytes (Akira et al., 1990; Jang et al., 2004; Linkhart 
et al., 1991; Yasukawa et al., 2003). The functions of IL-6 range from bone resorption to 
the proliferation of lymphocytes, differentiation of B cells, and the induction of both pro-
inflammatory (Veldhoen et al., 2006) and  anti-inflammatory responses (Rincon et al., 
1997). IL-6 has been shown to inhibit the production of other pro-inflammatory cytokines 
such as TNFα and IL-1β by monocytes (Maimone et al., 1997; Tilg et al., 1994). Overall, 
IL-6 seems to have a role in both the initiation and down-regulation of inflammatory 
responses. This idea is supported by the induction of IL-6 by IL-12 early on, but the 
inhibition of IL-12 and Th1 responses by IL-6 during later stages of schistosomiasis (La 
Flamme et al., 2000). 
1.2.3.5 Nitric Oxide 
The production of nitric oxide (NO) occurs through the enzyme nitric oxide sythase (NOS), 
to which three isoforms exhist; neuronal NOS(nNOS), endothelial NOS (eNOS) and 
inducible NOS (iNOS) (Alderton et al., 2001). nNOS and eNOS are primarily produced in 
neuronal or endothelic tissue (Alderton et al., 2001), however most NO occurs primarily 
through inducible nitric oxide sythase (iNOS). This can be induced in many different cell 
types although macrophages are believed to be a major producer of NO during immune 
responses (MacMicking et al., 1997). All three NOS enzymes exhibit different catalytic 
functions and can lead to various consequences, and this can also be demonstrated in 
vivo, where iNOS but not eNOS or nNOS is essential for maintaining the production of NO 
in order to control infection with the intracellular parasite Leishmania spp (Stenger et al., 
1996). 
1.2.4 Macrophage activation states 
A recent system of classification was proposed by Mosser et al in 2008 to separate 
activated macrophages based on their functional phenotypes: host defence, wound 
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healing, and immune regulation. Mosser et al (2008) and Stout et al (2004), in a similar 
review, also emphasize the importance of understanding that macrophages exhibit not 
only the three currently recognized states of activation (i.e. classical, alternative and type 
II), but a broad spectrum of activation states. Because macrophages are highly plastic 
(Stout et al., 2004), and are not simply restricted to a single activation state, there may be 
distinct macrophage states which exhibit characteristics of two or more activation states, 
termed ‘hybrid’ macrophages (Mosser et al., 2008). However, for the purpose of this 
thesis only the three well-characterized types of macrophage activation states, namely 
classical, type II (regulatory), and alternative, will be covered. 
1.2.4.1 Classical 
In response to microbial products, macrophages are activated via TLR signalling 
pathways, into a state that exhibits anti-microbial actions (Campbell et al., 1996; Janeway 
et al., 2002). Macrophages activated in this manner are termed classically activated. 
Classically activated macrophages are efficient at presenting antigen to T cells, and once 
activated, can induce both the proliferation of T cells, and Th1 polarisation (Campbell et 
al., 1996; Mosser, 2003; Seder et al., 1996). In vitro studies inducing classically activated 
macrophages, often stimulate them into such a state with interferon gamma (IFNγ), 
followed by LPS (Held et al., 1999; Sutterwala et al., 1997). In vivo, IFNγ can be derived 
from cells of both the innate immune system (e.g. NK T cells), and adaptive immune 
system (e.g. Th1 cells) (Germann et al., 1993). TNFα is one of the first cytokines 
produced by classically activated macrophages, with secretion occurring as early as two 
hours after stimulation (Crume et al., 2007). IFNγ can stimulate the production of TNFα by 
macrophages, which further enhances the anti-microbial functions of classically activated 
macrophages through increased production of NO (MacMicking et al., 1997; Vila-del Sol 
et al., 2007). Classical activation requires these two signals, as IFNγ primes the cell to 
enable a full response to LPS (Held et al., 1999). Such macrophages then produce high 
amounts of pro-inflammatory cytokines (e.g IL-12, TNFα, and IL-6), and chemokines (e.g 
MCP-9, MCP-1) (Anderson et al., 2002b; Grazia Cappiello et al., 2001; Steube et al., 
1999). Classically activated macrophages up-regulate the expression of surface 
molecules  that are involved in antigen presentation, such as MHC II (Edwards et al., 
2006), as well as co-stimulatory molecules like CD40 and  CD80 which are involved in 
regulating and maintaining the interaction between macrophages and T cells (Nolan et al., 
2008; Qin et al., 2005; Tierney et al., 2009).  
During infections with intracellular pathogens, the classical activation of macrophages is 
essential. For example, infection of macrophages with the intracellular parasite 
Leishmania major, renders them incapable of producing NO and killing the parasite. This 
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inhibition results in exacerbation of disease (Liew et al., 1990; Stenger et al., 1996). 
However, although the pro-inflammatory responses induced by classical macrophages are 
required for protection from invading pathogens, the mediators can be detrimental when 
the production is uncontrolled. Such an uncontrolled pro-inflammatory response occurs in 
septic shock, which is associated with the overproduction of TNFα and reactive oxygen 
intermediates (Victor et al., 1998), or in autoimmunity when the response is 
inappropriately directed at self antigens. In particular, during the autoimmune disease 
multiple sclerosis (MS), classically activated macrophages cause damage to the central 
nervous system (CNS) as a result of IL-23, IL-12p40 and IL-6 production, as well as the 
production of proteases such as matrix metalloproteases (MMPs) (Becher et al., 2002; 
Langrish et al., 2005; Tran et al., 1998; Veldhoen et al., 2006).  
1.2.4.2 Alternative 
In the presence of IL-4, IL-13 or glucocorticoids, macrophages are activated into a state 
distinct from those which exhibit the classical anti-microbial functions described above 
(Modolell et al., 1995; Stein et al., 1992). These macrophages are believed to be primarily 
involved in wound healing rather than microbial killing (Pesce et al., 2009a). Central to this 
difference in function is the altered metabolism of L-arginine to precursors for collagen 
synthesis as opposed to NO for microbial killing (Albina et al., 1990; Modolell et al., 1995). 
Alternatively activated macrophages dominate during infection with Schistosoma spp, and 
are involved in the generation of granulomas that surround the parasite eggs which 
become trapped in tissues (Hesse et al., 2001).  Alternatively activated macrophages are 
essential to host survival during schistosomiasis as in their absence, schistosome-infected 
mice succumb to severe mobidity and death (Herbert et al., 2004).  
In addition to their contribution to tissue remodelling, alternatively activated macrophages 
also differ from classically activated macrophages in several other regards. For instance, 
these macrophages are not efficient at presenting antigen to T cells, do not produce 
significant amounts of NO, and do not produce pro-inflammatory cytokines like IL-12 
(Corraliza et al., 1995; Edwards et al., 2006; Schebesch et al., 1997). In contrast, they 
produce anti-inflammatory cytokines such as IL-10. In vitro and in vivo, alternatively 
activated macrophages can be identified by their high levels of arginase1 (Hesse et al., 
2001), RELMα (FIZZ1) (Raes et al., 2002), and chitinase (YM-1) (Edwards et al., 2006). 
Furthermore, alternatively activated macrophages do not up-regulate the activation 
markers CD40, CD80 or MHC II, but can be identified through their high expression of 
programmed death ligand-2 (PDL-2) (Loke et al., 2003; Tierney et al., 2009). 
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1.2.4.3 Type II 
A third distinct state of macrophage activation is type II or regulatory activation. In contrast 
to classical activation where macrophages are stimulated with TLR agonists such as LPS, 
type II activation occurs when TLR stimulation is combined with ligation of FcγRs by 
immune complexes (Anderson et al., 2002b; Gerber et al., 2001). These macrophages 
exhibit anti-inflammatory effects, with increased production of IL-10 and reduced 
production of IL-12. Unlike alternatively activated macrophages, type II macrophages elicit 
the activation of T cells, as demonstrated by increased CD25 expression, and the biasing 
of T cell responses towards a Th2 dominated subset (Anderson et al., 2002b; Edwards et 
al., 2006).  
This pathway of activation by FcγR ligation was the first identified; however, it is important 
to note that since this first discovery, other means of type II or regulatory macrophage 
activation have been found. For example, glucocorticoids or IL-10, inhibit the production of 
pro-inflammatory cytokines by macrophages and enhance anti-inflammatory responses 
(Elenkov, 2004; Martinez et al., 2008). Also macrophages in the tumor microenvironment 
termed tumor associated macrophages (TAM) elicit characteristics similar to regulatory 
macrophages. They produce high levels of IL-10 and low levels of pro-inflammatory 
cytokines, but do not express iNOS or successfully present antigen to T cells (Dinapoli et 
al., 1996; Mantovani et al., 2002). Although these conditions can elicit regulatory 
macrophages, some characteristics differ between regulatory macrophages induced by 
these different pathways, such as iNOS expression (Martinez et al., 2008). Despite these 
differences, the main functional characteristic which appears to define regulatory 
macrophages is the preferential production of IL-10 over IL-12. 
The protective, anti-inflammatory effects of type II activated macrophages have been 
demonstrated in several animal models of pro-inflammatory disease such as septic shock 
(i.e. lethal endotoxemia) and multiple sclerosis (Gerber et al., 2001; Tierney et al., 2009). 
In these studies, transfer of type II activated macrophages protected mice from lethal 
doses of LPS (Gerber et al., 2001; Sutterwala et al., 1998), or CNS inflammation and 
disease (Tierney et al., 2009).  
Although beneficial against pro-inflammatory diseases (Gerber et al., 2001; Tierney et al., 
2009), as with classically activated macrophages, excessive regulatory macrophage 
responses can be detrimental to the host. For example, tumor associated macrophages, 
through their immunosuppressive effects, promote tumor growth (Lin et al., 2006). 
Furthermore, during Leishmania infection, high levels of circulating antibodies form 
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complexes with Leishmania, therefore eliciting FcγR ligation and inducing type II 
macrophage activation (Miles et al., 2005). This activation state is not beneficial to the 
host as it impairs the elimination of the parasite. 
1.3 CD4 T cells 
In the thymus, T cells undergo developmental changes involving the recombination of 
their T cell receptor (TCR) chains to generate unique TCRs (Swain, 1995). After TCR 
recombination takes place, T cells undergo processes which result in distinct populations 
of either CD4  or CD8 T cells (Li et al., 2007). Each population is involved in different 
immunological processes. CD8 T cells (Cytotoxic T cells)  are involved in the killing of 
virally-infected or cancerous cells (Barry et al., 2002), whereas CD4  helper T cells play an 
important role in providing support to other immune cells such as B cells, macrophages 
and CD8 T cells, as well as directing and regulating immune responses (Wan et al., 
2009).  
T cells leave the thymus as naïve cells that have never encountered their TCR-specific 
antigen. To activate a naive CD4 T cell successfully, at least two signals are required. 
First, the TCR must recognize a peptide antigen in the context of an MHC II molecule 
expressed on the APC, and secondly,  this interaction must be accompanied by a co-
stimulatory signal (discussed in more detail later) (Lechler et al., 2001). Upon activation, 
CD4 T cells proliferate, aided by the cytokine IL-2 (Jelley-Gibbs et al., 2000; Swain, 1995). 
After proliferation, T cells differentiate into effector T cells, capable of producing cytokines 
and mediators that activate or regulate other immune cells, or become memory T cells. 
The effector T cell subset into which naive CD4 T cells differentiate, largely depend on the 
cytokine environment at the time of activation, as can be determined by the activation 
state of the antigen presenting cell (Le Gros et al., 1990; Manetti et al., 1993; Mosser et 
al., 2008; Wan et al., 2009).  
CD4 T helper cells can be divided into several subsets based on their different effector 
functions. Mossman et al (1986) demonstrated the ability of two helper T cell populations 
(Th1 and Th2) to be identified based on the production of the cytokines IFNγ or IL-4, 
respectively. Furthermore, not only could the T cell subsets be defined by the cytokines 
they produced, but the cytokines also exhibited counter-regulatory activity on the 
differentiation of other T cell subsets (Maggi et al., 1992; Parronchi et al., 1992; Seder et 
al., 1992). Since then, more CD4 T cell subsets have been identified, and the major and 
most well-defined of which include Th1, Th2, Th17, and regulatory T cells (Mills, 2008; 
Zhu et al., 2008). As this thesis will focus mainly on T cell differentiation into Th1 and Th2 
cells, only these subsets will be discussed in depth. 
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1.3.1 Th1 cells 
Th1 cells function in cell mediated immunity and are essential for protection from 
intracellular pathogens such as Mycobacterium avium and Leishmania major (Campbell et 
al., 1996; Florido et al., 2004), as well as eliciting anti-tumour activity (Micallef et al., 
1997). However, the same responses which are beneficial during bacterial infections are 
detrimental when the responses are directed at targeting ‘self antigen’. This is seen in the 
dominant role Th1 cells have in eliciting pro-inflammatory responses during an animal 
model for multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), and 
rheumatoid arthritis (Becher et al., 2002; Leung et al., 2000).  
IL-12 is an essential cytokine in the development, proliferation and survival of Th1 cells 
(Manetti et al., 1993; Seder et al., 1993). In the absence of IL-12, such as that seen in 
mice lacking the IL-12 gene (Magram et al., 1996), or from macrophages defective in IL-
12 production (Anderson et al., 2002b), there is a severe impairment in type1 responses 
and the development of Th1 cells. The strength of the ability of IL-12 to induce the 
development of Th1 cells was demonstrated by Manetti et al (1993), where in the 
presence of a Th2-promoting antigen-Dermatophagoides pteronyssinus group1 (Derp1)-T 
cells elicited a Th1 rather than Th2 response after prior exposure  to IL-12.  At the level of 
transcription, the commitment to Th1 differentiation occurs via inhibition of GATA-3, a 
transcription factor associated with Th2 commitment (Nurieva et al., 2003), and the 
induction of STAT-1/T-bet (Szabo et al., 2000), involved in suppressing Th2 development. 
IFNγ is the most prominent cytokine derived from Th1 cells and mediates a range of 
inflammatory responses (Abbas et al., 1996). IFNγ activates macrophages into a state 
which produces higher amounts of toxic free radicals as well as pro-inflammatory 
cytokines essential to host protection from pathogens (Seder et al., 1993). The interaction 
of Th1 cells with APCs in the presence of IFNγ induces the activation and increased anti-
microbial activity of APCs (MacMicking et al., 1997). This interaction further enhances the 
production of IL-12 and other pro-inflammatory cytokines by the APCs. The production of 
IFNγ not only has important roles in activating macrophages and other APCs, but can also 
support cytotoxic T cell and B cell responses. Specifically, after exposure to Th1 subsets, 
the primary antibody isotypes produced by B cells are IgG2a and IgG3, which are isotypes 
involved in the opsonisation and phagocytosis by activated APCs (Coffman et al., 1993; 
Manetti et al., 1993). 
1.3.2 Th2 cells 
In an environment dominated by IL-4, CD4 T helper cells develop into the Th2 subset (Le 
Gros et al., 1990; Seder et al., 1992). There is no single cell type responsible for the 
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production of this cytokine, and the main source still remains a mystery. Cells 
hypothesized to contribute to the production of IL-4 include NKT cells, basophils, 
eosinophils and Th2 cells (Bjerke et al., 1996; Le Gros et al., 1990; Macaulay et al., 1997). 
Even in the context of an infection with a Th1 inducing pathogen, L. major, IL-4 
administration induces a potent Th2 response (Chatelain et al., 1992). The production of 
IL-4 by T cells works in an autocrine and paracrine manner, signalling through the IL-4 
receptor, a heterodimer of IL-4Rα and the common gamma chain (i.e. IL-2Rγ). This signal 
initiates a cascade of signalling events involving STAT-6, which results in the activation of 
transcription factors driving Th2 commitment (Kaplan et al., 1996). These transcription 
factors include GATA-3 and c-maf (Kurata et al., 1999), and just as T-bet inhibits IL-4 
production, GATA-3 inhibits IFNγ production (Ouyang et al., 1998; Szabo et al., 2000).  
Other cytokines are also thought to play a role in Th2 differentiation, including IL-2 and IL-
10. IL-2 was first identified for its effects on promoting T cell proliferation and 
differentiation (Smith, 1988), and is produced by a variety of cells including Th1 cells.  
Recently, IL-2 has been identified as a major cytokine determinant of early differentiation 
into the Th2 subset. Signalling via IL-2Rα induces STAT-5 dependant increased 
accessibility of the IL-4 locus, required for IL-4 production (Cote-Sierra et al., 2004), and 
enhances the expression of IL-4Rα (Liao et al., 2008), without which, no Th2 development 
would occur. In addition to the deviation towards a Th2 subset, IL-2 is important in the 
survival and function of regulatory T cells (Sakaguchi, 2004; Setoguchi et al., 2005). IL-2 
was also found important in preventing overzealous inflammatory responses, and was 
found capable of limiting T cell responses directly through various mechanisms such as 
the induction of apoptosis, termed activation induced cell death (Jelley-Gibbs et al., 2005). 
IL-10 is also thought to play a role in Th2 cell biasing, as IL-10 knockout mice are unable 
to elicit Th2 responses to the Th2-inducing parasitic worm, Schistosoma mansoni (Wynn 
et al., 1998). Furthermore, macrophages defective in IL-10 production are likewise unable 
to drive Th2 differentiation in vitro (Anderson et al., 2002b). 
The primary cytokines produced by fully differentiated Th2 cells include IL-4, IL-5 and IL-
13 (Wan et al., 2009). IL-4 is produced by basophils, NK cells, mast cells, eosinophils, T 
cells, and macrophages under specific conditions (Mukherjee et al., 2009; Pouliot et al., 
2009). Not only does IL-4 induce the development of Th2 cells (Le Gros et al., 1990; 
Seder et al., 1992), but also activates macrophages into an altered state such that they no 
longer produce pro-inflammatory cytokines, but instead elicit anti-inflammatory responses 
involved in wound healing and repair (Albina et al., 1990; Raes et al., 2002). In the setting 
of pro-inflammatory diseases such as EAE, IL-4 is associated with protection rather than 
pathogenesis (Begolka et al., 1998; Shaw et al., 1997).  
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In contrast to Th1 cells, Th2 cells takes longer to differentiate as demonstrated by the 
dependency of IL-4 production on cell cycle progression (Bird et al., 1998). Effector Th2 
cells have major roles in humoral immunity, elimination of extracellular pathogens (e.g. 
parasitic helminths) (Sher et al., 1992), and through cytokine production, counter-regulate 
or “suppress” the pro-inflammatory responses elicited by Th1 or Th17 cells (Zhu et al., 
2008).  IL-12 and IFNγ aid Th1 development and inhibit Th2 responses, whereas IL-10 
and IL-4 are potent antagonists to Th1 responses. Furthermore, IL-4 and IL-10 are 
capable of inhibiting the development and proliferation as well as the effector functions of 
Th1 cells through the inhibition of a range of pro-inflammatory cytokines involved in driving 
Th1 responses (D'Andrea et al., 1993; Fiorentino et al., 1991; Murray, 2006). As with Th1 
cells, CD4 T cells of the Th2 subset can induce antibody production by B cells, however 
the predominant antibody isotypes produced are IgG1 and IgE (Manetti et al., 1993). 
Although Th2 responses have been associated with recovery from pro-inflammatory 
diseases (Gerber et al., 2001; Shaw et al., 1997), as with Th1 responses, the same 
mechanism which elicits protection can lead to pathology under different environmental 
settings. For example, excessive Th2 responses induces atopic asthma and dermatitis 
(Wierenga et al., 1990), and during schistosomiasis, can lead to excessive fibrosis 
through the production of IL-13 (Herbert et al., 2008; Ramalingam et al., 2009). Thus it is 
the balance between these diverse immune responses that is critical to maintain. 
1.3.3 Th17 cells 
The discovery that another subset of CD4 T cells was involved in the pathogenesis of the 
pro-inflammatory disease, EAE, led to the identification of Th17 cells. IL-6 and TGFβ 
enable de novo development of Th17 cells (Veldhoen et al., 2006), and IL-23 plays an 
important role in the stabilisation of this T cell subset (Langrish et al., 2005). After 
activation, Th17 cells produce high amounts of IL-6, TNFα, IL-21, IL-22 and IL-17. Unlike 
Th1 cells, they produce very little IFNγ (Jager et al., 2009; Langrish et al., 2005; 
Stockinger et al., 2007). Effector Th17 cells elicit anti-pathogenic roles, eliminating various 
infections with which Th1 cells require help, such as Leishmania, Salmonella and 
Mycobacterium tuberculosis (Wan et al., 2009) . Th17 cells also promote pro-inflammatory 
autoimmune responses and have been implicated in the pathogenesis of EAE, psoriasis 
and T cell mediated Colitis (Langrish et al., 2005; Yen et al., 2006). 
1.3.4 Regulatory T cells 
Another distinct subset of CD4 T cells are regulatory T cells (Tregs). Naturally occurring 
regulatory T cells (nTregs) develop in the thymus (Sakaguchi, 2004; Wan et al., 2009). 
However naive CD4 T cells can also be induced to develop into a regulatory state in the 
periphery, termed inducible Tregs (iTreg) (Zhu et al., 2008). Naturally occurring Tregs 
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express high levels of CD25 (IL-2Rα), glucocorticoid induced tumour necrosis factor 
receptor family related gene (GITR), and the transcription factor FOXp3 (Bettelli et al., 
2006; Nakamura et al., 2001), with FOXp3 being a widely used marker to identify nTregs 
(Fontenot et al., 2005). FOXp3 was found to not only act as a marker, but also play a role 
in the development of nTregs in the thymus (Fontenot et al., 2003). Although the 
discovery of FOXp3 in nTregs has been extremely beneficial in their identification, it has 
also become clear than FOXp3 can also be induced in non-nTreg effector T cells, through 
STAT-5 signalling (Roncarolo et al., 2008). Inducible Tregs can be induced by IL-10 and 
TGFβ (Zhang et al., 2010). Unlike nTregs, iTregs do not constitutively express FOXp3, but 
can do so after induction, and only express it transiently.   
Upon activation, Tregs produce cytokines such as IL-10 and TGFβ, and suppress T cell 
responses (Sakaguchi, 2004). The suppression of T cell responses is believed to occur 
through a range of mechanisms. For example, high levels of CD25 (IL-2Rα) on Tregs can 
induce T cell death, due to deprivation of IL-2 in the environment which is required for 
CD4 T cell survival (Pandiyan et al., 2007). Also, apoptosis can be induced by the 
production of granzymes (Vignali et al., 2008). Immune responses can also be 
suppressed by the inhibitory cytokines IL-10 and TGFβ, and through the ability of Tregs to 
alter the function of APCs to produce immunosuppressive molecules such as indoleamine 
2,3-dioxygenase (IDO), which directly inhibits T cell proliferation (Munn et al., 1999). 
Overall, Tregs function primarily to promote self tolerance and prevent exacerbated 
inflammatory responses (Vignali et al., 2008). The role of Tregs in limiting self reactive 
immune responses has been seen in mice and humans, where a lack of Tregs results in 
severe autoimmune lymphoproliferative diseases. Patients with mutations with FOXp3, 
suffer from x-linked diabetes melitis, and enteropathy (Wildin et al., 2001). 
1.4 Macrophage-T cell Interactions  
Macrophages are one of the main professional APCs in addition to DCs and B cells. This 
process results in the direct interaction between the macrophage and T cell in an antigen-
specific manner as described in Section 1.2.2.3. Although the recognition of peptide in the 
context of a self-MHC molecule by the T cell’s TCR forms the foundation of this 
interaction, other molecules are important in determining the outcome of this exchange in 
terms of the level of T cell activation, the type of subset differentiation, or type of 
macrophage effector functions. These molecular interactions include but are not limited to 
CD28:CD80/86, CD40L:CD40, and PD-1:PDL-1/PDL-2. 
1.4.1 CD28/CD80 co-stimulation 
Naïve T cells cannot be activated by TCR recognition of peptide bound to MHC alone, but 
instead require a second signal – co-stimulation (Lamb et al., 1983; Lechler et al., 2001). 
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The first co-stimulatory molecules to be identified were CD80 and CD86, which are 
expressed on APCs, and their T cell-expressed ligands, CD28 and CTLA-4 (Linsley et al., 
1991). The interaction between CD28 and CD80 or CD86 sends a positive signal and 
leads to T cell activation (Alegre et al., 2001), while CTLA-4 binding to CD80 or CD86 
sends an inhibitory signal and limits T cell activation (Waterhouse et al., 1995). CD28 is 
constitutively expressed on T cells, however co-signalling molecules alter their levels of 
expression depending on the environment. Therefore, APCs presenting self antigen to 
self-reactive T cells in the absence of activation, should not be expressing high levels co-
stimulatory molecules. In this circumstance, T cells are not receiving the required 
activation signals and instead become un-responsive  (Lechler et al., 2001). This is 
beneficial in the prevention of autoimmunities. Conversely, TLR (or another PRR) 
stimulation, which occurs during an infection, results in the up-regulation of CD80 or CD86 
on APCs and thus promotes the activation of antigen-specific naïve T cells to fight the 
invading organism (Janeway et al., 2002). 
1.4.2 The dual role of CD40/CD40L co-stimulation 
Another co-signalling molecule is CD40 present on B cells, macrophages, monocytes, 
platelets, astrocytes and endothelial cells. This molecule was identified in 1986 as a co-
stimulatory molecule involved in the induction of B cell growth and isotype switching 
(Armitage et al., 1993; Banchereau et al., 1994; Clarke, 2000). Its’ ligand, CD40L 
(CD154), is present on activated T cells, and was identified in 1992 by Armitage et al. The 
interaction between CD40L on T cells and CD40 on B cells is essential for isotype 
switching by B cells. This was demonstrated in patients with a genetic mutation of CD40L 
termed X-linked hyper IgM syndrome, whereby B cells were unable to elicit isotype 
switching. They only produced  IgM antibodies, which resulted in recurrent infections (Hill 
et al., 1993). However the role of the CD40/CD40L interaction goes beyond B cells, and 
has also shown to have important roles in the activation of many cell types including T 
cells, monocytes/macrophages and epithelial cells (Grewal et al., 1998; Grewal et al., 
1996).  
CD40/CD40L interaction is important in both T cell and APC activation (Stout et al., 
1996b). In the absence of CD40L, antigen-specific T cells show reduced capacity to 
produce cytokines in response to antigen in vitro (Grewal et al., 1998), implicating this 
interaction as playing a role in the induction of T cell unresponsiveness in the periphery. 
Ligation of CD40 on macrophages and monocytes via CD40L, induces the up-regulation 
of cytokines/chemokines and surface markers associated with the induction of T cell 
responses, and cell-mediated immunity (Stout et al., 1996a; Toes et al., 1998). For 
example, CD40 ligation by CD40L up-regulates CD80, MHC II and cytokines such as 
TNFα, IL-6, and IL-12 (Alderson et al., 1993; Campbell et al., 1996; Caux et al., 1994), 
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involved in promoting inflammatory Th1 responses. The CD40/CD40L interaction not only 
enhances the ability of APCs to activate T cells through the production of IL-12 and 
expression of MHC II, but is also essential for the induction of anti-microbial activity and 
activation of the APC itself (Campbell et al., 1996; Stout et al., 1996b). Th1-derived IFNγ 
along with CD40/CD40L signalling increases the production of nitric oxide (NO)  (Tian et 
al., 1995), essential for the killing of intracellular pathogens. CD40/CD40L interactions can 
also induce the up-regulation of other co-stimulatory molecules such as CD80/86 on B 
cells, making them more efficient at presenting antigen and stimulating T cells (Wu et al., 
1995). 
The role of CD40/CD40L in directing T cell subset differentiation has been under intense 
investigation, as some studies have demonstrated the role is not strictly limited to the 
induction of Th1 responses. The production of prototypic Th1 and Th2 cytokines (IFNγ and 
IL-4 respectively) are significantly abrogated in the absence of CD40L in mice; implying 
CD40 plays a role in both Th1 and Th2 immune responses (Poudrier et al., 1998). This 
has been further supported by MacDonald et al (2002), who demonstrated in vitro and in 
vivo that the CD40/CD40L interaction between the T cell and DC was essential to induce 
an immune response by Th2- but not Th1-inducing stimuli (MacDonald et al., 2002). In 
addition, Hancock et al (1996) found that administration of anti-CD40L antibody resulted in 
a reduction in IFNγ and IL-12, and an increase in Th2 associated cytokines IL-4 and IL-10, 
suggesting that CD40/CD40L alterations can promote Th2 induction. Therefore, while it 
seems CD40 is involved in both Th1 and Th2 responses, many studies also support a 
preferential role for CD40 in Th2 biasing. 
This reciprocal role of CD40 in regulating both Th1 and Th2 responses may be down to 
the level of signalling received. Indeed, corroborating with this is in vitro data by Mathur et 
al (2004), performed on primary microglia and macrophage cell lines. Mathur et al 
demonstrate high levels of CD40 signalling induces the production of the pro-inflammatory 
cytokine IL-12, while low level signalling elicits a reduction in IL-12 and increase in the 
anti-inflammatory cytokine IL-10. Thus CD40/CD40L signalling represents a single 
interaction which elicits dual counter-regulatory roles. The exact mechanisms involved in 
inducing these reciprocal responses are unknown, and studies are currently underway. In 
this thesis, the mechanisms involved in altering the CD40/CD40L interaction and the 
effects of this altered interaction on macrophage as well as CD4 T cell phenotypes are 
investigated.  
1.4.3 PD-1/PDL-1 co-signalling 
Co-inhibitors as well as co-stimulators exist to limit the extent of immune activation.  Like 
CTLA-4, Programmed Death 1 (PD-1) is an inhibitor of T cell responses. PD-1 was first 
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identified in 1992 by Ishida et al, in studies on the programmed death of cells. PD-1 is not 
constitutively expressed, but as with CTLA-4, is induced by T cell activation. Its’ role in 
peripheral tolerance and prevention of autoimmunites has become apparent, with PD-1 
deficient mice suffering from spontaneous autoimmunities such as lupus-like arthritis 
(Nishimura et al., 1999), and autoimmune mediated cardiomyopathy (Nishimura et al., 
2001b). 
There are two ligands for PD-1; Programmed Death ligand 1 and 2 (PDL-1 and PDL-2) 
(Freeman et al., 2000; Latchman et al., 2001), and the functions of these ligands remain 
controversial. Some studies indicate the PD-1 ligands inhibit T cell activation and 
proliferation (Freeman et al., 2000), however there have also been conflicting evidence 
that they are involved in T cell stimulation (Tseng et al., 2001). Other studies have shown 
that the PD-1 ligands may inhibit the response of APCs through reverse signalling as seen 
in DCs (Kuipers et al., 2006). PDL-1 is constitutively expressed on a range of cells 
including T cells, DCs, B cells and macrophages as well as non-haemopoietic tissue, with 
its up-regulation occurring by exposure to inflammatory stimuli such as LPS (Yamazaki et 
al., 2002). PDL-2, a second ligand for PD-1 (Latchman et al., 2001) is less widely 
expressed, and its expression on DCs and macrophages only occurs after stimulation with 
cytokines such as IFNγ, GMCSF, or IL-4 (Loke et al., 2003; Yamazaki et al., 2002). PDL-1 
and PDL-2 exhibit some overlapping functions, where both induce inhibition of T cell 
responses as exhibited by reduced IFNγ and IL-2 by T cells (Keir et al., 2006). The ligands 
for PD-1 seem to exhibit functions both similar and distinct from each other, having effects 
not only on the inhibition/stimulation of T cell responses, but also having diametrically 
opposed roles in Th1/Th2 responses (Loke et al., 2003), implying they may elicit 
differential roles in deviating immune responses. 
1.5 Schistosomiasis  
1.5.1 Lifecycle 
More than 250 million people are affected by schistosomiasis world wide (Chitsulo et al., 
2000). Schistosomiasis is infection with the trematode worm of the schistosoma genera 
(Butterworth et al., 1994). The species which cause the majority of infection in humans are 
S.mansoni, S.japonicum, and S. Haematobium.  All are endemic  in tropic and subtropical 
equatorial areas (Kurtzke, 2000), and although the risk of mortality is less than that of 
other infectious diseases such as M.tuberculosis, schistosomiasis as with other helminth 
diseases, results in severe long lasting morbidity (Ouma et al., 2001). 
The infective cercariae derived from fresh water snails residing in contaminated water, 
penetrate the skin of humans while gathering water, catching fish, or washing. After 
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travelling through the blood stream, matured worms reside in the hepatic portal 
vasculature where they mate and produce their eggs about  5-6 weeks post infection 
(Dunne et al., 2005). Eggs must then traverse the intestine to exit out through the feces 
(S.mansoni , S.Japonicum) or pass through the urine in the case of urinary 
schistosomiasis caused by S. Haematobium (Hu et al., 2004). After deposition of the egg-
containing feces or urine into the waterways, miracidia hatch from the eggs and infect the 
snail host continuing the infectious cycle.  
1.5.2 Schistosomiasis immunology 
Although the schistosome worm itself can live for up to 40 years undetected by the 
immune system (Chabasse et al 1985 as cited in Dunn et al., 2005 and Hu et al., 2004), 
the eggs they produce induce a strong inflammatory response which is required for the 
eggs to exit out through the intestine/bladder to continue their life cycle. However, many 
eggs get lodged in organs such as the liver (S.mansoni) where they reach a dead end in 
their life cycle progression. The inflammatory response which ensues is largely driven by 
polarised Th2 responses  (Grzych et al., 1991; Pearce et al., 2004), which orchestrates a 
granulomatous/fibrotic response at these foci of eggs (Pearce et al., 2004). This Th2 
driven response is both essential for host protection, and at the same time is the cause of 
host pathology. In S.mansoni infection, IL-4 prevents excessive damage to the liver 
induced by reactive oxygen radicals produced in response to bacterial components which 
seep out of the intestine, as shown in IL-4 deficient mice which suffer severe liver damage 
associated with significant increases in NO (La Flamme et al., 2001), as well as in mice 
deficient in the IL-4 receptor (Herbert et al., 2004). However, in excess, the same 
response can be detrimental to the host.  At the site of granuloma formation, mediators 
and cytokines in the local environment, derived predominantly by macrophages, induce 
Th2 cells to secrete IL-4 and IL-13, which are pro-fibrotic cytokines (Wynn et al., 2004). As 
well as having important roles in altering macrophage and T cell responses into an anti-
inflammatory state and perpetuating responses involved in tissue remodelling, IL-4 and IL-
13 also directly induce collagen synthesis from fibroblasts (Jakubzick et al., 2003; 
Sempowski et al., 1994) which when in excess, results in severe pathologies as seen 
during the chronic stages of schistosomiasis. Such pathologies include liver fibrosis, 
hepatosplenomegaly, the development of portal ascites, as well as portal hypertension, all 
of which may lead to organ failure (Ouma et al., 2001; Pearce et al., 2004). However, the 
immune responses to eggs aid in the movement though the gut/bladder wall for those 
destined to those sites. It also prevents systemic deposition of trapped eggs within the 
liver/intestine and through its counter regulation of Th1 responses, prevents exacerbated 
Th1-driven inflammation (Herbert et al., 2008; Pearce et al., 1991). Therefore, Th2 
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dominant immune responses, although pathology-inducing, are essential for host 
protection from severe schistosomiasis. 
1.5.3 Macrophage activation during Schistosomiasis 
Macrophages and DCs are altered in the presence of schistosome egg or soluble egg 
antigen (SEA). Both DCs and macrophages show a significant reduction in the ability to 
promote Th1 responses and produce pro-inflammatory cytokines such as IL-12 (La 
Flamme et al., 2004; Zaccone et al., 2003). This effect of reducing the activation in 
response to pro-inflammatory conditions occurs independently of MyD88 in DCs, a 
characteristic signalling molecule involved in the production of pro-inflammatory cytokines 
(Kane et al., 2008). In the presence of LPS in vitro, which is a likely contaminant during 
infection with schistosomiasis, macrophages exposed to SEA produce lower levels of the 
pro-inflammatory cytokine IL-12 and increased production of IL-10 (La Flamme et al., 
2004). Therefore, SEA can induce cytokine deviation at the level of the macrophage, such 
that Th1 inducing cytokines are reduced while Th2 or Treg-inducing cytokines are 
increased. This ability to counter-regulate the response to LPS is likely a mechanism 
which occurs in vivo, in the setting of contaminating bacterial components which seep out 
of the intestine from  pores created by the traversing of eggs through the gut wall (Herbert 
et al., 2008). 
Alternatively activated macrophages are essential for host survival during schistosomiasis 
(Herbert et al., 2004), and IL-4 in the absence of alternatively activated macrophages 
does not elicit protection, indicating macrophages as the major elicitors of IL-4 induced 
protection. Further studies identified that in the absence of IL-4Rα on bone marrow 
derived cells such as macrophages, severe mortality ensues (Herbert et al., 2008). This 
was associated with severe inflammation in the liver, which may have been caused by the 
lack of anti-inflammatory mediators and cytokines, and the removal of the suppressive 
effect of alternatively activated macrophages on T cell responses (Herbert et al., 2008). 
As well as alternatively activated macrophages inducing Th2 responses, they are also 
capable of suppressing these same Th2 responses, and this dual effect is essential in 
maintaining a balance of Th2 induced protection and Th2 induced pathology (Nair et al., 
2009; Pesce et al., 2009a).  
The effect of schistosome infection on type II activation is currently unknown. As with type 
II macrophage activation (Tierney et al., 2009), schistosome infection either with worm, 
egg, or soluble egg antigen (SEA), protects mice against EAE (La Flamme et al., 2003; 
Sewell et al., 2003; Zheng et al., 2008). Furthermore, some of the responses associated 
with protection are similar. As with type II activation, protection by schistosome infection is 
dependent on immune deviation resulting in polarised Th2 responses, and reductions in 
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Th1 responses (La Flamme et al., 2006; La Flamme et al., 2003; Sewell et al., 2003; 
Tierney et al., 2009; Zheng et al., 2008). Schistosome egg antigen complexes elicit 
greater anti-inflammatory responses than schistosome egg antigen alone, with high levels 
of IL-10 and reduced production of IL-12 (La Flamme et al., 2004), which is a 
characteristic shared by type II macrophage activation (Anderson et al., 2002b). During 
infection, schistosome eggs are potent inducers of inflammation, aiding in the exit of eggs 
into the intestine across the gut wall (Pearce et al., 2004). This results in increased 
intestinal permeability, and as the intestine is a reservoir of bacteria, leakage of bacterial 
components such as LPS occurs. Furthermore, this is accompanied by high levels of 
inflammatory mediators such as IFNγ and IL-12 (Herbert et al., 2008). In addition to the 
presence of IFNγ and LPS, schistosomiasis is also accompanied by circulating immune 
complexes (de Jesus et al., 2002; Santoro et al., 1979). Type II activation is induced by 
exposure to immune complexes in the presence of inflammatory mediators such as LPS 
and IFNγ (Gerber et al., 2001). Therefore schistosome infection elicits an environment in 
support of type II macrophage activation, and it is therefore possible such an activation 
state occurs in vivo. 
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1.6 Objectives of this investigation 
It is essential to identify different macrophage phenotypes as particular phenotypes are 
associated with disease pathogenesis, or more importantly, with disease 
prevention/recovery. To date, the number of distinct markers for differentiating type II 
activation from other regulatory states is quite limited. Furthermore, very little is 
understood in terms of the mechanisms involved during type II activation, and whether this 
activation state contributes to the protection schistosome infection provides against EAE. 
This thesis investigates the effects of schistosome immune complexes on macrophage 
activation with the hypothesis that schistosome immune complexes are able to induce 
type II macrophage activation, similarly to opsonised SRBCs. Understanding the effects of 
schistosome products on macrophages, and whether the induction of type II activation is 
involved, will provide further insight into the possible mechanisms involved in protection 
from inflammatory diseases.  
This thesis also investigates mechanisms involved in promoting the type II macrophage 
phenotype. In particular, the role CD40 alterations have in the effector functions elicited by 
type II activation is investigated. The hypothesis is that low levels of CD40 present on type 
II macrophages promote the anti-inflammatory profile elicited by this activation state and 
are involved in T cell biasing in favour of the Th2 subset. 
The goal of this investigation is to provide a greater understanding of mechanisms 
involved in anti-inflammatory responses elicited by macrophage activation, with the notion 
that a greater understanding of mechanisms involved in immune deviation will aid the 
development of more effective treatments for autoimmunities. 
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Chapter 2: General Methods 
2.1 Animals 
All experiments involving animals were approved by the Victoria University Animal Ethics 
Comittee (AEC). C57BL/6 mice were obtained from and bred at eitherthe Biomedical 
Research Unit of the Malaghan Institute of Medical Research (MIMR), or the Otago 
School of Medicine Biomedical Research Unit, Wellington, New Zealand.  
Transgenic OTII mice with a transgenic TCR for OVA 323-339 on a C57BL/6 background 
(Robertson et al., 2000) were generously donated by Ian Hermans and Franca Ronchese, 
and were bred at the Biomedical Research Unit of the Malaghan Institute of Medicine, 
Wellington, New Zealand.  
Following guidelines specified by the ministry of agriculture and forestry (MAF), mice were 
housed at Victoria University of Wellington in the animal facility. Mice aged 6-12 weeks 
were used for experiments following AEC guidelines.  
2.2 Primary Cell culture 
2.2.1 General Macrophage culture  
Bone marrow derived macrophages (BMMØ) were cultured from C57BL/6 mice. After 
euthanasia, mice were soaked with 70% ethanol as were the instruments used for 
dissection. With the use of a 23 g needle and syringe, bone marrow was flushed from the 
femurs and tibias with divalent cation free Dulbecco’s PBS (dPBS-Invitrogen, Auckland, 
NZ) with collections made into a 50 ml falcon tube (BD Bioscience, Franklin Lakes, NJ, 
USA). Cells were broken apart by homogenisation, washed by centrifugation at 760xg in 
wash buffer (Appendix B), followed by lysis of red blood cells with 2 ml of RBC lysing 
solution (Sigma, St Louis, MO, USA) for 2 minutes. After further washing cells in wash 
buffer, cells were then seeded at 106cells /ml in T75 tissue culture flasks (BD Bioscience, 
Franklin Lakes, NJ, USA) in complete T cell media (CTCM-In appendix B). After overnight 
culture at 37oC in 5% CO2, adherent cells were removed and the remaining progenitor 
cells were cultured on 90 mm non-tissue culture-treated, gamma-sterilized petri dishes ( 
Raylab, NZ ) in CTCM with 5 ng/ml rGMCSF and rIL-3 ( Peprotech, N.J ) at 37oC in 5% 
CO2  for 8-10 days until fully differentiated into macrophages. Cells were then removed by 
carrying out several rounds of incubation in ice-cold dPBS at 4oC followed by vigorous 
pipetting. 
For stimulation assays, macrophages were cultured in 96 well plates  (BD Bioscience) at 
105 cells/well in CTCM, and were primed overnight in 20 U/ml IFNγ (BD Biosciences) 
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followed by exposure to the various culture conditions (as specified in figures). 
Macrophages were stimulated with 200 ng/ml lipopolysaccharide (LPS- Sigma) in the 
presence or absence of opsonised sheep red blood cells (SRBC-IgG), un-opsonised 
SRBC (Taylor Preston Limited), opsonised schistosome whole egg, un-opsonised 
schistosome egg (Dalton et al 1997), opsonised soluble egg antigen (SEA), or un-
opsonised SEA (Boros et al 1970). Cells were incubated at 37oC in 5%CO2. 
2.2.2 Generation of immune complexes 
2.2.2.1 SRBC immune complexes 
For each batch of new sheep red blood cells (SRBC), an agglutination assay was carried 
out in order to determine the optimal concentration of rabbit anti-SRBC IgG (Sigma, St 
Louis, MO, USA) for opsonisation. Two fold serial dilutions of rabbit anti-SRBC antibody 
were made in round bottom 96 well plates (BD Bioscience) starting with a 1:50 dilution in 
1xPBS (Appendix B). Fresh SRBCs were added to all wells at a final concentration of  108 
cells/ml, and incubated at room temperature for 1-2 hours. The highest non-agglutinating 
concentration was determined by visualising the plate under a light source. Optimal 
concentrations ranged between 1:200 to 1:400 of rabbit anti-SRBC IgG. 
Opsonised SRBCs were generated by incubating SRBCs (108 cells/ml) with rabbit anti-
SRBC antibody at predetermined non-agglutinating titres.  Incubation of the SRBCs and 
antibody was carried out at room temperature with rotation of the mixture for 30-40 
minutes. Cells were then washed and the remaining SRBC-IgG complex was added to the 
macrophage culture at a ratio of 10 SRBC: 1 macrophage.  
2.2.2.2 Schistosome whole egg immune complexes 
Schistosome whole egg complex was generated by incubation of 1000 Schistosoma 
mansoni eggs with serum from schistosome infected C57BL/6 mice at a 1:100 dilution of 
serum. The solution was incubated at room temperature while rotating, for 30 minutes. 
Following incubation, non-bound serum was removed by washing the solution in PBS, and 
resuspending the remaining schistosome egg-complex at the desired concentration such 
that there were 1000 eggs per well.  
2.2.2.3 Schistosome soluble egg antigen (SEA) immune complexes 
Antibody (IgG) from schistosome infected mice was purified on a protein G sepharose 
column (Sigma), by Dr J. Tierney. To obtain the SEA-immune complex, SEA (either 5 or 
10 µg/ml) was incubated with anti-SEA IgG (either 10 or 20 µg/ml) in 1xdPBS. The 
solution was incubated for 1 hour while rotating at room temperature.  
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2.2.3 Obtaining single cell splenocyte suspensions  
After removal from OTII C57BL/6 mice, spleens were mechanically mashed using the 
back of a 1 ml plunger belonging to a 1ml syringe (BD Bioscience), through 70 µm cell 
strainers (BD Bioscience) into 50 ml falcon tubes to create single cell suspensions. After 
washing in wash buffer followed by CTCM (Appendix B), splenocytes were incubated for 2 
minutes in red blood cell lysing solution. Cells were washed at 760xg centrifugation and 
resuspended in CTCM at a desired concentration for CD4 T cell isolation.  
2.2.4  Isolation of CD4  T cells from OTII positive mice using Dynabeads and 
DETACHaBEAD (Brief outline of manufacturer’s instructions) 
Splenocytes from OTII positive mice were isolated (described above) and resuspended at 
1x107 cells/ml in isolation buffer (Appendix B). Mouse CD4 (L3T4) Dynabeads (Invitrogen 
Dynal, Norway) were washed and added to the resuspended cells at 25 µl per 1x107 
splenocytes, and incubated for 20 minutes while rotating at 4oC. CD4 negative T cells 
were then removed by carrying out several rounds of placing the tube on a DynaMag 
magnet (Invitrogen) for 2 minutes before discarding the supernatant and resuspending the 
cells in 100 µl CTCM per 1x107 cells. The remaining bead-bound CD4 T cells were 
isolated by adding 10 µl of mouse CD4 DETACHaBEAD (Invitrogen) per 1x107 cells, and 
incubated while rotating at room temperature for 45 minutes. The CD4 T cells were then 
isolated by placing the tube on the magnet and collecting the supernatant. This was 
carried out for several rounds to obtain a maximum amount of CD4 T cells. These were 
then resuspended at the desired concentration for later use in functional assays or flow 
cytometry (specified in figures). For stimulation assays with macrophages, the CD4 T cells 
were plated at approximately 1x106 cells/ml (2.5x105cells/well) in 96 well plates containing 
the macrophage cultures, and incubated at 37oC in 5% CO2 for 72 hours. 
2.3 CFSE staining protocol of CD4 T cells. 
CD4  T cells, purified as described above (2.2.4), were resuspended in sterile 1xdPBS at 
a concentration of 2x107 cells/ml before incubating with Carboxyfluorescein succinimidyl 
ester (CFSE, Invitrogen) used at 625 nM.  After incubation for 8 minutes at room 
temperature while wrapped in foil, an equal volume of 100% foetal calf serum (FCS- ICP 
biologicals, Auckland) was added to quench the CFSE and terminate the reaction. Cells 
were thoroughly washed to remove extracellular CFSE by several rounds of centrifugation 
in CTCM, after which cells were resuspended at the desired concentration of 2.5 x 106 
cells/ml prior to culture in 96 well plates containing macrophage cultures. 
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2.4 Cytokine detection 
2.4.1 Enzyme linked immunosorbant assay (ELISA) 
To determine levels of cytokines in the supernatants collected from cell cultures, a 
sandwich enzyme-linked immunosorbent assay was carried out following manufacturer’s 
recommendations (BD Pharmingen, Franklin Lakes, NJ). All ELISA antibodies were 
purchased from BD Bioscience unless otherwise stated. In brief: 
The cell culture supernatant was removed and stored at -20 oC until used.  96 well ELISA 
plates were coated with 50 µL of capture antibody specific to the cytokine of interest 
(specified in figures). Dilutions of capture antibody were made in capture buffer before 
transfer to the ELISA plate according to the manufacturer’s guidelines for that antibody 
(See Appendix A table1).  ELISA plates were incubated at 4 oC overnight. 
Plates were then flicked to remove any unbound antibody in solution, and incubated in 
blocking solution (1 x dPBS containing 5% FCS) at room temperature for approximately 2 
hours to block non-specific binding.  Plates were washed 2-3 times in a washing solution 
of 1xPBS (Appendix B) containing  0.05% Tween-20 (Sigma) (TPBS), after which samples 
were added to the wells either as neat or diluted in blocking solution. Cytokine standards 
were added to the top two rows in 2 fold serial dilutions with the concentration of the first 
well specified in appendix A.  Plates were incubated for either 2 hours at room 
temperature, or overnight at 4oC. 
After washing plates in TPBS approximately 4 times, biotinylated detection antibody (BD 
Bioscience) was diluted in blocking solution at the recommended concentration, and 50 µl 
was added to the wells.  Plates were incubated for 1 hour at room temperature. Plates 
were then washed in TPBS, and incubated in Streptavidin-HRP (SA-HRP-BD Bioscience) 
for 30min-1 hour depending on the cytokine of interest.  
Directly after washing plates in TPBS, equal volumes of substrate reagent A and B (BD 
Bioscience) were added to each well and allowed to develop at room temperature under 
visual supervision. The substrate induced a colour change which allowed one to be able 
to decide the appropriate time to stop the reaction, at which time 0.18 M sulphuric acid 
(STOP solution) was added to each well. 
Absorbance of each well was then read at 450 nm using a VersaMax plate reader. 
2.4.2 Cytometric Bead array (CBA) 
For the detection of MCP-1, IL-6, and TNFα in addition to IL-10 and IL-12, a CBA mouse 
inflammation kit (BD Bioscience) was performed as per manufacturers instructions. 
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In brief: 
BD Standards were prepared in BD assay diluent, with a range of 0-1667 pg/ml. The 
‘mixed capture beads’ were prepared by mixing together 2.5 µl aliquots of each of the 6 
capture beads per well to be analysed, in a 1:1 dilution with assay buffer. BD PE detection 
was diluted in assay buffer in a 1:1 dilution. Following this, 25 µl of the ‘Capture bead mix’ 
was added to all wells in a 96-well round bottom plate. This was followed by the addition 
of 25 µl of samples and 25 µl of standards to the appropriate wells. Additionally, 25 µL of 
the diluted PE detection was added to all wells, followed by a 2 hour incubation at room 
temperature in the dark. The plate was then washed in BD wash buffer (BD Bioscience) 
two times, prior to resuspending the bead-sample pellet in 300 µl of wash buffer for 
analysis on the flow cytometer as reported in 2.5. 
2.5 Flow Cytometry  
Cells were harvested from 96 well plates at the end of the culture period. For macrophage 
cultures, cells from duplicate cells were combined in order to acquire enough cells for flow 
cytometry. Prior to staining, cells were washed to remove excess CTCM. The Fc 
receptors of cells were blocked by incubation with rat anti-CD16/32 Fc block (1µg/ml) for 
10 minutes. Cells were stained with fluorescently labelled antibodies (BD, Serotec, 
eBioscience-Appendix B) at dilutions determined by either optimisation within the lab, or 
recommended by the manufacturers guidelines. Cells were stained and incubated with the 
fluorescently labelled antibodies for the markers of interest as well isotype controls 
following the manufacturers recommendations (BD Pharmingen). After staining for 
markers of interest, cells were analysed using the FACScan flow cytometer (BD 
Bioscience). For analysis of primary macrophages, 900-1500 live events were collected 
per assay. For examination of splenocytes or CD4 T cells, 5000- 10,000 live events were 
collected. 
The live cell population was determined using the forward scatter (FSC) and side scatter 
(SSC) data of the non-stained population, which was gated around. Isotype controls and 
single stains were used to determine background fluorescence and compensation 
respectively. 
Analysis of results was carried out using the CELLQuest pro software (BD, Franklin 
Lakes, NJ, USA).  
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2.6 Western Blot 
2.6.1 Obtaining lysate 
Macrophages were removed 9 hours following primary stimulation under the different 
culture conditions (in figures). Supernatant was removed and macrophages were 
incubated for 5 minutes in trypsin (TrypLE express, Invitrogen) at 37oC in 5% CO2. Fetal 
calf serum (FCS-ICP biologicals, Auckland) was added to quench the reaction. Cells were 
washed two times to remove excess trypsin, with the final wash in 1xdPBS. Cells were 
then incubated with 100 µl of lysing buffer (10 µl of protease inhibitor cocktail (Sigma) per 
1 ml of RIPA buffer (Appendix B)) for 1 hour at 4oC while shaking. The solution was then 
centrifuged at 2000xg for 25 minutes to remove debris. Protein concentrations were 
assessed using a BCA kit (Pierce). The supernatant containing proteins of interest was 
removed and stored at -20 or -80oC for future assessment.  
2.6.2 Running western blot 
Preparation of lysates for running in gels was carried out as follows;  80 µg of each lysate 
(or 22 µl max) from 2.6.1 were transferred into fresh tubes, and incubated with 8 µl of the 
reducing buffer mix (1:10 dilution of 2-mercaptoethanol (Sigma) in 5 x reducing buffer-
containing bromophenol blue in running buffer), at 90oC for 10 minutes. 
SDS PAGE (Sodium dodecyl sulfacte polyacrylamide gel electrophoresis ) was performed 
with 30 µl of lysates containing reducing buffer along with 3 µl of dual colour ladder 
(Biorad) .This was run at 200V for 45 minutes (Appendix B for gel recipe). Proteins were 
transferred onto a PVDF membrane (GE Healthcare, Amersham) by running the transfer 
for 4 hours at 50 V in a 4oC cold room. Immunoblots were removed and blocked using 5% 
non-fat skim milk in TTBS (Appendix B) for 1 hour at room temperature. Membranes were 
then probed with the primary antibody of interest (Dilutions in Appendix A table2). 
Membranes were probed with the primary antibody for 2 hours at room temperature, or 
overnight at 4oC. This was followed by 3 x 5 minute washes in TTBS. Membranes were 
probed with a secondary fluorescently labelled antibody against the species for which the 
primary antibody was derived from, for 2 hours at room temperature. Depending on the 
primary antibody, this was anti-rabbit cy3, or anti-mouse cy5 (GE Healthcare). 
Immunoblots were washed with 3 x 5 minute washes in TTBS. Images of the probed 
membranes were then obtained on a Fuji Film FLA-5100 scanner.  The same membranes 
were then washed with 3 x 5 minute washes in TTBS and the same process was repeated 
for each primary antibody used. Dependant on the experiment, the primary antibodies 
included rabbit anti-SPHK1 (Abcam), rabbit anti-RELMα (Abcam) or mouse anti-iNOS 
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(Transduction laboratories). Scanned images were analysed using Image Quant. Western 
blots were normalised to α tubulin. 
2.7 Graphing and statistical analysis 
Results were analysed and graphed in GraphPad, Prism v. 4.0 for Windows (GraphPad 
Software, San Diego California USA, www.graphpad.com).  Statistical analysis was 
carried out using one way ANOVA or two-way ANOVA with Bonferroni correction. 
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Chapter 3: Defining key mechanisms of type II 
macrophage activation 
3.1 Introduction 
Macrophages are highly plastic innate cells capable of altering their physiology and 
therefore their functions depending on changes in the micro-environment (Stout et al 
2004). As such, they are able to elicit a broad spectrum of activation states (Mosser et al., 
2008) of which the major states include classical, alternative, and type II. Macrophages 
activated in response to pro-inflammatory stimuli are termed classically activated 
macrophages. These macrophages elicit cell mediated, Th1-promoting pro-inflammatory 
responses (Liew et al., 1990; Stenger et al., 1996), and can be characterised by high 
levels of NO, essential in the killing of intracellular pathogens, as well as the production of 
inflammatory cytokines and chemokines  such as IL-12, TNFα, IL-6 and MCP-1 (Steube et 
al., 1999). Also associated with the activation of classically activated macrophages is the 
expression of co-signalling molecules like CD80 and CD40, which are up-regulated during 
inflammation (Alderson et al., 1993; Caux et al., 1994b; Tierney et al., 2009). In the 
absence of co-stimulatory markers, cell-mediated responses are significantly impaired 
(Campbell et al., 1996; Florido et al., 2004). This phenotype has been shown to be 
detrimental in autoimmunities such as MS, and reductions in the level of macrophages 
exhibiting classical activation, or inhibition of the inflammatory mediators produced by 
these macrophages, are associated with protection against CNS inflammation (Cua et al., 
2003; Huang et al., 2001b; Sewell et al., 2003).  
In 1992 Stein et al identified a novel macrophage state induced by IL-4, which elicited 
distinct functions from that of classically activated macrophages (Stein et al., 1992). Unlike 
classically activated macrophages, alternatively activated macrophages convert L-arginine 
into precursors for collagen synthesis and are involved in tissue remodelling and wound 
repair as opposed to pathogen killing (Raes et al., 2002). This pathway is in contrast to 
the conversion of L-arginine to NO by iNOS in classically activation macrophages 
(Modolell et al., 1995). Also expressed in alternatively activated macrophage is RELMα, 
which along with arginase 1, exhibits roles in wound repair as well as the suppression of 
overzealous inflammatory responses (Nair et al., 2009; Pesce et al., 2009a; Pesce et al., 
2009b). Alternatively activated macrophages are poor at presenting antigen to T cells, 
unlike classically activated macrophages (Edwards et al., 2006), and are more inhibitory 
than stimulatory of T cell responses (Schebesch et al., 1997).  
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Adding to the repertoire of macrophage subsets was the discovery of type II activated 
macrophages (Anderson et al., 2002; Gerber et al., 2001; Sutterwala et al., 1997). These 
macrophages were classed under the same category as alternatively activated 
macrophages, due to their differences from classically activated macrophages; however 
the pathway to activation is completely different. Type II activation occurs via the ligation 
of Fcγ receptors in the presence of LPS and significantly alters the responses to 
inflammatory stimuli by reducing the expression of co-stimulatory markers (Tierney et al., 
2009) and deviating the cytokine profile to promote anti-inflammatory cytokines such as 
IL-10, over pro-inflammatory cytokines such as IL-12 (Gerber et al., 2001). Unlike 
alternatively activated macrophages, type II macrophages express iNOS and can be 
distinguished from classically and alternatively activated macrophages by high expression 
of the enzyme sphingosine kinase 1 (SPHK1) (Edwards et al., 2006). Furthermore, type II 
macrophages have the ability to present antigen to T cells and induce Th2 cell biasing 
(Anderson et al., 2002; Lucas et al., 2005). It is this ability to elicit a Th2 polarized immune 
response that is believed to counter-regulate Th1-mediated inflammatory responses and 
provide protection against inflammatory diseases such as endotoxemia and EAE, an 
animal model of MS (Gerber et al., 2001; Tierney et al., 2009). However, the exact 
mechanisms involved in type II activation and how these effects provide protection against 
EAE are currently unknown. Because type II activation is a strong polarizer of anti-
inflammatory Th2 responses, understanding the mechanisms involved in the ability of type 
II activation to deviate immune responses would provide greater understanding of how to 
increase or prevent beneficial or pathological processes respectively.  
Aims: 
To better understand the mechanisms involved in type II activation, we examined several 
aspects of type II macrophage activation. These aspects included assessing changes in 
cytokines and surface markers over a period of time following stimulation, and the 
involvement of IL-10 and CD40 in regulating the phenotypic alterations in type II 
macrophages. Overall, there were three specific aims to be addressed: 
1. To assess the kinetic changes in the expression of co-signalling molecules and 
cytokine profiles, in order gain an insight into the kinetics involved in type II activation. 
2. Investigate the contribution of IL-10 in the ability of type II macrophages to reduce 
inflammatory cytokines and surface markers, to determine whether the increase in IL-10 is 
essential for this macrophage phenotype. 
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3. Study the role of CD40 signalling, with regards to the phenotypic changes elicited by 
type II activation, and investigate whether increased signalling impairs the anti-
inflammatory phenotype. 
3.2 Results 
3.2.1 Ability of opsonised SRBCs to induce type II macrophage activation  
In order to investigate the mechanisms involved in type II macrophage activation, we first 
characterized the phenotype of the type II activated macrophages in our experimental 
system. Additionally, we wished to identify broader changes occurring in response to type 
II activation to aid in a greater understanding of how type II activation protects against 
EAE as well as other inflammatory disorders. For all experiments, we used opsonised 
sheep red blood cells (SRBCs) in the presence of LPS to induce type II macrophage 
activation, while LPS alone or in the presence of un-opsonised SRBC was used to induce 
classical activation. The production of various cytokines was assessed 8 h following 
stimulation.  
SRBC or SRBC:IgG (opsonised SRBC) in the absence of LPS elicited similar effects to 
medium alone with respect to cytokine production (IL-10, IL-12, MCP-1, IL-6, TNFα; 
Figure 3.1). Moreover, stimulation with SRBC in the presence of LPS elicited a similar 
level of cytokine production to that seen by stimulation with LPS alone, indicating SRBC 
alone has no effect on macrophage activation (Figure 3.1). In contrast to the effect of un-
opsonised SRBC, the effects seen by opsonised SRBC in the presence of LPS differed 
significantly from LPS stimulation alone. For example, IL-10 production in response to 
SRBC:IgG + LPS is significantly higher than that induced by LPS or SRBC + LPS (un-
opsonised). Furthermore, macrophages stimulated with LPS produced high levels of IL-
12p40 while the addition of SRBC:IgG to cultures with LPS resulted in a significant 
reduction in IL-12. These results confirm that the addition of SRBC:IgG has induced type 
II as opposed to classical macrophage activation in our system. 
Exploring the effect of type II activation on the production of other cytokines, we assessed 
MCP-1, IL-6, IL-4, and TNFα. MCP-1, also known as CCL2, was up-regulated by 
macrophages stimulated with LPS, and this level of production remains largely unaffected 
by the addition of SRBC, with only a slight reduction observed. However, MCP-1 levels 
are reduced by the addition of SRBC:IgG to LPS-stimulated cultures. Although statistically 
non-significant, this is similar to the effect seen on IL-12 production. LPS stimulated 
macrophages produce very high levels of IL-6, and in contrast to the effects seen on IL-
10, MCP-1 and IL-12, SRBC in the presence of LPS appear to reduce the production of 
IL-6, to a similar degree to that observed by SRBC:IgG + LPS (Figure 3.1). This finding 
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indicates the reduction in LPS-induced IL-6 is not due specifically to the ligation of Fcγ 
receptors, but rather due to an unknown mechanism involving the presence of SRBC. 
Similarly, high levels of TNFα are also produced by LPS stimulated macrophages, but 
appear to be reduced by the presence of un-opsonised SRBC in LPS cultures. 
Interestingly, no reduction in TNFα is observed by stimulation of macrophages with LPS in 
the presence of SRBC:IgG. However as the data are from only 1 experiment, further 
investigation is required to confirm these results since this effect has not been reported 
previously. In response to LPS, macrophages produced nearly undetectable levels of IL-4 
similar to non-activated macrophages (Figure 3.1). Macrophages stimulated with LPS in 
the presence of SRBC:IgG showed a higher production compared to non-activated and 
LPS-activated macrophages, however the difference was not statistically significant. 
These cytokine profiles indicate stimulation with LPS in the presence of SRBC:IgG 
increases the production of IL-10, while reducing pro-inflammatory cytokines IL-12 and 
MCP-1, as well as having effects on IL-6 and possibly TNFα. MCP-1 reductions by type II 
activation have not been previously reported, nor have reductions in any other 
chemokines. As chemokines such as MCP-1 contribute to the pathogenesis of 
inflammatory illnesses, further investigation into the effects of type II activation on 
chemokines is warranted. 
In order to further validate the activation state induced upon stimulation with LPS in the 
presence of SRBC:IgG, the enzymatic profile of macrophages activated either with LPS or 
LPS + SRBC:IgG was assessed via western blotting. The levels of iNOS and sphingosine 
kinase 1 (SPHK1) enzymes were normalised to the expression of α tubulin, one of an 
array of house-keeping proteins. Figure 3.2 shows the normalised % of control for the 
expression of iNOS and SPHK1 in comparison to the levels seen in macrophages 
stimulated with LPS alone. Macrophages stimulated with LPS have high levels of iNOS 
indicating successful induction of classically activated macrophages (Figure 3.2), and as 
expected, macrophages stimulated with LPS + SRBC:IgG express similar iNOS levels as 
LPS alone (figure 3.2). Sphingosine kinase 1 (SPHK1), a marker for type II macrophage 
activation, is significantly up-regulated in macrophages stimulated by LPS in the presence 
of SRBC:IgG compared to stimulation with LPS alone, indicating the induction of type II 
macrophage activation. As with the cytokine profile, results from the western blot further 
support the notion that our system of activating macrophages with opsonised SRBC plus 
LPS induces type II macrophage activation. The ability of these type II activated 
macrophages to enhance anti-inflammatory cytokines (e.g. IL-10) while reducing its 
inflammatory counterparts (e.g. IL-12p40 and MCP-1), along with the enhanced 
expression of SPHK1 generates a viable means to assess type II macrophage activation 
for further studies within this project. Finally, this work is the first report of type II 
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macrophages reducing the expression of MCP-1, or any chemokine, therefore illustrating 
type II macrophages reduce a wider but selective range of inflammatory mediators than 
IL-12. 
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Figure 3.1 SRBC:IgG + LPS elicit different cytokine profiles by macrophages than LPS alone.  
Primary BMMØ (106 cells/ml) derived from C57BL/6 mice were primed with 20 U/ml IFNγ overnight 
followed by stimulation with un-opsonised SRBC (ratio of 10 SRBC: 1 MØ), opsonised SRBC 
44 
 
(SRBC:IgG), 200 ng/ml LPS alone, or LPS plus un-opsonised or opsonised SRBC. After 8 h 
culture, IL-10 (a), IL-12 (b), MCP-1 (c), IL-6 (d), TNFα (e) and IL-4 (f) production were measured 
via ELISA or a CBA assay (sec 2.4). *P<0.05: One way ANOVA followed with Bonferroni post test; 
Conditions versus LPS. Data points (a-c) represent mean +SEM of combined duplicate wells of two 
experiments. (D-F) represent data points of single wells, resulting in no error bars. (F) represents a 
single ELISA containing samples for the three conditions of Medium, LPS and SRBC:IgG+LPS. 
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Figure 3.2 Macrophages exposed to SRBC:IgG up-regulate SPHK1 and iNOS expression. Primary 
BMMØ (106 cells/ml) derived from C57BL/6 mice were primed with 20 U/ml  IFNγ overnight followed 
by stimulation with 200 ng/ml LPS (classical-inducing) or opsonised SRBC plus LPS (10 per MØ) 
(type II-inducing). After 9 h culture, expression levels of SPHK1, iNOS and αTubulin were assessed 
via western blotting (sec 2.6) with anti-SPHK1 pAb (1:700), anti-α Tubulin pAb (1:1000), and anti-
iNOS pAb (1:700). Band densities were normalised to the expression of α tubulin, and presented 
as a % control compared to LPS. * P<0.05: One way ANOVA followed with Bonferroni post test; 
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SRBC:IgG+LPS versus LPS. Data represents the mean+SEM of 2-3 experiments. Diagram (b) is a 
single membrane representative of the membranes assessed to derive graph (a). 
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3.2.2 Kinetics of cytokines and co-stimulatory markers altered by type II 
macrophage activation 
Previous studies identified that type II activated macrophages not only alter their cytokine 
profile, but also significantly change the expression of surface markers in response to 
inflammatory stimuli (Tierney et al., 2009). Other than the study by Tierney  et al, there 
has been only one other report of alterations in surface markers (Edwards et al., 2006). In 
order to gain an understanding of possible mechanisms involved during type II 
macrophage activation, this thesis investigated the kinetics of cytokine and surface marker 
alterations by assessing changes over a period of time after classical of type II 
macrophage stimulation. By understanding which alterations occur at which time, the aim 
was to identify mechanisms involved in determining the type II activated macrophage 
phenotype. 
Represented in this section (Figure 3.3-3.4) are the effects seen by the addition of various 
stimulants in the presence of LPS. Unless otherwise stated, the effects of SRBC or 
SRBC:IgG in the absence of LPS mimic that seen by the media controls. Figure 3.3 a-b 
show the changes in IL-10 and IL-12 concentration over time, while Figure 3.3 c-d show 
the same conditions represented as a % of control (LPS alone). Unless otherwise stated, 
there was very little difference in the response of macrophages to LPS stimulation in the 
presence of SRBC and stimulation with LPS alone. From 2-8 h, the production of IL-12 by 
classically activated macrophages steadily increased with high levels maintained 24 h 
post-stimulation. Production of this pro-inflammatory cytokine was significantly reduced by 
type II activation (SRBC:IgG+LPS) at 24 h post stimulation. Additionally, at 8 -24 h post 
stimulation, type II activated macrophages produced higher levels of IL-10 than LPS 
stimulation alone, and these levels peaked at 8 h post stimulation. Together these results 
indicate that the changes in cytokine production are apparent at all time points post 
stimulation and are not a result of an accelerated time course in the type II activated 
cultures. 
In addition to cytokine assessments, the expression of CD40, CD80, MHC II, and PDL-1 
was assessed at the different time points via flow cytometry (Figure 3.4). Data is 
presented as a % control (a-d) in comparison to classical activation (LPS), with the raw 
data in a2-c2 representing changes over time for all conditions. Exposure of macrophages 
to SRBC in the presence of LPS induced the same levels of expression of surface 
markers to that of LPS stimulation alone. Classically activated macrophages (LPS alone) 
had high levels of CD40 present on their surface, and as with IL-12, levels of CD40 
increased over time with the highest levels measured 30 h post-stimulation (Figure 3.4). 
By 8 h post stimulation, differences in CD40 expression were observed. Type II 
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macrophages (SRBC:IgG+LPS) had higher levels of CD40 than non-activated 
macrophages, which barely expressed CD40, but had significantly lower expression of 
CD40 compared to LPS stimulation. Moreover, the levels of CD40 on type II activated 
macrophages remained constant 8-24 h post stimulation, whereas by 30 h post 
stimulation, the levels of CD40 on type II macrophages began to increase towards the 
levels expressed on classical macrophages. In terms of CD80 expression, macrophages 
exposed to LPS or medium alone exhibited the same levels of expression. Type II 
macrophages (SRBC:IgG+LPS) had levels of CD80 significantly lower than levels seen on 
classically activated macrophages, and the levels on these macrophages remained nearly 
constant over time from 8-30 h with the greatest % reduction in comparison to LPS-
stimulation occurring at 24 h post-stimulation.  PDL-1 expression occurred much later than 
the expression of CD40 and CD80 on activated macrophages. By 24 h of culture, 
significant changes are observed with LPS-treated macrophages exhibiting increased 
expression of this surface marker. Type II activated macrophages showed reduced 
expression of PDL-1 at 24 and 30 h post stimulation with the most notable reduction in 
PDL-1 compared to LPS-stimulation occurring 24 h after stimulation.  
By 8 h after stimulation, up-regulation of MHC II (IAb) expression is observed on all 
macrophages treated with LPS. No real difference in the levels of MHC II on macrophages 
from the three different treatment groups were seen until 24 and 30 h post stimulation. 
Exposure to SRBC:IgG significantly reduced the expression of MHC II in response to LPS, 
most significantly at 24-30 h of culture. This data is representative of only one experiment 
for the 8-30 h post stimulation time points. Therefore, caution must be used in drawing 
conclusions. 
Observations from these kinetic analyses indicate alterations in cytokine production occur 
at an earlier time point than the alterations in expression of co-signalling markers. This 
finding may suggest a causal relationship whereby the increased IL-10 or reduced IL-12 
plays an important role in the alterations of CD80, CD40, and PDL-1 induced by type II 
macrophage activation. Understanding mechanisms involved in perpetuating the 
phenotype elicited by type II macrophage activation will expand our knowledge on 
mechanisms involved in the induction of anti-inflammatory responses.   
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Figure 3.3 Type II activation induces the most significant alteration in the IL-10/IL-12 ratio at 8 h 
post stimulation. Macrophages derived from C57BL/6 mice were primed overnight with 20 U/ml 
IFNγ and stimulated with 200 ng/ml LPS alone (classical-inducing stimuli) or LPS in the presence of 
SRBC or opsonised SRBC (type II-inducing stimuli). Cells were also left non-stimulated in media. 
After 2, 4, 8, and 24 h culture, IL-12 (a,c) and IL-10 (b,d) were assessed via ELISA. (c-d) represent 
the compilation of data, presented as % compared to LPS (classical activation). *P<0.05 **P<0.01 
***P<0.001: Two way ANOVA with Bonferoni post test; SRBC:IgG+LPS  versus LPS. Data points 
represent the mean+SEM of two experiments (c-d), or duplicate wells from one experiment (a-b). 
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Figure 3.4 Type II activation induces the most significant alterations in surface marker expression 
at 24 h post stimulation. Macrophages derived from C57BL/6 mice were treated as described in 
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Figure 3.3. After 2, 4, 8, 24, and 30 h culture, CD40 (a), CD80 (b), PDL-1 (c) and MHC II (d) were 
assessed via flow cytometry. * P<0.05, **P<0.01, ***P<0.001: Two way ANOVA with Bonferroni 
post test; SRBC:IgG+LPS versus LPS. Data points represent the mean +SEM of two experiments, 
but in some instances (d) data points represent a single experiment. 
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3.2.3 Involvement of IL-10 in the type II macrophage profile 
The kinetic analysis (sec 3.2.2) revealed that type II activation results in significant 
increases in IL-10 and reductions in IL-12 prior to reductions seen in the expression of co-
signalling molecules. Previous literature emphasizes the suppressive effects of IL-10 on 
inflammatory cytokines/chemokines such as TNFα, IL-12 and MCP-1 (de Waal Malefyt et 
al., 1991), with reports of IL-10 also reducing the expression of CD40 in response to LPS 
(Qin et al., 2006). To investigate possible mechanisms involved in determining phenotypic 
characteristics of type II activated macrophages, the role of the increase in IL-10 elicited 
by type II activation was investigated in order to elucidate whether it is responsible for 
some of the observed characteristics.  
Classical and type II activated macrophages were cultured in the presence of either  5 
ng/ml recombinant IL-10 to enhance IL-10 levels, or 2 µg/ml anti-IL-10 antibody (ab)  to 
block IL-10. Cytokine and cell surface markers were assessed 8 and 24 h post 
stimulation.  Upon the addition of anti-IL-10 ab (Figure 3.5), no IL-10 was detected in any 
of the cultures indicating IL-10 has been successfully inhibited. Looking at IL-12 
production, it can be seen that the inhibition of IL-10 led to an increase in IL-12 production 
by both classically and type II activated macrophages. In contrast, the addition of rIL-10 to 
cultures led to an almost complete inhibition of IL-12 production with only very low levels 
of IL-12 detected in cultures with classical and type II macrophages. Importantly, the 
absence of IL-10 did not impair the ability of type II activated macrophages to reduce IL-
12 in comparison to classically activated macrophages. 
MCP-1 and IL-6 production were also assessed in response to IL-10 inhibition with anti-IL-
10 ab, although not in response to the addition of IL-10. In the absence of IL-10, type II 
activation maintained reduced MCP-1. However the % reduction was not as significant as 
seen under normal conditions. Both classically and type II activated macrophages 
increased MCP-1 production in the absence of IL-10, indicating IL-10 may cause  some 
suppression of MCP-1 either directly or through the alterations of other important 
cytokines. While IL-6 was only assessed for one experiment, it appeared that IL-6 
production was unaffected by the blockage of IL-10. 
We wished to assess whether the increased IL-10 by type II activation was essential for 
the observed reductions in CD40 and CD80 expression. Contrary to expectations, the 
blockage of IL-10 had very little effect on CD40 or CD80 expression by both classically 
and type II activated macrophages. Moreover, the addition of rIL-10 to cultures also had 
no effect on the expression of these co-stimulatory markers with classical and type II 
macrophages exhibiting the same response seen under normal circumstances. As a 
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whole, these data indicate that IL-10 alone does not play an essential role in regulating 
the cytokine and co-stimulatory marker profile elicited by type II activation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
 
 
 
         
a 
e 
b 
d c 
f 
NS 
NS 
NS 
*
*
**
*
**
*
Figure 3.5 IL-10 inhibition does not alter the phenotype of type II activated macrophages. Bone 
marrow derived macrophages derived from C57BL/6 mice were exposed to classical and type II-
inducing stimuli (Figure 3.3), with the addition of anti-IL-10 antibody (2 µg/ml) or recombinant IL-10 
(5 ng/ml), or rat IgG as an isotype control (5 ng/ml). After 8 h culture IL-10 (a), IL-12 (b), MCP-1 (c) 
and IL-6 (d) were assessed via ELISA. *P<0.05 **P<0.01: Two way ANOVA with Bonferroni post 
test; Effects of  classical versus type II activation under Normal conditions or IL-10 blockage. Data 
points (a-d) represent mean +SEM from duplicate wells. Data points in (d) represent single wells. 
After 24 h culture CD40 (e) and CD80 (f) were assessed via flow cytometry. Data points represent 
a single experiment. 
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3.2.4 Involvement of CD40 signalling in changes to the type II macrophage 
profile 
CD40 ligation induces the up-regulation of inflammatory cytokines such as IL-6 and IL-12, 
as well as co-stimulatory markers including CD80 (Alderson et al., 1993; Caux et al., 
1994a). Studies have shown low levels of CD40 signaling induce IL-10 and inhibit IL-12 
production, while strong signaling does the opposite in altering the cytokine environment 
to drive pro-inflammatory responses (Mathur et al., 2004).  Our studies have shown that 
type II activated macrophages elicit an anti-inflammatory profile with significantly lower 
expression of CD40 compared to classically activated macrophages. Thus, we wished to 
determine the effect of the reduced CD40 expression on the anti-inflammatory profile by 
looking particularly at whether low levels of CD40 signalling were involved in perpetuating 
the anti-inflammatory phenotype of type II macrophages. 
An agonistic anti-CD40 antibody (8 µg/ml) was added to cultures of classical and type II 
activated macrophages, and IL-12 and IL-10 levels were assessed 8 and 24 h following 
primary stimulation. Figure 3.6 illustrates the effects of additional CD40 stimulation on the 
expression of IL-12 and IL-10. IL-12 production by both classical and type II activated 
macrophages increased slightly upon additional CD40 stimulation. Addition of the isotype 
control had no effect on IL-12 or IL-10 production, indicating the effects were not due to 
non-specific binding. Although CD40 stimulation enhanced IL-12 production, the levels 
produced by type II activated macrophages in comparison to classical macrophages was 
still significantly reduced. Furthermore, IL-10 production by type II activation remained 
higher than levels produced by classical activation, both under normal circumstances and 
with the addition of the CD40 stimulatory antibody suggesting that the stimulation through 
CD40 did not shift the activation state of the macrophage from type II to classical or vice 
versa.  
To identify the effects of altered CD40 signalling on the expression of co-signalling 
markers, CD80, MHC II and CD40 levels were assessed via flow cytometry. The 
expression of CD80 on type II activated macrophages remained unaltered by the addition 
of the stimulatory CD40 antibody, as did MHC II expression (Figure 3.6). CD40 expression 
on classical and type II activated macrophages was significantly reduced after the addition 
of stimulatory CD40 antibody. However, this reduction was most likely due to the agonistic 
stimulatory antibody preventing binding of the fluorescently labelled CD40 antibody used 
for flow cytometry. Irrespective of this, it can be seen that the levels of CD40 on type II 
activated macrophages remain lower than levels on classical macrophages, indicating 
enhanced CD40 signalling did not ablate the ability of type II activation to reduce this 
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expression. However, because the data presented in Figure 3.6 is from one experiment, 
careful considerations must be made in drawing strong conclusions before confirmation of 
the findings. Together, these experiments indicate that CD40 signalling in type II activated 
macrophages has very little effect on the anti-inflammatory profile, despite the lower levels 
of CD40 expression. This suggests the macrophage phenotype occurs via a different 
pathway other than through altered CD40 signalling in the macrophage. This conclusion 
does not however exclude the possible role of reduced CD40 expression and thus 
signalling, through CD40L on T cells in response to type II activated macrophages, and 
requires further investigation. 
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Figure 3.6 CD40 stimulation does not alter the phenotype of type II activated macrophages. 
Macrophages derived from C57BL/6 mice were exposed to classical and type II-inducing stimuli 
(Figure 3.3), with the addition of 8 µg/ml stimulatory rat-anti-mouse CD40 antibody (3/23) and 8 
µg/ml IgG isotype control. After 8 h culture, IL-12 (a) and IL-10 (b) levels were accessed via ELISA. 
*P<0.001: Two way ANOVA with Bonferroni post test; Type II versus classical before and after 
CD40 stimulation. Bars represent duplicates from one experiment. After 24 h culture, CD80 (c), 
MHC II (d) and CD40 (e) were assessed via flow cytometry. Bars represent one experiment. 
57 
 
3.3 Discussion 
Type II activation deviates immune responses in a manner which significantly prevents the 
onset of inflammatory diseases (Gerber et al., 2001; Tierney et al., 2009). The 
mechanisms involved in type II activation are currently unknown, and full characterisation 
of the type II macrophage phenotype has yet to be elucidated. Therefore, this thesis 
investigated the effects of type II activation on a broader range of characteristics including 
cytokines, chemokines and surface markers. Until 2006, many researchers relied heavily 
on the IL-10/IL-12 ratio, and the Th2 biasing effect to identify type II activation (Anderson 
et al., 2002; Lucas et al., 2005; Sutterwala et al., 1997). Although there has been the 
identification of additional biochemical markers including enzymes and surface markers, 
the characterisation of this activation state is still limited. Therefore this thesis investigates 
the effects of type II activation on an array of markers to add to our existing repertoire of 
cytokines and surface markers altered by type II activation, while utilizing enzymatic 
profiling for further validation of this activation state. 
In order to verify that our system induced type II macrophage activation, both the cytokine 
and enzymatic profile of primary macrophages stimulated classically with LPS was 
compared to those stimulated with opsonised SRBC in the presence of LPS. Classically 
activated macrophages stimulated with LPS, induced high production of IL-12, IL-6 and 
MCP-1 with little IL-10, in accordance with previous studies (Mantovani et al., 2004; 
Mosser et al., 2008). A more anti-inflammatory cytokine profile was elicited by exposure to 
LPS in the presence of opsonised SRBC.  As seen previously seen by Gerber et al and 
Lucas et al, FcγR ligation via immune complexes in the presence of LPS suppressed the 
production of the pro-inflammatory cytokine IL-12, in parallel to increased production of 
the anti-inflammatory cytokine IL-10. The increase in IL-10 was specific to the ligation of 
FcγRs in the presence of TLR signalling via LPS, as no significant IL-10 production is 
seen in the presence of FcγR ligation alone (opsonised SRBC without LPS). These results 
support previous observations (Lucas et al., 2005; Zhang et al., 2006), which 
demonstrated the requirement for the two signals for IL-10 up-regulation.  
We also investigated the effect of FcγR ligation on the response of macrophages to the 
production of other cytokines/mediators. We found that as with IL-12p40, FcγR ligation 
reduced the production of MCP-1 and IL-6 in response to LPS. The effect of type II 
activation on chemokine production has not been previously reported, however the effects 
seen on IL-6 somewhat contradict previous literature (Gerber et al., 2001; Grazia 
Cappiello et al., 2001). Capiello et al reported the reduction in pro-inflammatory cytokines 
was specific to IL-12, and not IL-6, TNFα, or IL-1β. However this conclusion came from 
the expression of IL-6 mRNA, not IL-6 protein secretion which we show here. It is possible 
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that although IL-6 mRNA is unaffected (Grazia Cappiello et al., 2001), repressive effects 
may be occurring at the post transcriptional stages leading to reduced IL-6 secretion in 
response to type II activation.  Additional work is required to verify whether this hypothesis 
is correct. 
Th2 responses are associated with protection against EAE, through the counter-regulation 
of inflammatory immune responses (Cua et al., 1995; Kennedy et al., 1992; Shaw et al., 
1997). Although type II activation increases the production of the prototypic Th2 cytokine 
IL-4 by CD4  T cells (Anderson et al., 2002; Tierney et al., 2009), it was unknown whether 
macrophages themselves were a contributor to Th2 development through macrophage-
derived IL-4 production. IL-4 has often been regarded as a T cell-derived cytokine with 
important roles in B cell proliferation/antibody production, as well as the commitment of T 
cells towards a Th2 subset via STAT-6 signalling (Kaplan et al., 1996; Le Gros et al., 
1990). Until recently, it was not believed that macrophages could be a major source of IL-
4. However, IL-4 production in alveolar macrophages and macrophage cell lines have 
been reported (Buttner et al., 1997; Mukherjee et al., 2009; Pouliot et al., 2009), leaving 
open the question of whether type II macrophages can produce IL-4. Macrophages 
treated with LPS plus opsonised SRBC produced levels of IL-4 slightly greater than that of 
LPS treated macrophages; however, this increase did not reach significance suggesting 
that in this system, IL-4 is not produced to any great extent. Previous literature has 
reported the production of IL-4 by lung resident macrophages (Buttner et al., 1997), in the 
course of fibrosis induced by irradiation. However it was not fully understood how this 
occurred and what the implications were. Other than IL-4 production by alveolar 
macrophages and the RAW264.7 cell line, no other literature to date has fully examined 
the ability of macrophages to produce IL-4. Therefore, the appearance of IL-4 production, 
albeit at a low level, by the macrophages stimulated with LPS plus opsonised SRBC, 
indicates the possibility of type II macrophages producing IL-4. As IL-4 is largely involved 
in Th2 responses and protection against EAE (Le Gros et al., 1990; Shaw et al., 1997), 
further investigations into the effects of type II macrophages in IL-4 production and IL-4 
responsiveness is warranted, especially with regards to IL-10 production which has been 
shown to up-regulate IL-4 receptor expression (Lang et al., 2002; Rückerl et al., 2006), as 
type II macrophages are very strong inducers of IL-10. 
MCP-1 (monocyte chemotactic protein-1) is a chemokine involved in the chemotaxis of 
inflammatory cells such as monocytes, macrophages, and lymphocytes, and exacerbates 
inflammatory responses which are detrimental in the context of allograft rejection or EAE 
(Huang et al., 2001a; Lee et al., 2003; O'Shea et al., 2008). IL-6 is a pro-inflammatory 
cytokine which, when in the presence of TGFβ, promotes the development of Th17 cells 
which are highly pathogenic during EAE (Langrish et al., 2005; Perona-Wright et al., 2009; 
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Serada et al., 2008). High levels of IL-6, IL-12, and MCP-1 are associated with the peak of 
disease during EAE or MS (Maimone et al., 1997; McManus et al., 1998). Importantly, 
mice lacking MCP-1 are protected against EAE, associated with a lack of macrophage 
recruitment to the CNS, required for the induction of inflammatory Th1 responses (Huang 
et al., 2001a). Furthermore, inhibition of IL-6 protected mice against EAE through 
inhibition of Th17 development (Okuda et al., 1998; Serada et al., 2008). IL-12p40, 
through either IL-12p70 (IL-12p40/p35) or IL-23 (IL-12p40/p19) (Oppmann et al., 2000), 
also contributes to disease, through its induction of pathogenic Th1 or Th17 cells 
respectively (Becher et al., 2002; Cua et al., 2003). Reductions in IL-12-producing 
macrophages in the CNS and inhibition of IL-23 protect mice from developing EAE (Cua 
et al., 2003; Sewell et al., 2003). Therefore, the reduction in these pro-inflammatory 
mediators (IL-12p40, IL-6 and MCP-1), may be a mechanism which contributes to the 
protection type II activated macrophages elicit against inflammatory illnesses (Gerber et 
al., 2001; Tierney et al., 2009). Understanding mechanisms involved in perpetuating anti-
inflammatory responses by type II activated macrophages is therefore key to better 
understanding how to treat MS. 
Edwards et al (2006) identified the differential expression of the enzyme sphingosine 
kinase 1 (SPHK1), specifically up-regulated in type II activated macrophages. We 
therefore underwent enzymatic profiling, comparing the effects of LPS to that of opsonised 
SRBC plus LPS on the production of iNOS and SPHK1. Figure 3.2 demonstrated the high 
expression of SPHK1 in cells stimulated with opsonised SRBC in the presence of LPS in 
comparison to LPS alone. Furthermore, iNOS was produced by macrophages in response 
to LPS, as well as LPS + opsonised SRBC, with similar levels of expression. These 
enzymatic profiles correlate to the enzymatic profile of type II activation, previously 
reported (Edwards et al., 2006). Therefore both the cytokine profile and enzymatic profile 
from our experiments correlate with previous studies, validating the successful induction 
of type II macrophage activation. How these enzymes contribute to the effector functions 
of type II macrophages is not yet known, but given the unique profile, further work is 
merited. 
Although it was observed that type II activation significantly alters the cytokine profile 
away from inflammatory responses, it was unknown which processes contributed to the 
anti-inflammatory phenotype. To address this, changes in cytokine and surface marker 
expression on type II activated macrophages were assessed over a period of time after 
stimulation. As IL-10 and IL-12 production show the most distinctive alterations in 
response to type II activation, kinetic analyses were carried out on these two cytokines in 
order to identify which time point the most notable changes occurred. Over a period of 
time from 2-24 h, type II activation maintains reduced levels of IL-12 compared to classical 
60 
 
macrophages, with no significant changes in the % difference over time. However, there is 
a significant difference in the % increase in IL-10 over time. Type II activated 
macrophages exhibit the most significant increase in IL-10 at 8 h post-stimulation, 
illustrating the optimal time point of 8 h for assessing the immune-modulating effects of 
type II activation on cytokine production.  
In addition to cytokines, co-signalling molecules are also important for regulating the type 
of immune response which follows (Lenschow et al., 1996). The effects of type II 
macrophage activation on the expression of co-signalling markers CD40, CD80, PDL-1 
and MHC II was assessed via flow cytometry. As with IL-12, expression of these surface 
markers are up-regulated on macrophages stimulated classically with LPS and IFNγ 
(Edwards et al., 2006; Qin et al., 2006; Tierney et al., 2009). In correlation with these 
observations, data presented in this thesis also show classically activated macrophages 
up-regulate these surface markers. Compared to the media controls, the increased 
expression of MHC II on LPS-stimulated macrophages correlates with observations by 
Edwards et al (2006). Levels of MHC II are up-regulated on antigen presenting cells such 
as macrophages in response to the prototypic cytokine IFNγ, and are an indicator of the 
ability of macrophages to induce CD4 T cell responses (Edwards et al., 2006; O'Keefe et 
al., 2001). At the 8 h time point, there is very little difference seen in the levels on type II 
activated macrophages compared to classical macrophages, as also demonstrated by 
Tierney et al (2009). However, this effect changes with time, as type II activation elicits 
reductions in MHC II in response to LPS at 24-30 h. These results contrast previous 
studies, which indicated MHC II levels for type II activated macrophages increased 24 h 
post stimulation (Edwards et al., 2006). This difference may be due to slight differences in 
the experimental setting under which type II activation was induced, leading to differences 
in the timing of certain responses. Also, as this data on MHC II is from a single 
experiment, repeats are required to confirm this observation. Aberrant MHC II expression 
is associated with the induction of autoimmunities  such as MS, where certain MHC II 
haplotypes are associated with increased risk of developing multiple sclerosis (MS) 
(Dyment et al., 2005). High levels of MHC II are expressed in the CNS during 
inflammatory disorders such as EAE, and Alzheimer’s, implicating their role in 
inflammatory immune responses (Baranzini et al., 2000; Perlmutter et al., 1992). In mice 
immunized to exhibit EAE, a deficiency in the transactivator of MHC II expression, which 
is involved in regulating the expression of inducible MHC II genes, resulted in protection 
from disease (Stuve et al., 2002). This demonstrates the possible benefits of type II 
macrophages reducing their expression of MHC II in the context of preventing 
inflammation. 
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The expression of a co-stimulatory molecule CD80 was also assessed. CD80 is an 
important co-stimulatory molecule involved in T cell responses. Through the binding of 
CD80 to CD28 or CTLA-4 on T cells, CD80 is able to promote or inhibit the activation of 
CD4 T cells in collaboration with MHC II (Alegre et al., 2001). Corresponding with previous 
observations by Tierney et al (2009), no significant difference in the expression of CD80 in 
media-treated or LPS-treated macrophages was seen 2, 4, 8, 24 and 30 h after 
stimulation. Again correlating with Tierney et al, type II activated macrophages exhibited a 
significant reduction in the expression of CD80. This reduction in CD80 expression could 
be observed not only at 8 h post stimulation (Tierney et al., 2009), but also at 2, 4, 24 and 
30 h post stimulation. The most significant reduction in CD80 expression was observed 24 
h after stimulation. CD80, as with CD40, is an important co-stimulatory molecule which 
binds to CD28 on T cells, and aids in determining the outcome of the macrophage-T cell 
interaction. CD80 and CD40 both play synergistic roles in the induction of pro-
inflammatory responses, as demonstrated in a cecal ligation by puncture (CLP) model of 
polymicrobial sepsis where mice deficient in CD80 exhibited a reduced rate of mortality, 
accompanied by reduced pro-inflammatory cytokines (Nolan et al., 2009). On the other 
hand, wild type mice with CLP had high levels of CD80 accompanied by increased 
mortality. In patients with MS, increased levels of CD80 are seen at lesion sites 
(Windhagen et al., 1995), and in EAE, high levels of CD80 have been correlated with 
disease progression (Karandikar et al., 1998). The fact that the levels of CD80 and MHC II 
expression on type II activated macrophages are below that seen on classical 
macrophages indicates type II activation may be impairing the ability to drive T cell 
responses, and present antigen to T cells. This could be beneficial in the context of 
autoimmunities whereby a reduction in the activation of autoreactive T cells can prevent 
progression of disease.  
PD-1 is a molecule present on T cells, which has a role in limiting T cell responses and 
maintaining peripheral tolerance (Nishimura et al., 1999). PDL-1 is a ligand for PD-1, 
which is constitutively expressed on a variety of cells including macrophages, and is up-
regulated in response to inflammatory stimuli (Freeman et al., 2000; Yamazaki et al., 
2002). We investigated PDL-1 expression on type II and classically activated 
macrophages. Previous experiments (Tierney et al., 2009) looking at an 8 h time point 
have demonstrated a significant reduction in PDL-1 by type II activation in comparison to 
classically activated macrophages. Correlating with Tierney et al, at 8 h post stimulation a 
reduction in PDL-1 on type II activated macrophages can be seen in comparison to 
classical activation. However, this reduction is minimal in comparison to the significant 
decrease exhibited 24 or 30 h post stimulation. This emphasizes the importance of looking 
at multiple time points when assessing the effects of type II activation on surface marker 
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expression. PD-1, to which PDL-1 binds to, is associated with inhibition of T cell 
responses through the inhibition of proliferation and cytokine production (Freeman et al., 
2000; Latchman et al., 2001), and has been associated with the induction of peripheral 
tolerance where its absence has lead to the development of autoimmunites such as 
arthritis, lupus and cardiomyopathy (Nishimura et al., 1999; Nishimura et al., 2001). Due 
to the role of PD-1 ligation in inhibiting T cell proliferation, it was previously presumed type 
II activated macrophages which have reduced levels of the ligand for PD-1, would support 
T cell proliferation. However, in addition to inhibition of T cell proliferation, other effects  of 
the PD-1 ligands have been noted, where their involvement in enhancing, rather than 
inhibiting T cell responses has been observed (Tseng et al., 2001; Wang et al., 2003). 
Furthermore PDL-1 and PDL-2 have shown differential responses to Th1/Th2 cytokines 
(Loke et al., 2003). Therefore it is possible that the reduction in PDL-1 plays a role in 
inhibiting or promoting Th1/Th2 biasing. If PDL-1 was associated with Th1 biasing, as has 
been previously suggested as a possibility (Loke et al., 2003), a reduction in PDL-1 by 
type II activation may be beneficial during inflammatory disease. Studies are currently 
underway to try and further understand the complexity of the PDL-1/PD-1 interaction and 
their different functions. 
CD40 is an important co-signalling molecule involved in the activation of Th1 cells 
(Campbell et al., 1996; Kelsall et al., 1996). At 24-30 h where CD40 is most highly 
expressed in response to LPS (Figure 3.4), type II activated macrophages exhibited the 
most significant reduction in the expression of this co-stimulatory molecule. The 
observation corresponds to that previously reported at an 8 h time point (Tierney et al., 
2009). The level of CD40 on type II activated macrophages is above that seen on non-
activated macrophages, but significantly lower than levels on classically activated 
macrophages. CD40 is an essential co-stimulatory molecule for the induction of Ag-
specific T cell responses (Grewal et al., 1998). Although CD40 is associated with cell-
mediated inflammatory responses (Stout et al., 1996), studies have also shown in the 
absence of this co-stimulatory molecule, Th2 development is impaired (MacDonald et al., 
2002b), illustrating the dual role of CD40 in promoting both Th1 and Th2 counter 
regulatory responses. CD40 ligation has also been attributed to increased production of 
inflammatory mediators and surface molecules such as CD80, which aids Th1 responses 
(Alderson et al., 1993; Caux et al., 1994b). Furthermore, CD40 promotes the development 
of pathogenic Th17 cells through the production of IL-6 (Perona-Wright et al., 2009). A 
reduction in CD40 on type II activated macrophages may therefore promote the 
suppression of inflammatory mediators, thus reducing inflammatory disease. Some 
studies have also shown the ability of CD40 to promote anti-inflammatory or pro-
inflammatory responses depending on their level of signalling (Mathur et al., 2004; 
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Murugaiyan et al., 2006). Therefore the particular low level of CD40 expressed on type II 
activated macrophages may be instrumental in preventing the development of 
inflammatory responses by Th1 and Th17 cells, while promoting anti-inflammatory Th2 
responses, to provide protection against EAE. The role of CD40 requires further 
investigation, as does the contribution of the increased IL-10 by type II activation. 
We investigated whether the increase in IL-10 is essential for the type II activation 
phenotype, which consists of a reduction in  CD40 ,CD80, PDL-1 as well as decreased IL-
12 and MCP-1. Our finding that rIL-10 addition significantly decreases IL-12 production 
correlates with previous studies demonstrating a direct suppressive effect of IL-10 on IL-
12 (Schottelius et al., 1999). IL-12 production from cells including monocytes (de Waal 
Malefyt et al., 1991), the RAW264.7 cell line (Rahim et al., 2005), as well as primary 
macrophages (Anderson et al., 2002), are inhibited by IL-10. More importantly, in 
agreement with previous studies (Anderson et al., 2002), the reduction in IL-12 production 
observed with type II activation was in no way affected by the blockage of IL-10. The 
ability of type II activated macrophages to reduce the production of MCP-1 and IL-6 was 
also largely unaffected by the absence of IL-10, again implicating an independent 
mechanism involved in the reduction of inflammatory cytokines by type II activation. The 
mechanism whereby additional IL-10 is able to inhibit IL-12, yet IL-10 is not required for 
the inhibition of IL-12, IL-6 or MCP-1 by type II activation, is yet to be understood. 
The role of IL-10 on alterations in surface markers by type II activation was also assessed. 
Previous literature reported a reduction in CD40 on macrophage cell lines in response to 
LPS plus IL-10 (Qin et al., 2006). However, this investigation found, as with the cytokine 
profile, reductions in the expression of co-stimulatory markers CD40 and CD80 was not 
dependant on IL-10, although the data on the expression of these surface markers is only 
from one experiment and must be interpreted with caution. However, these preliminary 
results are a good indicator that even though IL-10 and IL-12 alterations occur prior to 
changes in surface marker expression, these alterations do not solely direct reductions in 
the expression of surface markers and other pro-inflammatory cytokines. This indicates 
type II activation reduces inflammatory cytokines/surface markers through an alternative 
mechanism other than IL-10.  It is necessary to identify these mechanisms, which may in 
fact be occurring in synergy with IL-10. Once these essential mechanisms are identified, it 
may be possible to enhance the ability of macrophages to promote anti-inflammatory 
responses.  
Due to the dual role of CD40 previously mentioned (Mathur et al., 2004), we wished to 
investigate if CD40 stimulation was involved in the other phenotypic properties of type II 
activated macrophages. We hypothesized that this reduction in CD40 by type II activation 
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causes a reduced level of signaling such that low levels induce the production of anti-
inflammatory cytokines and suppress pro-inflammatory responses. Previous studies have 
demonstrated low level signaling up-regulates IL-10 in comparison to high level signaling 
which promotes IL-12 production by DCs (Murugaiyan et al., 2006). To my knowledge, the 
dual role of CD40 signaling in primary macrophages from C57BL/6 mice has not been 
investigated. This investigation utilized an agonistic stimulatory antibody for CD40, in 
order to enhance signaling on type II activated macrophages. The theory being, that if the 
reduction in CD40 occurred with the goal to reduce signaling and elicit anti-inflammatory 
characteristics, by increasing CD40 signaling, the anti-inflammatory effect of type II 
activation will be impaired.   
High levels of CD40 stimulation had no effect on the ability of type II activated 
macrophages to reduce the production of IL-12 and increase IL-10 in comparison to 
classically activated macrophages. These observations conflict those seen by Mathur et al 
(2004). Mathur et al demonstrated low levels of CD40 signalling with 2-4 µg/ml of anti-
CD40 ab increased IL-10 in BALB/c derived peritoneal macrophages. We observed that at 
high levels of CD40 signalling, type II activated macrophages maintained higher levels of 
IL-10 and reduced IL-12 in comparison to classical macrophages. This indicates the 
increased production of IL-10 and reduced IL-12 occurred independently of any reductions 
in CD40 signalling by type II activation. 
Previous studies have demonstrated enhanced expression of surface markers in 
response to CD40 signalling (Alderson et al., 1993). Data presented in this thesis 
demonstrates enhanced CD40 stimulation has no effect on the expression of CD80 or 
MHC II by both classically activated and type II activated macrophages. Furthermore, type 
II activated macrophages maintained reduced CD40 levels compared to classical 
macrophages, as seen under normal stimulation conditions. The significant reduction in 
CD40 detected by both macrophage subsets is most likely due to the CD40 stimulatory 
antibody remaining bound to CD40 present on macrophages. This preliminary data 
indicates low levels of CD40 signalling is not essential for the type II macrophage 
phenotype, as indicated by the effects of enhanced CD40 signalling. These observations 
correlate to the previously described lack of effect of IL-10 alterations on the phenotype 
induced by type II activation. However, one explanation for differences between Mathur et 
al and this data may be that the responses by bone marrow-derived C57BL/6 
macrophages and peritoneal BALB/c macrophages differ in the specific levels of CD40 
which define low level and high level signalling. This possibility requires further 
investigation. 
65 
 
Although this thesis identified increased CD40 signalling did not impair the ability of type II 
activation to elicit an anti-inflammatory phenotype, identifying the effect of reducing CD40 
expression or signalling on classical macrophages would provide more information on the 
importance of CD40 expression levels. This investigation identified additional effects of 
type II activation on cytokine/chemokine and surface marker expression in addition to 
illustrating that the anti-inflammatory profile occurs independently of IL-10. These findings 
expand our current knowledge of the type II activation state, and further emphasise the 
importance of understanding the mechanisms involved in promoting the phenotypic 
properties elicited by type II activation, as many of the characteristics are indicative of 
eliciting beneficial effects against inflammatory disease. 
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Chapter 4: Elucidating the effects of type II 
macrophages on T cell responses 
4.1 Introduction 
T cell differentiation into Th1, Th2, or other subsets is largely determined by the cytokine 
environment under which the T cells are stimulated. Antigen presenting cells such as 
macrophages and dendritic cells which produce a variety of cytokines in response to 
different micro-environments play a major role in determining the outcome of T cell 
differentiation (Stein et al., 1992; Stout et al., 2004). Once differentiated, the subset 
functions are characterised by the cytokines the T cells subsequently produce (Abbas et 
al., 1996; Wan et al., 2009). Th1 cells produce IFNγ and support cell-mediated responses 
whereas Th2 cells can be characterised by their production of regulatory cytokines such 
as IL-13, IL-5, and IL-4 (Abbas et al., 1996; Wan et al., 2009). Strong promoters of Th1 
development are IL-12, and Th2 development IL-4 and IL-2 (Cote-Sierra et al., 2004; Le 
Gros et al., 1990; Liao et al., 2008). In addition to cytokines in the environment, direct 
interaction between T cells and APCs through MHC:TCR and co-stimulatory molecules is 
essential in the development of different T cell subsets. Of particular interest is the co-
stimulatory molecule CD40 ligand (CD40L) present on T cells and its’ receptor CD40 on 
APCs (Grewal et al., 1998).  
CD40 signalling exhibits dual roles. It has a well documented role in promoting cell 
mediated immunity and driving pro-inflammatory responses which are essential for the 
clearance of intracellular pathogens and anti-tumour responses (Campbell et al., 1996; 
DeKruyff et al., 1997; Florido et al., 2004; Stout et al., 1996). It has also been reported as 
an essential mechanism of Th2 development (MacDonald et al., 2002b). Benefits of 
blocking the Th1-promoting effects of CD40L signalling have been demonstrated in animal 
models of EAE (Girvin et al., 2000; Howard et al., 1999), yet in terms of Th2 development, 
the exact effects of CD40 signalling between T cells and macrophages is less well 
understood.  In the absence of CD40 or CD40L as seen in knockout mice, Th2 responses 
are inhibited (MacDonald et al., 2002a). Furthermore, studies have found that CD40 
inhibition in vivo by administration of anti-CD40L antibodies, polarises immune responses 
from a Th1 dominant one into a Th2 biased response (Hancock et al., 1996). This dual 
role of CD40 may lie in the length (Lee et al., 2002), or strength of signal, where strong 
CD40 signalling induces Th1 dominant responses which are useful for inducing anti-
tumour responses (Schoenberger et al., 1998), whereas  low level signalling increases the 
production of regulatory cytokines such as IL-10 by APCs, which promote Th2 and anti-
inflammatory responses (Mathur et al., 2004; Murugaiyan et al., 2006). Much still remains 
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to be investigated in order to understand the exact mechanisms which determine the 
ability of CD40/CD40L interactions to drive counter-regulating Th1/Th2 immune 
responses.  
Type II activated macrophages are capable of biasing T cell responses towards the 
development of Th2 cells (Anderson et al., 2002; Gerber et al., 2001), and mechanisms 
involved in this biasing need elucidation. The role of CD40 in the context of type II 
activation is unknown; however, recent studies have shown that type II activation reduces 
CD40 as well as PDL-1 expression on macrophages (Tierney et al., 2009). The ability of 
type II activated macrophages to alter adaptive immune responses has beneficial 
consequences in the protection from inflammatory illnesses such as endotoxemia (Gerber 
et al., 2001) and EAE (Tierney et al., 2009), and the type of interaction which occurs 
between T cells and macrophages can determine whether a protective Th2 response 
occurs (Cua et al., 1995), or pathology-inducing Th1/Th17 response ensues (Becher et 
al., 2002; Langrish et al., 2005).Therefore, it is important to understand the different 
mechanisms involved in regulating the outcome of T cell subset differentiation.  
This thesis investigates the mechanisms involved in Th2 biasing by type II activated 
macrophages with the long term goal of understanding mechanisms that may lead to 
protection against pro-inflammatory diseases. 
Aims: 
The ability of type II activated macrophages to induce Th2 cell biasing has previously 
been reported (Anderson et al., 2002; Gerber et al., 2001), and has been shown to 
promote protection from EAE (Tierney et al., 2009). However, the mechanisms by which 
type II activated macrophages drive such responses are still unclear. Both Th1 and Th2 
responses have demonstrated a dependency of CD40/CD40L signalling (Campbell et al., 
1996; MacDonald et al., 2002a). Other studies demonstrate enhanced Th2 development 
by CD40L inhibition (Hancock et al., 1996). These contradictory observations may be due 
to differences in the level of CD40 inhibition, whereby a particular low level of inhibition 
elicits Th2 polarisation, which is otherwise inhibited in the complete absence of CD40L. 
This idea is supported by studies that show different levels of CD40 signalling on dendritic 
cells and macrophage cell lines, promote counter-regulatory Th1/Th2 responses both in 
vitro and in vivo (Mathur et al., 2004; Murugaiyan et al., 2006). 
As discussed in chapter 3, type II activated macrophages exhibit significant reductions in 
the expression of CD40 and PDL-1, while still being a potent inducer of Th2 responses 
(Anderson et al., 2002). The goal of this thesis was to investigate mechanisms involved in 
T cell biasing by type II activated macrophages. To further understand mechanisms 
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involved in promoting Th2 development, we examined how altering the level of signalling 
between CD40 and CD40L influences Th (T helper) cell subset differentiation. In 
particular, we addressed three specific aims: 
1. To compare the effects of type II activation and classical activation on T cell 
proliferation and activation, given the reduced expression of PDL-1 on type II 
macrophages.  
2. To determine if low levels of CD40 signalling promote the generation of Th2 cells. 
3. To investigate whether Th2 cell biasing can be enhanced by reducing the 
CD40/CD40L interaction. 
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4.2 Results 
4.2.1 Effects type II activation has on CD4 T cell proliferation 
In Chapter 3, the difference in the phenotype of type II and classically activated 
macrophages was investigated. As with previous studies (Tierney et al., 2009), a 
significant reduction in the expression of several co-stimulatory molecules including CD40 
and PDL-1 expression was observed on type II activated macrophages. PDL-1 has been 
associated with the induction of T cell anergy, as well as T cell stimulation (Keir et al., 
2006; Latchman et al., 2001; Tseng et al., 2001). Given that a reduction in PDL-1 would 
be expected to enhance T cell proliferation, investigations were carried out to assess if T 
cell proliferation was altered in our experimental system, given the observed reduction in 
PDL-1 on type II activated macrophages. 
To investigate T cell subset differentiation, we used naïve T cells isolated from OTII mice 
whose T cells express a transgenic TCR specific for OVA323-339 peptide in the context of 
MHC II. Macrophages were non-activated or were classically or type II activated as 
previously described (sec 2.2). Purified CD4 OTII cells were stained with 
carboxyfluorescein diacetate succinimidyl ester (CFSE) and added to the macrophage 
cultures 2-3 h post-stimulation, either in the absence or presence of OVA protein or 
OVA323-339 peptide. 72 h following co-culture, T cells were removed and assessed by flow 
cytometry for their degree of proliferation as determined by CFSE dilution. Because CFSE 
is a cytoplasmic dye which is split evenly between daughter cells upon mitosis, the 
reduction in the fluorescence of cells correlates to the level of proliferation that has 
occurred (Lyons et al., 1994). 
All macrophages were able to present antigen and activate T cell proliferation (Figure 4.1). 
T cells exposed to either classical or type II activated macrophages presenting OVA 
protein or OVA323-339 peptide exhibited similar levels of antigen-specific proliferation 
(Figure 4.1). The response to the different antigen forms were similar, except that OVA323-
339 peptide was more antigenic and induced greater T cell proliferation. T cells exposed to 
non-stimulated macrophages presenting OVA323-339 peptide had similar levels of antigen-
specific proliferation as those induced by classical and type II activation; however, no 
proliferation was exhibited in response to non-stimulated macrophages that presented 
OVA protein. Only background proliferation was detected in co-cultures of T cells and 
macrophages containing only medium. Therefore, T cell proliferation in response to 
antigen presented by macrophages was similar irrespective of whether they were classical 
or type II activated. 
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IL-2 cytokine production was also assessed (Figure 4.2a), as another indicator of a T cell 
activation. T cells cultured alone did not produce significant amounts of IL-2, nor did T 
cells cultured with macrophages in the absence of antigen. In contrast, T cells exposed to 
macrophages in the presence of antigen, showed significant production of IL-2, and T 
cells cultured in the presence of non-stimulated macrophages had the highest amounts of 
IL-2 detected in their supernatant. In comparison, T cells exposed to classical 
macrophages showed lower levels of IL-2, and T cells cultured with type II activated 
macrophages had the lowest levels of antigen-specific IL-2 detected in the supernatant. 
These results may suggest that less IL-2 is produced by T cells stimulated by type II 
activated macrophages; however, increased reuptake of IL-2 may be another explanation. 
This possibility was further explored by assessing the expression of IL-2Rα on T cells in 
these cultures. Interestingly the expression of this high affinity IL-2 receptor is increased 
and may account for increased reuptake of IL-2 (Figure 4.2b). 
Overall, this data suggests type II activated macrophages elicit similar proliferative 
responses by CD4 T cells to that induced by classically activated macrophages.  
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Figure 4.1 Type II and classical activation support similar levels of antigen-specific T cell 
proliferation. Macrophages (106 cells/ml) were exposed to classical or type II activating stimuli. 
CD4 T cells were isolated from OTII mice (sec 2.2) and stained with CFSE. CD4 T cells (2.5x106 
cells/ml) plus 1 µM OVA323-339 peptide or 150 µg/ml OVA protein were added to macrophage 
cultures 3 h after classical or type II activation. After 72 h culture, CFSE was assessed by flow 
cytometry and presented as relative proliferation compared to cultures without antigen. The data 
from two experiments is shown. Note: Bars for ‘OVA peptide’ represent one experiment. *P<0.05: 
Two way ANOVA with Bonferroni post-test; Responses to macrophage states with antigen present 
versus antigen absent. Bars represent data points (mean+SEM) of two experiments. Relative 
proliferation = % decrease in CFSE of co-culture conditions in the presence of antigen relative to 
conditions in the absence of antigen. 
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Figure 4.2 Type II and classical activation induce different levels of antigen-specific IL-2 
production. Macrophages (106 cells/ml) were co-cultured with CD4 T cells (2.5x106 cells/ml) as 
described in Figure 4.1. After 72 h culture, IL-2 was assessed via ELISA (a), and IL-2Rα was 
assessed via flow cytometry (b), and presented as % of control compared to cultures with non-
activated macrophages. The data from two experiments is shown. *P<0.01, **P<0.001: Two way 
ANOVA with Bonferroni post-test; (a) Responses to macrophage states with antigen present vs 
antigen absent. (b) P> 0.05: One way ANOVA; responses to type II versus classical MØ. Bars 
represent data points (mean+SEM) from duplicate wells of two experiments.  
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4.2.2 Effect of type II activation on CD4 T cell biasing 
Previous studies have identified the ability of type II activated macrophages to alter 
adaptive immune responses through the polarisation of a pro-inflammatory Th1 response 
into a Th2 dominant response (Anderson et al., 2002; Gerber et al., 2001; La Flamme et 
al., 2006; Tierney et al., 2009). In order to identify ways of enhancing Th2 biasing, we first 
needed to understand the effects of type II activated macrophages on naive CD4 T cells in 
the context of our experimental system. To this end, naïve CD4 T cells from OTII mice 
were cultured with either non-stimulated, classically activated or type II activated 
macrophages in the presence of OVA323-339 peptide. Cultures were maintained for 72 h, 
after which IFNγ and IL-4 were analysed via ELISA and IL-4Rα and IL-2Rα (CD25) 
expression were assessed via flow cytometry. 
Figure 4.3 demonstrates that similar levels of IFNγ were detected by T cells cultured with 
non-stimulated or classically activated macrophages (a). In comparison, IFNγ production 
by CD4 T cells exposed to type II activated macrophages was significantly reduced, 
indicating a biasing against differentiation into IFNγ-producing Th1 cells. Although IL-4 
production is the best marker of Th2 cells, only very low levels of IL-4 were detected in the 
cultures and no difference between the presence of the different macrophage activation 
states was found. These results confirm that classically activated macrophages and not 
type II activated macrophages promote Th1 differentiation. 
As another measure of Th2 biasing, we investigated the responsiveness of T cells to IL-4 
by measuring the expression level of its receptor IL-4Rα (b). T cells exposed to non-
stimulated and classically activated macrophages had much lower levels of IL-4Rα 
expression in comparison to those exposed to type II activated macrophages, suggesting 
that type II macrophages induce T cells to become more responsive to this prototypic Th2 
cytokine. Additionally, IL-2Rα was highly expressed on T cells exposed to type II activated 
macrophages (Figure 4.2). While IL-2Rα expression on T cells was also up-regulated in 
response to classically activated macrophages, the levels were below those of T cells 
exposed to type II activated macrophages. These results indicate that type II activation 
increases CD4 T cell responsiveness to IL-4 and IL-2 and thus may promote the 
differentiation of these cells to the Th2 phenotype. 
As previously seen in other systems (Anderson et al., 2002; Edwards et al., 2006; Gerber 
et al., 2001), the findings presented here indicate type II activated macrophages are 
capable of inducing Th2 cell biasing as identified by increased responsiveness to IL-4Rα 
and IL-2Rα as well as reduced production of IFNγ. Investigations are still underway to 
identify the exact role of IL-2 in Th1/Th2 biasing, but our results further support the notion 
that IL-2Rα expression in addition to other factors such as IL-4Rα, have an active role in 
74 
 
inducing Th2 biasing (Cote-Sierra et al., 2004; Liao et al., 2008). As IL-4 cytokine 
production cannot be reliably detected due to the low levels at the time points tested, the 
use of IL-2Rα expression in conjunction with other markers makes it possible to carry out 
further experiments elucidating mechanisms involved in T cell biasing by type II activated 
macrophages.  
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Figure 4.3 Type II activation reduces Th1 while increasing Th2 responsiveness. Macrophages (106 
cells/ml) were co-cultured with CD4 T cells (2.5x106 cells/ml) as mentioned in Figure 4.1. After 72 h 
culture, IFNγ was assessed via ELISA (a), and IL-4Rα was assessed via flow cytometry (b) and 
presented as % of control. * P<0.05: One way ANOVA with Bonferroni post test; Antigen specific 
responses to type II versus classical MØ. Bars represent data points (mean+SEM) from two 
experiments.  
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4.2.3 Role of CD40/CD40L interactions during CD4 T cell biasing 
Studies have demonstrated the dual effects of CD40 on dendritic cells and macrophage 
cell lines, in perpetuating both pro-inflammatory and anti-inflammatory responses 
depending on the level of CD40 signaling (Murugaiyan et al., 2006). We previously 
demonstrated type II activated macrophages have reduced levels of CD40, suggesting 
that the reduced interaction between CD40/CD40L may have a possible role in Th2 cell 
biasing. In order to identify mechanisms of enhancing Th2 biasing in response to classical 
and type II activated macrophages, we investigated the effect of reducing the 
CD40/CD40L interaction between CD4 T cells and macrophages. 
IFNγ production by T cells exposed to classical and non-activated macrophages is equal, 
whereas T cells exposed to type II activated macrophages have a significant reduction in 
IFNγ (Figure 4.4). This finding indicates there are less developing Th1 cells in cultures 
with type II activated macrophages. Upon addition of 0.1-2 µg/ml inhibitory CD40L 
antibody (MR1), IFNγ production is increased under all conditions of macrophage 
activation (Figure 4.4). At higher levels of the inhibitory antibody (4-8 µg/ml), IFNγ 
production is decreased under all macrophage activation conditions (a), such that levels 
are lower than those seen in the absence of CD40/CD40L inhibition. Comparing the effect 
of CD40/CD40L inhibition on the relative reduction in IFNγ induced by type II 
macrophages in comparison to classical macrophages, no significant effect can be seen 
(b). However, with increasing concentrations of inhibitory antibody, T cells exposed to type 
II activated macrophages maintain reduced IFNγ production compared to exposure to 
classically activated macrophages. This indicates the ability of type II activated 
macrophages to reduce the development of Th1 cells independently of interactions 
between CD40 and CD40L. 
The effects of CD40/CD40L inhibition on the expression of Th2-associated receptors were 
also assessed. As shown previously (Figure 4.3), IL-4Rα expression on CD4 T cells in 
response to classical macrophages is similar to levels in response to non-stimulated 
macrophages. Furthermore, the level of IL-4Rα expression in response to classically 
activated macrophages remains unchanged irrespective of CD40/CD40L inhibition (Figure 
4.5). IL-4Rα expression in response to type II macrophages is much higher than other 
culture conditions, but while 2 µg/ml of inhibitory antibody had no real effect, 4-8 µg/ml of 
inhibitory antibody reduced the expression of IL-4Rα on T cells. IL-2Rα expression, which 
is normally high in response to type II activation, was similarly reduced in the presence of 
0.5-8 µg/ml of inhibitory CD40L antibody (Figure 4.5). At 8 µg/ml of antibody, IL-2Rα 
expression on T cells exposed to type II activated macrophages decreased to levels 
expressed in response to classical and non-stimulated macrophages.  
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IL-10 production was assessed in response to CD40/CD40L inhibition. Anti-CD40L 
antibody at 0.1 µg/ml had no effect on IL-10 in response to type II or classically activated 
macrophages (Figure 4.6), although IL-10 production in co-cultures with type II activated 
macrophages was much higher than co-cultures with classically activated macrophages. 
At 0.5 µg/ml a slight decrease in IL-10 was seen; however at 2-8 µg/ml, the levels of IL-10 
in response to type II activated macrophages were similar to the levels seen prior to 
inhibition. At 2-8 µg/ml, in an almost dose dependant fashion, IL-10 production in 
response to classically activated macrophages significantly increased compared to IL-10 
produced in the absence of CD40/CD40L inhibition. This illustrates a possible suppressive 
effect of CD40/CD40L signaling on IL-10 production. In contrast, IL-12 production 
remained unchanged by CD40/CD40L inhibition (Figure 4.6), and co-cultures with type II 
activated macrophages had far lower levels of IL-12 compared to co-cultures with 
classically activated macrophages. Taken together, these studies demonstrate a 
necessary role for  CD40/CD40L signaling in the induction of Th2 responses by type II 
activated macrophages, as previously described in dendritic cells (MacDonald et al., 
2002a) and found that type II activated macrophages are able to depress Th1 responses 
irrespective of the level of CD40/CD40L signaling. Also illustrated in this investigation is 
the suppressive effect of CD40/CD40L signaling on IL-10 production in response to 
inflammatory stimuli, presenting a new avenue of investigation. 
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Figure 4.4 Type II macrophages reduce Th1 development independant of CD40/CD40L 
interactions. Macrophages (106 cells/ml) were exposed to classical or type II inducing stimuli. CD4  
T cells were isolated from OTII mice (sec 2.2.4) and stained with CFSE. CD4 T cells (2.5x106 
cells/ml) plus 1 µM OVA323-339 peptide was added to macrophage cultures, along with varying 
concentrations (0.1 - 8 µg/ml) of anti-mouse CD40 ligand antibody (MR1) 3 h after classical or type 
II stimulation. After 72 h culture, IFNγ was assessed via ELISA. *P<0.05 **P<0.01 ***P<0.001: Two 
way ANOVA with Bonferroni post test ; Responses to Type II versus Classical MØ. (a) Represents 
data points (mean + SEM) from duplicate wells of one experiment. (b) Represents combined 
datapoints (mean + SEM) from two experiments presented as % of control compared to cultures 
with classical macrophages. 
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Figure 4.5 CD40/CD40L inhibition reduces Th2 responsiveness by type II macrophages. 
Macrophages were co-cultured with CD4 T cells as mentioned in Figure 4.4. After 72 h culture IL-
4Rα (a) and IL-2Rα (b) were assessed via flow cytometry. *P<0.05: Two way ANOVA with 
Bonferroni post test; Responses to Type II versus Classical MØ. Graphs represent data points 
(mean + SEM) from two experiments presented as % of control compared to cultures with classical 
macrophages. 
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b a 
Figure 4.6 CD40/CD40L inhibition increases IL-10 in response to classical macrophages.  
Macrophages were co-cultured with CD4 T cells as mentioned in Figure 4.4. After 72 h culture, IL-
10 (a) and IL-12 (b) were assessed via ELISA. *P<0.05 **P<0.01 ***P<0.001: Two way ANOVA 
with Bonferroni post test: Responses to Type II versus Classical MØ. Graphs represent data points 
(mean + SEM) from two experiments, presented as % of control compared to cultures with classical 
macrophages. 
The red dot in (4.4b) and (4.6a-b) represent the average level of cytokines in co-cultures with 
non-stimulated macrophages. [see appendix A for complete graphs] 
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4.3 Discussion 
Earlier investigations found that signalling through CD40 and IL-10 did not play an 
important role in defining the phenotypic characteristics of type II macrophages (Chapter 
3). However, these experiments did not assess the effects of the CD40/CD40L interaction 
between macrophages and CD4 T cells in co-cultures. CD40L signalling on CD4  T cells 
is essential for promoting an appropriate response to antigen (Grewal et al., 1998). In 
recent years, it has come to light that CD40L is not only essential for the induction of 
inflammatory Th1 responses (Alderson et al., 1993; Florido et al., 2004), but also in the 
development of Th2 responses (MacDonald et al., 2002a; Poudrier et al., 1998), whereby 
a deficiency in CD40L results in an inability to elicit protective Th2 responses during 
infection with a parasitic helminth. These different observations on the effect of CD40L 
inhibition on T cell responses may correspond to the dual ability of macrophages to 
perpetuate pro-inflammatory and anti-inflammatory responses (Mathur et al., 2004). Type 
II activated macrophages protect against EAE with Th2 biasing implicated in the protective 
effects (Tierney et al., 2009). Because CD40 levels are significantly reduced on type II 
activated macrophages, it is possible that type II activated macrophages have low level 
CD40/CD40L interactions with T cells, which influences T cell biasing (La Flamme et al., 
2006; Tierney et al., 2009). Therefore, identifying the role of the reductions in CD40 on T 
cell biasing may enhance our understanding of how type II activated macrophages protect 
against pro-inflammatory diseases. 
In order to further investigate mechanisms involved in T cell biasing by type II activation, 
studies were carried out to elucidate the effects of type II activated macrophages on naive 
T cell function (e.g. proliferation, cytokine production) upon first antigenic exposure. A 
previous study demonstrated that type II activated macrophages had a significantly 
reduced expression of PDL-1 (Tierney et al., 2009). This co-signalling molecule has been 
associated with T cell suppression through its interaction with PD-1 (Keir et al., 2006), but 
has also been implicated in T cell stimulation under certain conditions (Tseng et al., 2001), 
thus making it difficult to predict the role of PDL-1 reductions by type II activation. As type 
II activated macrophages exhibit a significant reduction in this molecule in comparison to 
classical activation, it was suggested by Edwards et al (2006) and Tierney et al (2009) 
that type II activation may promote greater T cell proliferation than classical activation. 
However, we found that CD4 T cells exposed to classical and type II activated 
macrophages proliferated similarly in response to OVA peptide or protein (antigens). This 
finding conflicts with those of Edwards et al where a slight increase in proliferation in 
response to the type II activated macrophages was reported (Edwards et al., 2006).  
One possible explanation for the difference may be in the experimental systems used. 
Edwards et al used IgG-coated OVA as the immune complex and used T cells from the 
81 
 
DO11.10 TCR transgenic mouse line while our system utilized IgG-coated SRBC as the 
immune complex and T cells from OTII mice. Although both recognise the same core 
amino acid within OVA protein, it is possible that differences in other TCR contact 
residues between the two cells resulted in different responses (Robertson et al., 2000). 
Additionally, Edwards et al reported enhanced T cell proliferation to type II activation, 
however as PDL-1 was not the focus of their investigation, levels were not assessed. 
Thus, no direct correlation between PDL-1 and proliferation was discussed.   
This investigation indicates that the significant reduction observed in PDL-1 expression by 
type II activation does not lead to enhanced CD4 T cell proliferation over that observed 
with classically activated macrophages. This finding could suggest a role of PDL-1 other 
than its inhibitory functions on T cells. Such a role may include T cell activation and/or T 
cell biasing. In support of this idea, previous literature demonstrate effects of PDL-1 that 
are unrelated in their anti-proliferative role (Loke et al., 2003; Tseng et al., 2001; Zhu et 
al., 2006). Using different murine models of EAE, Zhu et al (2006) demonstrated instances 
in which PDL-1 blockage had no effect on disease progression, irrespective of the 
reported role of PDL-1 in limiting auto-reactive responses (Keir et al., 2006). Furthermore, 
Loke et al (2003) illustrated the differential regulation of PDL-1 and PDL-2 by counter-
regulatory Th1/Th2 responses respectively, implicating a possible role for the different 
ligands in the counter-regulatory T cell responses. Therefore, the observed reductions in 
PDL-1 on type II activated macrophages may serve a role in Th1/Th2 cell biasing as 
opposed to T cell proliferation. 
Prior to carrying out further investigations into the mechanisms involved in T cell biasing, 
another goal was to validate the induction of T cell biasing by type II activation using our 
system. This investigation also set out to identify ways of assessing T cell biasing for 
future investigations using the same system.    
IFNγ is a prototypic cytokine produced by Th1 cells (Abbas et al., 1996; Szabo et al., 
2000), involved in the induction of Th1 responses which aid the activation of anti-
microbial, pro-inflammatory responses by macrophages and surrounding T cells (Alderton 
et al., 2001; Campbell et al., 1996; Li et al., 1997; MacMicking et al., 1997). The prototypic 
cytokine for developing Th2 cells is IL-4 (Abbas et al., 1996; Kaplan et al., 1996; Le Gros 
et al., 1990; Seder et al., 1992). Our studies showed that T cells exposed to either non 
activated or classically activated macrophages produce high amounts of IFNγ, indicative 
of Th1 cell biasing. In contrast, T cells exposed to type II activated macrophages 
produced significantly less IFNγ compared T cells cultured with classically activated 
macrophages. This reduction in IFNγ-producing cells is indicative of a reduction in Th1 
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development in response to type II macrophage activation, corroborating with previous 
literature (Gerber et al., 2001; La Flamme et al., 2006).  
Although IL-4 is the best marker for Th2 polarization, only very low levels of IL-4 were 
detected in the T cell cultures. These low levels of IL-4 may be due to the long time IL-4 
takes to be produced by T cells (Bird et al., 1998), along with re-uptake of IL-4 through the 
IL-4 receptor on T cells. As we were unable to assess Th2 development by IL-4 detection, 
the effects of type II activated macrophages on the expression of surface markers 
associated with developing Th2 cells was assessed. IL-4Rα as well as IL-2Rα are 
implicated in increasing the responsiveness of CD4 T cells to Th2-inducing cytokines. 
Signalling through IL-2Rα via the STAT-5 signalling molecule is essential in the 
expression of IL-4Rα (Liao et al., 2008), as well as the production of IL-4 in CD4 T cells 
(Cote-Sierra et al., 2004). In this investigation, very little IL-4Rα was expressed on cells 
exposed to non-activated or classically activated macrophages. In contrast, IL-4Rα 
expression was up-regulated on T cells exposed to type II activated macrophages, and 
this increase in IL-4Rα corresponded to an increase in IL-2Rα expression, further 
supporting the relationship between IL-4Rα and IL-2Rα expression. Although type II 
activation has previously demonstrated the increase in IL-2Rα (Edwards et al., 2006), this 
is the first demonstration of such a large increase in IL-4Rα by type II activation. 
Furthermore, previous studies have not assessed the involvement of IL-2Rα expression in 
T cell biasing as opposed to being used as an indicator of general activation by type II 
activated macrophages. Although much remains to be investigated to fully elucidate a 
direct correlation in the setting of type II activation, previous reports have demonstrated a 
direct link between IL-2Rα, IL-4Rα and increased IL-4 responsiveness (Cote-Sierra et al., 
2004; Liao et al., 2008). This suggests type II activation increases the responsiveness of 
CD4 T cells to Th2-inducing cytokines, while reducing the development of IFNγ-producing 
Th1 cells. This Th2 cell biasing corresponds with previous observations (Anderson et al., 
2002; Tierney et al., 2009), and validates the use of IL-4Rα as well as IL-2Rα in 
conjunction with cytokine profiles, to identify Th2 cells. 
Although data presented on IL-2Rα expression is preliminary, it warrants further 
investigation in light of recent literature supporting a role of IL-2 in many regulatory 
responses not associated with proliferation. This project has not yet investigated the 
effects of type II activated macrophages on regulatory T cell induction which is also 
associated with increased  IL-2 responsiveness (Pandiyan et al., 2007); however, the lack 
of inhibition on T cell proliferation supports the conclusion that Tregs are not the dominant 
subset induced. Further studies looking at FoxP3, a widely used marker of Tregs, is 
required to ascertain the exact involvement of inducible Tregs (iTregs) in protection 
mediated by Type II activated macrophages (Roncarolo et al., 2008), as it is possible that 
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the cytokine environment and phenotype induced by type II activation supports the 
development of Th2 as well as iTregs, both of which are associated with protection 
against EAE. 
Th1 cells are involved in promoting pathological processes during EAE (Becher et al., 
2002), with administration of the Th1 cytokine IFNγ resulting in exacerbations of MS , and 
levels of IFNγ detected at the peak of disease (Begolka et al., 1998). Therefore the 
reduction in IFNγ demonstrated by type II activated macrophages is a contributing factor 
to the prevention of Th-1 mediated disease. Th2  responses are associated with 
protection from inflammatory diseases such as EAE (Cua et al., 1995; Shaw et al., 1997; 
Weber et al., 2007), and the protection type II activation provides against EAE is 
associated with Th2 polarisation (Tierney et al., 2009). Treatments which enhance Th2 
development, such as glatiramer acetate (GA), are also beneficial in the treatment of MS 
(Weber et al., 2007). Therefore, as well as the ability of type II activated macrophages to 
reduce inflammatory responses by macrophages, the reduction in  Th1 T cell responses 
and increase in Th2 T cell responses elicited by type II activation presents beneficial 
effects against inflammation. Given that these findings demonstrate the ability of type II 
activated macrophages to alter T cell biasing, the next step is to identify mechanisms 
involved in promoting this effect. 
This thesis focused on the role of CD40, as a role for CD40 in promoting both Th1 and 
Th2 responses has been reported (Becher et al., 2000; MacDonald et al., 2002a; 
MacDonald et al., 2002c). Because CD40 expression is significantly reduced on type II 
activated macrophages, we set forth to investigate the effect of altered levels of 
CD40/CD40L signalling on T cell biasing. The different levels of CD40/CD40L signalling 
were regulated by titrating the concentration of anti-CD40L blocking antibody. Blockage 
between CD40 and CD40L resulted in reduced general responses of T cells as exhibited 
by the reduced levels of IFNγ detected in all co-cultures. This reduction agrees with 
previous literature emphasizing the requirement for CD40 signaling to elicit IFNγ 
production by Th1 cells (Alderson et al., 1993; Campbell et al., 1996). However, 
contradictory to this is the lack of effect of full CD40/CD40L inhibition on the production of 
IL-12. Additionally, co-cultures with type II activated macrophages maintained significantly 
lower levels of IL-12 compared to classically activated macrophages, and their general 
production of IL-12 in response to either type II or classical activation remained unaltered 
irrespective of the level of CD40 inhibition. This finding corresponds to the previous 
observation where alterations in CD40 signaling did not affect the cytokine profiles of type 
II activated macrophages, but contradicts studies which found that CD40/CD40L signaling 
was essential for antigen-specific IL-12 production derived from activated macrophages, 
dendritic cells and microglia (Becher et al., 2000; DeKruyff et al., 1997; Kelsall et al., 
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1996). One possible reason for the lack of alteration in IL-12 production by CD40/CD40L 
inhibition, is that IL-12 production in the presence of a strong Th1-inducing stimulus such 
as LPS, occurs independent of CD40 ligation (Reis e Sousa et al., 1997). As LPS is 
involved in the induction of both type II and classical activation, this explanation has merit.  
The ability of type II activated macrophages to reduce IFNγ-producing Th1 cells is 
maintained irrespective of full inhibition of CD40/CD40L interactions, indicating this 
reduction occurs independently of the CD40/CD40L interaction, as does the reduction in 
IL-12 production. This result illustrates a possible relationship whereby the ability of type II 
activated macrophages to maintain reduced IL-12 production is associated with the 
maintained reduction of Th1 development.  In addition to Th17 cells, Th1 cells constitute 
an important cell type involved in the pathogenesis of EAE (Becher et al., 2002; Langrish 
et al., 2005). Since IL-12 is important in the development of IFNγ-producing Th1 cells 
(Howard et al., 1999; Kelsall et al., 1996; Seder et al., 1996), the maintained reduction of 
this cytokine by type II activation may be key to inhibiting Th1 development and promoting 
protective effects against EAE. 
Even though the reduction in Th1 development mediated by type II activation occurs 
independently of CD40/CD40L, we wished to identify whether this interaction was 
essential for Th2 biasing by type II activated macrophages, as seen previously by 
dendritic cells (MacDonald et al., 2002c). With 2 µg/ml of inhibitory CD40L antibody, there 
is a slight but non-significant reduction in the expression of IL-4Rα on T cells exposed to 
type II activated macrophages. Under these conditions, these cells still exhibit much 
higher levels of expression compared to T cells exposed to non-activated or classically 
activated macrophages indicating low level inhibition of CD40/CD40L still enables Th2 
biasing by type II activation while maintaining the inhibitory effect on Th1 development. 
However 4-8 µg/ml of inhibitory antibody reduces the expression of IL-4Rα expression in 
response to type II activation, to levels detected on T cells exposed to non-activated 
macrophages. A similar effect can be seen with the expression of IL-2Rα, which 
dramatically decreases upon CD40/CD40L inhibition. At full inhibition of the CD40/CD40L 
interaction (8 µg/ml), a complete reduction in the expression of IL-2Rα can be seen, 
illustrating the dependency of Th2 responsiveness on CD40/CD40L signaling. The lack of 
effect low levels of CD40/CD40L inhibition have on IL-4 responsiveness suggests a 
possible explanation for the induction of Th2 polarization upon administration of anti-
CD40L antibody reported by Hancock et al (2006). Although this is not the first report of a 
requirement for CD40L signaling in Th2 development (MacDonald et al., 2002a), it is the 
first study to demonstrate the requirement for this interaction in Th2 biasing by type II 
activation.  
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Our previous studies indicated IL-10 derived from macrophages did not have a significant 
effect on the macrophage phenotype elicited by type II activation. However, IL-10 derived 
from macrophages and T cells can be different both in their regulation (Shoemaker et al., 
2006), and their function (Roers et al., 2004). Therefore, we assessed the effect of 
CD40/CD40L alterations on IL-10 production by T cells exposed to type II activated 
macrophages. IL-10 production in co-cultures with type II activated macrophages 
remained higher than levels detected in co-cultures with classically activated 
macrophages and were not further enhanced by CD40/CD40L inhibition. However, co-
cultures with classically activated macrophages exhibited increased production of IL-10, in 
a dose dependant manner with increasing inhibition of CD40/CD40L. At full CD40/CD40L 
inhibition, the level of IL-10 in co-cultures with classically activated macrophages equaled 
the levels of IL-10 in co-cultures with type II activated macrophages. This indicates 
CD40/CD40L interactions may be having a suppressive effect on IL-10 production, which 
has not been previously reported.  
In summary, these studies uncovered a suppressive effect of CD40/CD40L on IL-10 
production, which could be overcome by inhibiting the CD40/CD40L interaction. The 
resulting alterations in IL-10 may be a contributing factor to the regulation of Th1 and Th2 
responses seen at high and moderate levels of CD40/CD40L signaling respectively. 
These findings also provide a greater understanding into how CD40 inhibition prevents 
Th2 development, as previous studies have not investigated the effects of CD40 inhibition 
on the receptors for IL-4 and IL-2, or on the production of the suppressive cytokine IL-10. 
Although we were unable to enhance Th2 biasing by type II activated macrophages, we 
now have a greater understanding of some of the critical mechanisms involved in Th2 and 
Th1 biasing. 
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Chapter 5: Effects of schistosome complexes on 
macrophage activation 
5.1 Introduction   
In recent times, a strong negative correlation between the exposure to infectious diseases 
and the development of autoimmunity has been reported (Cook, 1996; Fleming et al., 
2007), suggesting that chronic infection with some parasites provides a level of protection 
against autoimmune diseases. For example, schistosomiasis has been shown to provide 
protection from autoimmune diseases such as type1 diabetes, graves thyroiditis and 
multiple sclerosis, in mouse models of these diseases. Interestingly, exposure to the 
schistosome egg (Cooke et al., 1999; Sewell et al., 2003) or soluble egg extract (SEA) 
(Zaccone et al., 2003; Zheng et al., 2008), and not just live infection (La Flamme et al., 
2003), provides similar protection. This suggests that it is the immune response to the 
eggs which regulate autoimmune responses. While it has been shown that this protection 
is dependent on a polarised Th2 response (Sewell et al., 2003), the mechanism by which 
schistosome infection provides protection is not known.  
Previous research (Herbert et al., 2004) found that alternatively-activated macrophages 
were important during schistosomiasis as their absence resulted in severe morbidity 
despite the presence of a strong Th2 response. This study indicates that during 
schistosomiasis, macrophages regulate immune responses and promote survival. To 
date, the main role for alternatively activated macrophages has been associated with their 
role in wound repair/fibrogenesis (Albina et al., 1990) and the down-regulation of 
inflammatory responses (Herbert et al., 2008; Pesce et al., 2009a). These macrophages 
can be identified by various markers, some of which include up-regulation of arginase1 
and RELMα (Loke et al., 2003; Modolell et al., 1995; Raes et al., 2002). Thus, one 
possible mechanism by which schistosome infection may protect from autoimmunity is by 
altering macrophage activation. 
Macrophages exhibit extreme plasticity (Mosser et al., 2008; Stout et al., 2004), and can 
alter their phenotypic properties accordingly with the situation at hand. While it has been 
shown that schistosome infection leads to alternative activation of macrophages, it is also 
possible that other states of activation occur as well, such as type II activation. 
Furthermore, if these different activation states do occur during schistosomiasis, it is 
reasonable to presume that these states may also be contributing to protection from pro-
inflammatory diseases such as EAE. In support of this idea, recent studies have shown 
that altering macrophage activation to support type II macrophages protects from EAE 
and the protection is Th2-dependant (La Flamme et al., 2006; Tierney et al., 2009). Thus, 
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we wished to examine whether schistosome immune complexes can induce type II 
macrophage activation in vitro.  
Aims: 
The mechanism by which schistosome infection protects from EAE and other pro-
inflammatory diseases is still under study, although it is clear that it is Th2-dependant (La 
Flamme et al., 2003; Sewell et al., 2003; Zheng et al., 2008). Type II macrophages induce 
Th2-biased responses (Anderson et al., 2002), but no study to date has identified whether 
macrophages are activated into a type II state during schistosome infection. Type II 
activation is typically induced via Fcγ receptor ligation by exposure to immune complexes 
in the presence of inflammatory stimuli. During schistosome infection, high levels of 
schistosome-specific antibodies and immune complexes are in the blood and tissue 
(Dunne et al., 2005; Santoro et al., 1979), as well as inflammatory stimuli caused by 
leakage of bacterial components due to egg passage through the intestine (Herbert et al., 
2008). Therefore, the environment generated during schistosome infection is capable of 
inducing type II macrophage activation. Indeed, it has been demonstrated that 
macrophages exposed to LPS in the presence of SEA or SEA complexed with serum from 
an infected mouse, produce far less IL-12 and increased IL-10 (La Flamme et al., 2004), 
suggesting that type II activation does occur. We aim to investigate fully the effects of 
schistosome immune complexes on macrophages in vitro to determine whether type II 
activation occurs. To this end, we addressed 2 specific aims: 
 
1. To identify the cytokine and surface marker profiles on murine bone barrow 
derived macrophages induced by schistosome whole egg complexes 
(Egg:Serum), and soluble egg antigen immune complexes (SEA :IgG), in order to 
elucidate responses indicative of type II activation.  
2. To determine if schistosome egg antigen complexes (SEA:IgG) induce a similar 
enzymatic profile to that of type II macrophages or to that of other known activation 
states (e.g. alternative or classical). 
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5.2 Results 
5.2.1 Anti-inflammatory effect of schistosome egg 
To investigate the effects of schistosome eggs on macrophage activation, primary bone 
marrow-derived macrophages were stimulated with LPS (i.e. classically activated) in the 
presence of either schistosome egg, or egg opsonised with serum from a schistosome 
infected mouse (i.e. immune complex). Because schistosome eggs are very large and 
polyvalent, it was expected that they would be good at ligating Fcγ receptors on 
macrophages and inducing type II activation. Cytokine analysis of culture supernatants 
showed that while LPS-stimulated macrophages produced high levels of IL-12 and low 
levels of IL-10, stimulation of macrophages with LPS in the presence of either egg or egg 
complex resulted in reduced levels of IL-12 and increased IL-10 (Figure 5.1), similar to the 
effect seen with type II activation by opsonised SRBC (Chapter3). In the absence of LPS, 
stimulation with either egg or egg complexed with infected serum (Egg:Ser) elicited the 
same response as non-stimulated macrophages. Kinetic studies indicate the most 
significant reduction in IL-12 and increase in IL-10 occur 8 h post stimulation as was 
noticed previously with type II activated macrophages. Interestingly, the modulating 
effects of schistosome eggs or eggs complexed with infected serum on the responses to 
LPS were very similar (Figure 5.1), suggesting that the alterations in macrophage 
responses may be occurring via a non-FcγR pathway.   
Unlike stimulation with opsonised SRBC, stimulation with LPS plus schistosome eggs or 
eggs complexed with infected serum only moderately alters the expression of co-
stimulatory molecules (Figure 5.2). While LPS-induced CD80 expression was slightly 
reduced by egg or egg complex 24 h post-stimulation, CD40 expression was unaffected 
except at 24 h where a reduction can be seen by both egg and egg complex in the 
presence of LPS. PDL-1, like CD40, remained unaffected 2-8 h post stimulation but 
reduced slightly 24 h after stimulation with schistosome egg plus LPS. This effect was not 
seen with schistosome egg complex.  Overall, there is a small reduction in the expression 
of activation/co-stimulatory markers 24 h after treatment with schistosome egg or egg 
complex compared to classical activation. However, these reductions in expression are 
significantly less than those seen by type II activated macrophages. Moreover, because 
the 24 h time point was only examined once, the consistency of this reduction needs 
verification.  
Taken together, these data indicate that schistosome whole eggs either alone or as an 
immune complex, are capable of activating macrophages into a state which exhibits an 
anti-inflammatory cytokine profile. Although the kinetics of the cytokine alterations are 
similar to type II activation, the expression profile of co-stimulatory markers differs to that 
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of type II activated macrophages. These findings, in addition to the similarity in responses 
to the egg immune complex and eggs alone in the presence of LPS, suggest that type II 
macrophage activation may not be induced by schistosome egg complexes. Rather, they 
indicate that the anti-inflammatory profile is generated through another unknown 
mechanism that warrants further investigation. 
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Figure 5.1 Schistosome egg and egg complex reduce LPS-induced IL-12 and increase IL-10. 
Primary BMMØ (106 cells/ml) derived from C57BL/6 mice were primed with 20 U/ml IFNγ overnight 
followed by stimulation with Media, LPS (200 ng/ml), Schistosome egg (1000/well), Egg + LPS, 
opsonised Egg (Egg:Serum from schistosome infected mouse), or opsonised Egg + LPS. After 0.5, 
2, 4 and 8 h culture IL-10 (a) and IL-12 (b) were assessed via ELISA. *P<0.001: Two way ANOVA 
followed by Bonferroni post test; Egg + LPS or Egg:Serum + LPS versus LPS. Graphs represent 
the mean + SEM from combined duplicate wells of two experiments. 
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Figure 5.2 Schistosome egg and egg complex induce no significant alterations in macrophage 
surface markers. Primary BMMØ (106 cells/ml) derived from C57BL/6 mice were treated as 
described in Figure 5.1. After 0.5, 2, 4, 8 and 24 h culture CD40 (a), CD80 (b) and PDL-1 (c) were 
assessed via flow cytometry. Difference between Egg + LPS or Egg:Ser + LPS versus LPS is NS  
P>0.05: Two way ANOVA with Bonferroni post test. Data represents the mean + SEM of two 
experiments. The 24 h time point represents one experiment. Data is presented as % of control 
compared to cultures with LPS. See Appendix A for full graphs with stimulants in the absence of 
LPS. 
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5.2.2 Ability of SEA/SEA complexes to activate macrophages of an anti-
inflammatory nature  
Because immune complexes consisting of soluble schistosome antigen (SEA) and not 
necessarily whole eggs circulate in the blood of infected subjects, the effect of 
schistosome soluble egg antigen immune complexes on macrophage activation was 
assessed. Primary murine bone marrow-derived macrophages were stimulated for 8 h 
and 24 h with LPS in the presence or absence of SEA or SEA complexed with purified IgG 
(SEA-IgG) from schistosome-infected mice, and compared to type II activation induced by 
opsonised SRBC. To determine the optimum ratio of SEA to purified IgG, various ratios of 
SEA and IgG were used and the reduction in LPS-stimulated IL-12 production was 
assessed. Although SEA alone induced a reduction in IL-12, the addition of purified IgG 
enhanced this reduction. Figure 5.3 indicates the optimal ratio of SEA to IgG is 5 µg/ml 
SEA to 20 µg/ml of purified IgG, as SEA-IgG ratios of 5-10 µg ,10-10 µg/ml or 10-20 µg/ml 
induce a less significant reduction in IL-12 compared to the 5-20 µg/ml SEA-IgG ratio.  
Using this optimal ratio of SEA-IgG, IL-10 production was assessed by macrophages 
treated with SEA complexes. Figure 5.4 indicates at the optimised ratio of SEA complex, 
the reduction in IL-12 was greater than that seen with type II activation and the increase in 
IL-10 was equal to the increase by type II activation. As type II activated macrophages are 
known to induce Th2 biasing, IL-4 expression was also assessed under the same 
conditions. As expected, classically activated macrophages (LPS) produced nearly 
undetectable levels of IL-4. However, while type II activated macrophages (SRBC 
complex plus LPS) produced low but detectable levels of IL-4, stimulation of macrophages 
with SEA complexes in the presence of LPS induced a significant increase in IL-4 
production. This is a novel finding, and the potential role of macrophage-derived IL-4 
during schistosome infection warrants further investigation. 
In order to investigate the effects of SEA complexes on co-stimulatory marker expression, 
expression levels were compared to that seen with type II activated macrophages and 
alternatively activated (i.e. IL-4-stimulated) macrophages. Figure 5.5 shows LPS 
stimulation induces a strong up-regulation in CD40 and a modest increase in CD80 and 
PDL-2 expression compared to non-stimulated macrophages. In contrast, macrophages 
exposed to LPS in the presence of SEA-complexes showed reduced levels of CD40 and 
CD80 expression compared to classical activation, and reduced the expression of PDL-2, 
which was up-regulated upon exposure to rIL-4. Based in this data, SEA-complexes 
induce a co-stimulatory marker and cytokine profile similar to that of type II activated 
macrophages, suggesting that SEA complexes may be inducing type II macrophage 
activation. Furthermore, there was a significant increase in IL-4 in response to SEA-
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complexes, which was not found in the other activation conditions (classical, type II or 
alternative). Therefore further investigations are merited to investigate whether type II 
activation occurs or whether a novel activation state has been induced. 
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Figure 5.3 Schistosome complex of 5-20 µg/ml elicits the greatest reduction in LPS-induced IL-12. 
As mentioned in Figure 5.2, primary BMMØ were primed overnight. Macrophages were then 
stimulated both in the presence and absence of LPS (200 ng/ml) , with 5 µg/ml or 10 µg/ml SEA, or  
SEA-IgG complex at various ratios of SEA bound to  purified IgG (5 µg/ml or 10 µg/ml SEA, with 10 
µg/ml or 20 µg/ml IgG). Cells were also classically (LPS) or type II activated (SRBC:IgG+LPS). 
After 8 h culture, IL-12 was assessed via ELISA.  *P<0.05: One way ANOVA; Conditions versus 
LPS. Data represents the mean+SEM from duplicate wells of one experiment. 
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Figure 5.4 SEA complexes elicit a similar IL-10/IL-12 ratio to type II macrophages but differ 
significantly in IL-4 induction. Primary BMMØ (106 cells/ml) derived from C57BL/6 mice were 
primed with 20 U/ml  IFNγ overnight followed by exposure to  5 µg/ml SEA or SEA-IgG (5 µg/ml -20 
µg/ml) in the presence and absence of LPS (200 ng/ml). Macrophages were also exposed classical 
and type II–inducing stimuli (Fig 5.3). After 8 h culture IL-10 (a), IL-12 (b), and IL-4 (c) were 
assessed via ELISA. IL-4 was measured in the absence of the treatments with un-opsonised SRBC 
and un-opsonised SEA. *P<0.05: One way ANOVA with Bonferroni post test; Conditions versus 
Classical. Data represents the mean+ SEM from duplicate wells of one experiment. NS represents 
P>0.05. 
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Figure 5.5 SEA complexes elicit similar alterations in surface markers to type II macrophages. 
Primary BMMØ (106 cells/ml) derived from C57BL/6 mice were treated as mentioned in Figure 5.4. 
Additionally, macrophages were stimulated with 20 U/ml rIL-4. After 24 h culture CD40 (a), CD80 
(b), and PDL-2 (c) were assessed via flow cytometry. Bars represent one experiment. 
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5.2.3 Enzymatic profile of macrophages exposed to SEA complexes 
In addition to cytokine production and surface marker expression, enzyme markers for 
classical, type II and alternative macrophage activation were investigated using western 
blotting to assess the activation state of macrophages induced by schistosome immune 
complexes plus LPS.  Macrophages were stimulated for 9 h and 24 h, and lysates were 
probed by western blotting for the expression of SPHK1 as a marker for type II activation, 
RELMα (FIZZ1) for alternative activation, and iNOS for classical activation. Alpha tubulin 
expression was used as a loading control and all samples were normalized to this protein. 
Similar to cytokine production, 9 h was found to be the optimal time to assess intracellular 
proteins of interest.  
Representative gels and calculated band densities are shown in Figures 5.6 and 5.7 for 
iNOS, SPHK1, and RELMα. Band densities are presented as a percentage of control 
compared to LPS, in order to compare the expression of the various markers to classical 
stimulation. Graphs were generated from 2-4 western blots for most samples, although 
SEA complex plus LPS-stimulated macrophages (SEA:IgG+LPS) were only run once. 
Figure 5.6 shows a similar expression of iNOS in type II activated macrophages to that of 
classical macrophages. iNOS was not detected in samples stimulated with SEA alone, but 
was expressed in macrophages exposed to SEA or SEA complexes in the presence of 
LPS. Unfortunately the samples including the lysate from macrophages stimulated with 
SEA complex alone were unsuccessful, so the direct effect of this immune complex on 
macrophages cannot be assessed at this time. However, this condition will be an essential 
control to include in all future work based on this study. Taken together, these results 
indicate that SEA or SEA complex-activated macrophages in the presence of LPS, 
produce iNOS similarly to classical and type II activated macrophages. 
To evaluate a type II-specific marker, the production of sphingosine-kinase 1 (SPHK1) 
was assessed in macrophages exposed to SEA complexes in the presence or absence of 
LPS and in type II activated macrophages. As expected, there was a significant increase 
in SPHK1 expression by type II activation in comparison to classical macrophages, further 
supporting its role as a marker for type II activation (Figure 5.6). Macrophages exposed to 
SEA alone or SEA in the presence of LPS exhibit higher SPHK1 expression than classical 
macrophages, but lower than that expressed in type II activated macrophages (Figure 
5.6). The production of SPHK1 in response to SEA alone, indicated the SPHK1 expressed 
in response to SEA plus LPS, is primarily driven by the effect of SEA, and not necessarily 
by the addition of LPS, unlike iNOS expression. In contrast, there is no detectable SPHK1 
expression in macrophages stimulated with SEA complexes plus LPS. However, as this 
condition was done only once, further work needs to be done to confirm this result.  
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RELMα expression was also assessed as a marker for alternative activation which is 
known to occur during schistosome infection, and is induced by IL-4. As shown previously, 
RELMα expression in classical and type II activated macrophages was very low (Figure 
5.7). In contrast, rIL-4-induced alternatively activated macrophages produced significant 
amounts of RELMα, validating its high expression as a marker for alternatively activated 
macrophages. Additionally, SEA complexes in the presence of LPS induced much higher 
levels of RELMα compared to alternatively activated macrophages, suggesting that this 
condition may share some of the features of alternatively activated macrophages. 
Furthermore, given that IL-4 is produced by macrophages stimulated with SEA complexes 
and LPS, this elevation in RELMα is likely to be induced by this cytokine and not directly 
induced by the SEA complexes and LPS. Overall, the analysis of the enzymatic profile of 
macrophages indicates SEA either alone or in a complex is capable of inducing a distinct 
activation state from classical macrophages. The expression of markers for type II 
activation as well as alternative activation indicates SEA complexes are inducing the 
activation of macrophages into a ‘hybrid’ state, which exhibits characteristics from more 
than one known activation state. 
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Figure 5.6 SEA induces SPHK1 expression and iNOS in macrophages. Primary BMMØ (106 
cells/ml) derived from C57BL/6 mice were primed with 20 U/ml IFNγ followed exposure to 5 µg/ml 
SEA, or SEA-IgG in the presence or absence of 200 ng/ml LPS (SEA-IgG: 5 µg/ml-20 µg/ml), or 
classical or type II-inducing stimuli. After 9 h culture, iNOS (a) and SPHK1 (b) were assessed via 
western blotting as mentioned in section 2.6, with anti-SPHK1 pAb (1:700), anti-iNOS pAb (1:700) 
and anti-αtubulin (1:1000). Bars represent the band densities of 1-3 experiments normalised to 
αtubulin. *P<0.05: One way ANOVA with Bonferroni post test; Conditions versus Classical 
activation (LPS). Bars for SEA:IgG + LPS represent a single experiment. Data is presented as % of 
control compared to cultures with LPS. (c-d) are representative of gels used to elucidate (a-b). 
Differences between the gels are represented by (^). Molecular weights: SPHK1 (69KDa), iNOS 
(135KDa), αTubulin (50KDa). 
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Figure 5.7 SEA complexes induce the expression of RELMα in macrophages. Primary BMMØ (106 
cells/ml) derived from C57BL/6 mice were primed with 20 U/ml IFNγ followed by exposure to SEA-
IgG + LPS (5 µg/ml-20 µg/ml), 20 U/ml rIL-4, or classical or type II-inducing stimuli. After 9 h 
culture, RELMα was assessed via western blotting (section 2.6), with anti-RELMα (1:700) followed 
by anti-αtubulin (1:1000). Bars represent the band densities of one experiment normalised to α 
tubulin. Data is presented as % of control compared to cultures with LPS. Diagram (b) is the gel 
used to elucidate the graph in (a). Molecular weights: αTubulin (50KDa), RELMα (12-15KDa).  
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5.3 Discussion 
During infection with the parasitic helminth of the Schistosoma genera, a polarized Th2 
response dominates in the host (Grzych et al., 1991; Pearce et al., 2004). Studies 
demonstrating an inverse correlation between areas prevalent in schistosome infection, 
and those prevalent in autoimmunities such as MS, has prompted researchers to 
hypothesise that schistosome infection may provide protection against MS (Fleming et al., 
2007). Indeed, schistosome infection or exposure to isolated schistosome eggs or soluble 
egg antigen elicits protection against animal models of MS and type 1 diabetes (Cooke et 
al., 1999; La Flamme et al., 2003; Sewell et al., 2003; Zaccone et al., 2003; Zheng et al., 
2008). The protection was accompanied by a reduction in Th1 inflammatory responses 
and an increase in Th2-type responses, and was abolished in the absence of this Th2 
response (La Flamme et al., 2003; Sewell et al., 2003). In a similar manner, inducing type 
II macrophage activation in vivo protects from the animal model of MS in a Th2 dependent 
manner (Tierney et al., 2009). Therefore, this thesis investigated the macrophage 
response to schistosome egg or egg antigen immune complexes, in order to determine 
whether type II macrophage activation may be induced during schistosome infection and 
may thus contribute to the reported protective effect against autoimmune diseases. 
The involvement of macrophages in driving protective Th2 responses to whole 
schistosome eggs is unknown; hence, we wished to identify the anti-inflammatory effects 
of exposure to schistosome eggs on macrophages. Furthermore, we assessed whether 
these egg immune complexes induced type II activated macrophages similar to those 
induced by SRBC complexes. We found that similar to opsonised SRBCs, schistosome 
egg and egg immune complexes, in the presence of LPS, significantly reduced IL-12 and 
increased IL-10 production in comparison to classically activated macrophages. However, 
unlike type II activation induced by opsonised SRBC, the effects seen with schistosome 
egg complexes were mirrored by the effects of schistosome egg in a non-complexed (i.e. 
non-opsonised) form. This result indicates the response is not specific to FcγR ligation as 
type II activation is (Lucas et al., 2005; Zhang et al., 2006a). However, macrophages 
activated in this manner by schistosome eggs may still be an important contributor to host 
protection due to their production of IL-10, given that IL-10 is essential for protection 
against severe disease caused by schistosomiasis  (Hoffmann et al., 2000). Finally, 
previous work has clearly shown that the increased IL-10 in conjunction with reduced IL-
12 plays an important role in immune deviation and host protection during schistosomiasis 
(Hesse et al., 2004) and EAE (Sewell et al., 2003). Our findings indicate that schistosome 
egg either alone or in a complex with serum from a schistosome infected mouse has the 
ability to induce anti-inflammatory cytokine profiles similar to that observed with type II 
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activation, however the mechanisms involved differ from that of type II macrophage 
activation. 
Type II activation by opsonised SRBC induces a significant reduction in the expression of 
CD80, CD40 and PDL-1 in response to LPS (Tierney et al., 2009) (Chapter 3), but the 
effect of schistosome egg on the expression of these surface markers is currently 
unknown. Assessing the changes in CD80, PDL-1 and CD40 by schistosome eggs and 
egg complexes in the presence of LPS, we found the expression profile more similar to 
classical macrophages than that of type II activated macrophages. While there were slight 
reductions in the expression of CD40 and CD80 at the 24 h time-point, these reductions 
occurred independent of whether or not schistosome egg was in a complex form. 
Furthermore, the expression of PDL-1 in comparison to classical macrophages remained 
largely unchanged by stimulation with schistosome egg or egg complexes in the presence 
of LPS.  
Thus, macrophages exposed to schistosome egg and egg complexes do not exhibit the 
same characteristics of type II activation in terms of the changes seen in activation marker 
expression. In addition to this, the similarity in response to the egg or egg complex 
suggests that the response induced by these products in the presence of LPS may be 
occurring through a different mechanism than that of Fcγ receptor ligation which evokes 
type II activation. It is more likely that components of the schistosome egg itself were 
eliciting the observed anti-inflammatory effects. These components may include 
glycosylated products (e.g. proteins, lipids) on the schistosome egg, which promote Th2 
cell biasing (Okano et al., 1999). Schistosome eggs have been demonstrated to promote 
highly polarised Th2 immune responses, capable of protecting against EAE (Sewell et al., 
2003), and this investigation further supports this finding by demonstrating that immune 
deviation can occur by direct interaction of the schistosome egg with macrophages. 
However, we have not shown that this effect on macrophages elicits Th2 cell biasing, but 
based on the cytokine profile, and previous in vivo observations (Sewell et al., 2003), it is 
highly possible. The ability of schistosome egg antigens, but not whole schistosome eggs, 
to induce Th2 biasing through the interaction with APCs has been previously reported 
(MacDonald et al., 2002c; Steinfelder et al., 2009). Dendritic cells exposed to a 
schistosome egg component, omega-1, altered their phenotype to elicit Th2 cell biasing 
upon contact with CD4 T cells (Steinfelder et al., 2009). It was concluded that the immune 
deviation was elicited by egg-induced changes in the level of signalling by DCs. 
Furthermore, in addition to the effects on DCs, the interaction of schistosome egg 
components with basophils has also been shown to induce immune deviation (Schramm 
et al., 2003) by up regulating IL-4, a strong inducer of Th2 development (Le Gros et al., 
1990). The exact mechanism involved in deviating the macrophage response presented in 
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this thesis is unknown; however further investigations using specific egg components like 
omega-1 should be carried out.   
In contrast to whole schistosome eggs, the majority of published work focuses on 
schistosome soluble egg antigen (SEA), which is extremely antigenic and induces strong 
Th2 responses  (Pearce et al., 2004; Zheng et al., 2008). Investigations have been carried 
out to elucidate the components of SEA which provide them with Th2-inducing properties, 
and some of the suggested components include IL-4 inducing principle of Schistosoma 
mansoni (IPSE) and N-fucopentaose III (Okano et al., 1999; Schramm et al., 2003), both 
of which induce highly polarised Th2 responses. Studies using SEA derived from 
Schistosoma japonicum have also shown that the SEA-specific Th2 responses are 
protective against EAE (Zheng et al., 2008). Because SEA immune complexes are 
generated during schistosomiasis (Rezende et al., 1997), it is possible that these 
complexes can promote type II activation as well as Th2 responses. Therefore, this 
investigation examined the effects of SEA complexes on macrophages in order to 
understand possible effects associated with prevention of inflammatory diseases like EAE.  
Using the SEA immune complex, we found a significant increase in IL-10 and reduction in 
IL-12 in the presence of LPS. This finding complements in vivo data, in which protection 
against EAE by schistosome infection is associated with reductions in IL-12 and increases 
in IL-10 (La Flamme et al., 2003). It also correlates with the IL-10/IL-12 profile elicited by 
exposure to SEA complexed with serum (La Flamme et al., 2004), and the cytokine profile 
induced by type II activation as demonstrated in Chapter 3. In contrast to SEA immune 
complexes, SEA and LPS had only a minor effect on cytokine production suggesting that, 
as with type II activation, the alternation in IL-10 and IL-12 occurred through ligation of 
FcγRs.  
SEA has been demonstrated to contain components which strongly induce the production 
of IL-4 by immune cells such as basophils (Schramm et al., 2003). IL-4 production was 
assessed in the cultures of classically activated and type II activated macrophages, with 
very little IL-4 detected. In contrast to the nearly undetectable levels noted by classical 
and type II activated macrophages, macrophages stimulated with SEA complexes in the 
presence of LPS produced very high levels of IL-4. Although IL-4 cytokines are increased 
during schistosomiasis (Grzych et al., 1991), to date there have been no reports of 
macrophages producing IL-4 in response to schistosome infection or exposure to 
schistosome products. In fact, the only studies reporting the production of IL-4 by 
macrophages used the RAW 264.7 cell line derived from a BALB/c mice and alveolar 
macrophages during pulmonary fibrosis (Buttner et al., 1997; Mukherjee et al., 2009; 
Sempowski et al., 1994).  Due to the important role of IL-4 in T cell biasing as well as in 
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differentially activating alternatively activated macrophages and perpetuating anti-
inflammatory responses, the ability of SEA complexes to initiate IL-4 production merits 
further investigation as this pathway may be an important mechanism involved in driving 
Th2 responses. 
Also investigated were the effects of SEA complexes on the expression of CD40, CD80, 
and PDL-2. In accordance with type II activation, SEA complexes in the presence of LPS 
induced a reduction in CD80 and CD40. Studies have previously demonstrated the 
requirement for CD40/CD40L signalling in the induction of Th2 responses (MacDonald et 
al., 2002c). As with type II activation, the reduction in CD40 but absence of complete 
inhibition in response to SEA complexes emphasizes the possible role of this particular 
level of CD40 signalling in promoting protective responses.  As with type II activation, the 
reduction in the expression of these co-stimulatory markers was most significant in 
response to the complex form of SEA.   
As IL-4 promotes alternative activation of macrophages (Raes et al., 2002; Stein et al., 
1992), we assessed the expression of PDL-2, a ligand for PD-1 differentially up-regulated 
on alternatively activated macrophages (Loke et al., 2003; Tierney et al., 2009). Although 
rIL-4-induced alternatively activated macrophages induced PDL-2, neither type II activated 
nor SEA complex plus LPS-activated macrophages up-regulated PDL-2 expression. 
Given the significant increase in IL-4 by exposure to SEA immune complexes and LPS, 
this finding was contrary to expectation. It is unclear as to why there is such a difference 
between the effects of IL-4 derived from SEA-complex treated macrophages and rIL-4, 
which induced alternatively activated macrophages with respect to PDL-2 expression. 
This difference may be because the concentration of IL-4 produced by SEA complex-
activated macrophages was below the threshold needed to drive all aspects of alternative 
macrophage activation or due to a difference in the mechanisms involved. The differences 
in the expression of PDL-2, CD80, CD40 and IL-12 by SEA complexes and LPS 
compared to rIL-4 indicate that these stimuli induce activation states with distinct profiles, 
whereas the SEA complex plus LPS condition follows a similar pattern of expression as 
type II activated macrophages.  
In order to aid our understanding of the activation state induced by SEA complexes, the 
expression levels of enzyme markers for classical, type II and alternative macrophage 
activation were assessed. SPHK1 has been identified as an indicator of type II activation 
(Edwards et al., 2006), RELMα (FIZZ1) of alternative activation (Edwards et al., 2006; 
Raes et al., 2002) and iNOS production of classically and type II activated macrophages 
(Edwards et al., 2006). 
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The similar production of iNOS by type II and classically activated macrophages 
corresponds to previous reports (Edwards et al., 2006), indicating both cell types are 
capable of eliciting immune responses against intracellular pathogens. This high 
expression of iNOS is in contrast to alternatively activated macrophages which do not 
express detectable levels of iNOS or NO but instead arginase 1 or RELMα (Modolell et al., 
1995; Raes et al., 2002). If SEA complexes were inducing alternative activation, it would 
be expected that iNOS expression would be reduced or absent. However, iNOS was 
produced by macrophages exposed to both SEA and SEA complexes in the presence of 
LPS, but was not expressed under the same conditions in the absence of LPS. This 
indicates SEA or SEA complex-activated macrophages in the presence of LPS are likely 
capable of carrying out processes involved in intracellular killing, a mechanism associated 
with classical and type II activated macrophages (Campbell et al., 1996; Edwards et al., 
2006), whereas in the absence of LPS, they are not.  
In agreement with previous work (Edwards et al., 2006), SPHK1 expression was 
significantly higher in type II activated macrophages in comparison to classically activated 
macrophages. To date, there is no published data on the expression of SPHK1 by SEA or 
SEA complex treated macrophages; thus, the finding that there is an increase in SPHK1 
expression in response to SEA compared to classically activated macrophages is a novel 
find. This SPHK1 expression was seen upon exposure to not only SEA alone, but also 
SEA in the presence of LPS, indicating SEA alone was driving this response rather than 
the presence of LPS. This is in contrast to the expression of iNOS which does depend on 
LPS exposure. It is important to note that the level of SPHK1 expression is less than that 
produced by type II activated macrophages, but much greater than any levels produced 
by classical macrophages. As such, its presence should not be used as a sole 
determinant of type II activation. It suggests the macrophages may be able to carry out 
similar functions to type II activated macrophages even if type II activation is not actually 
induced.  
The role of SPHK1 in type II activation is currently unclear. Sphingosine-1-phosphate, 
produced via SPHK1, has been implicated to have an inhibitory role on Th1 cytokine 
production (Yang et al., 2005), but also in aiding survival of macrophages during pro-
inflammatory stress (Wu et al., 2004). Recent studies have also indicated a role for 
sphingosine-1-phosphate in lymphocyte egress (Melendez, 2008), which may seem 
somewhat contradictory, but overall indicates a possible role in maintaining immune 
balance. The lack of expression of SPHK1 by SEA-complex and LPS-activated 
macrophages is an interesting finding as it does not follow the trend, in which SEA alone 
was seen to drive its production. This may indicate that when the SEA is in a complex 
form, the mechanism allowing SEA to induce SPHK1 expression is neutralised in some 
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manner by the functional characteristic induced by SEA complexes. However, this action 
does not correlate with the other phenotypic characteristics induced by SEA complexes 
such as CD80/CD40/PDL-2 reductions and iNOS expression, which resemble those of 
type II activated macrophages. Therefore, further investigation in the effect of SEA 
complexes and LPS on SPHK1 production by macrophages is merited.   
RELMα expression was assessed in order to elucidate whether alternative activation was 
occurring given the high production of IL-4 by SEA complex plus LPS-stimulated 
macrophages and the role of IL-4 in driving alternative activation (Stein et al., 1992). Type 
II activated macrophages produced nearly undetectable levels of RELMα, as did 
classically activated macrophages and this finding agrees with previous reports (Edwards 
et al., 2006). In contrast to classical and type II activation, macrophages exposed to 
recombinant IL-4 produced significant amounts of RELMα, corresponding with the 
induction of alternative activation (Raes et al., 2002). Thus, the appearance of high 
production of RELMα in response to SEA complexes in the presence of LPS, suggests the 
induction of alternative activation, with RELMα levels much higher than that expressed by 
macrophages exposed to even rIL-4.  
Based solely on this western blot analysis, one would conclude that SEA complexes 
induced alternative activation of macrophages. However, this conclusion is not justified 
given the expression of SPHK1 and the cytokine profile, which suggest that neither type II 
nor alternative activation is induced. Altogether our findings indicate that SEA complexes 
induce a novel activation state exhibiting a hybrid of characteristics, blended from type II 
activation and alternative activation as well as some characteristics from neither state. 
Although ‘hybrid’ activation states have been previously suggested (Mosser et al., 2008), 
no induction of such a state as this has been previously reported. 
The induction of this unique ‘hybrid’ activation state may have important beneficial 
implications to the regulation of autoimmunity as well as schistosomiasis. IL-4 is able to 
provide protection against EAE (Shaw et al., 1997) and schistosomiasis (Brunet et al., 
1999), through the induction of Th2 responses. Understanding mechanisms involved in 
increasing IL-4 production may have extremely beneficial consequences in the treatment 
of inflammatory diseases. For example, RELMα aids wound repair (Raes et al., 2002) as 
well as suppresses excessive Th2 responses (Nair et al., 2009; Pesce et al., 2009b), and 
during schistosomiasis, RELMα is essential for the prevention of lethal levels of hepatic 
fibrosis induced by Th2 responses (Nair et al., 2009). Similarly, RELMα expression may 
also benefit EAE by aiding in repair of the CNS and preventing excessive T cell 
responses. This thesis presents a novel activation state induced by schistosome egg 
antigen complexes and LPS, which exhibits a range of characteristics involved in 
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maintaining a balance between the Th2 polarised fibrogenic responses required for host 
survival during schistosomiasis (Herbert et al., 2004), and reducing overzealous 
inflammatory responses which would otherwise induce pathology (Pesce et al., 2009b). 
Therefore this state of activation may be beneficial in EAE as well, where the balance of 
immune responses is essential. 
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Chapter 6: General discussion 
6.1 Overall Summary of thesis 
Various studies have demonstrated the potent protective effects of immune deviation on 
inflammatory disorders (Tierney et al., 2009; Weber et al., 2007; Zheng et al., 2008). 
Macrophages are capable of deviating immune responses into pro-inflammatory or anti-
inflammatory responses dependant on their activation status (Edwards et al., 2006; 
Mosser et al., 2008a). In autoimmunites, studies have shown that protective immune 
deviation can be induced by pre-exposure to a Th2–inducing parasite Schistosoma 
mansoni, as well as pre-treatment with type II activated macrophages which elicit Th2 
biasing (La Flamme et al., 2003; Sewell et al., 2003; Tierney et al., 2009). The exact 
mechanisms involved in type II activation and the induction of protective anti-inflammatory 
responses during schistosomiasis are unknown and currently under investigation. 
Similarities exist between the effects of type II activated macrophages and schistosome 
infection in protection against an animal model of MS, EAE. It is unknown what effect 
schistosome infection has on macrophage activation, however high levels of  circulating 
immune complexes as well as inflammatory mediators occur during infection (Rezende et 
al., 1997; Santoro et al., 1979), making it likely that type II activation is a contributing 
factor in the protection schistosomiasis elicits. Understanding the immunological events 
involved in protection by either type II activation or other macrophage phenotypes which 
may be induced during schistosomiasis, may benefit the development of drugs which 
mimic or enhance the protective effects against autoimmune diseases. 
This thesis investigates mechanisms involved in perpetuating the phenotypic profile of 
type II activated macrophages, and promoting the deviation of T cell responses into 
polarised Th2 responses, with particular emphasis on IL-10 and CD40. This investigation 
also encompasses the effects of schistosome immune complexes on macrophage 
activation, in order to elucidate whether type II activation may be induced in the course of 
schistosome infection. 
A ‘hybrid’ activation state 
Although results from the schistosome investigations are preliminary and require 
validation, they provide new insight into possible effects of schistosome infection on 
macrophage activation. Mosser et al reported the notion that some macrophages elicit 
traits of more than one activation state, termed ‘hybrid macrophages’ (Mosser et al., 
2008b). To my knowledge, there are been no reports to date which have induced such a 
state. However this investigation may have identified such a ‘hybrid’ state, induced by 
exposure to schistosome egg antigen complexes. By only looking at surface markers, the 
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SPHK1 enzyme, and cytokines IL-10 and IL-12, it would suggest schistosome complexes 
induce type II macrophage activation. However, the high levels of RELMα (a marker of 
alternative activation (Raes et al., 2002)) and high IL-4 production (a characteristic 
unknown of any activation states) make this macrophage phenotype distinct from both 
type II activation and alternative activation. The high production of IL-4 was a novel find, 
as to date the only reports of IL-4 production by macrophages include alveolar 
macrophages (Buttner et al., 1997; Sempowski et al., 1994) and macrophage cell lines 
(Mukherjee et al., 2009). 
This activation state may elicit more beneficial effects compared to either type II or 
alternative activation states alone. The high levels of IL-4 and IL-10 and reduced IL-12 
may induce anti-inflammatory immune responses, promoting the development of Th2 and 
Treg cells as has been previously reported by this cytokine environment  (Le Gros et al., 
1990; Roncarolo et al., 2008; Skapenko et al., 2005), while inducing the activation of other 
innate cells into regulatory states (Mantovani et al., 2007). Furthermore, this macrophage 
phenotype may pose as one of the main initiators of Th2 responses, as the initial source 
of IL-4 during schistosome infection has previously been questioned. Understanding 
mechanisms involved in IL-4 production will be extremely beneficial in the context of 
inflammatory illnesses. IL-4, as opposed to IL-12, is associated with protection from EAE 
(Shaw et al 1997). Through the expression of RELMα and SPHK1, this activation state 
may be beneficial in both wound healing (Raes et al., 2002) as well as suppression of 
overzealous T cell responses (Nair et al., 2009; Pesce et al., 2009). These characteristics 
may therefore be beneficial in protection against severe schistosomiasis as well as EAE 
and other pro-inflammatory diseases which require immunoregulation. 
Features of anti-inflammatory macrophages 
Classically activated macrophages, IFNγ producing Th1 cells and IL-23-induced Th17 
cells are implicated as major cell types associated with the pathogenesis of EAE (Cua et 
al., 2003; Langrish et al., 2005; O'Connor et al., 2008; Tran et al., 1998). Conditions which 
alter the immune response and establish an anti-inflammatory environment to prevent the 
accumulation of inflammatory cells, protect against EAE. This has been demonstrated in 
mice, by the administration of type II activated macrophages or pre-infection with 
parasites of the Schistosoma spp., which deviate the immune response into a polarised 
Th2/Treg/anti-inflammatory status and prevent the initiation of inflammatory disease 
(Sewell et al., 2003; Tierney et al., 2009). Only minimal information on the mechanisms of 
protection provided by schistosome infection or type II macrophages is known, therefore 
we investigated a broader range of effects of type II activation in order to expand our 
current knowledge, and to gain a greater understanding of mechanisms of action. 
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Type II activation reduced the production of the chemokine MCP-1 in an inflammatory 
environment, as well as IL-6. High levels of IL-6 and MCP-1 are attributed to disease 
progression  (Maimone et al., 1997; McManus et al., 1998), and inhibition of MCP-1 as 
well as IL-6 have proven successful in preventing the infiltration of inflammatory cells into 
the CNS (Huang et al., 2001; Serada et al., 2008). Although this investigation, in 
accordance with previous literature, demonstrated the suppressive effects of IL-10 on the 
expression of pro-inflammatory cytokines and chemokines (Anderson et al., 2002; Bogdan 
et al., 1991), we found IL-10 was not responsible for the anti-inflammatory profile elicited 
by type II activation. This has been previously demonstrated by Anderson et al, but only 
with regards to IL-12 reductions. Our investigations support that of Anderson et al, while 
further illustrating that reductions in the expression of co-stimulatory markers, and 
inflammatory mediators MCP-1 and IL-6 by type II activation, occur independently of IL-
10. This implies the existence of a novel mechanism whereby selective pro-inflammatory 
responses are reduced by Fcγ receptor ligation. Also demonstrated here is the broader 
effect of type II activation on chemokine and cytokine production.  Although previous 
studies (Anderson et al., 2002; Gerber et al., 2001; Grazia Cappiello et al., 2001) have 
concluded type II activation has no effect on other pro-inflammatory cytokines such as IL-
6 and TGFβ, the observations made were at the mRNA level, and not the secreted 
protein.  This is the first study to my knowledge where a reduction in MCP-1 and IL-6 
protein by type II activation is demonstrated, illustrating additional mechanisms other than 
through reduced IL-12, which may aid in protection against EAE. 
As with CD40 reductions, another shared characteristic of anti-inflammatory phenotypes 
induced by type II activation or exposure to schistosome complexes, was the expression 
of spingosine kinase 1 (SPHK1), an enzyme whose activity in vivo is still controversial. 
SPHK1 is expressed in a variety of cells including T cells, mast cells, and basophils 
(Kihara et al., 2006; Yang et al., 2005). However, its significant up-regulation in 
macrophages has so far only been attributed to type II activation (Edwards et al., 2006). In 
this investigation, we reported a significant increase in this enzyme in response to 
schistosome immune complexes. Our investigations, as well as previous literature, 
illustrate the anti-inflammatory profile of macrophages elicited by exposure to schistosome 
immune complexes as well as type II-inducing stimuli, with both implicated in the biasing 
of T cell responses into the Th2 subset (MacDonald et al., 2002b; Okano et al., 1999; 
Zheng et al., 2008). Therefore, it is possible that in the context of the macrophages, 
SPHK1 supports functions involved in promoting Th2 development. SPHK1 activation in 
Th1 cells has demonstrated a role in reducing Th1 associated cytokines IFNγ and IL-2 
(Yang et al., 2005), therefore it is possible that similar effects occur, caused by 
macrophage-derived SPHK1. Humans and mice express three isoforms of SPHK1, all of 
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which exhibit slight variations in their catalytic activities (Billich et al., 2003; Kihara et al., 
2006). Therefore, it is possible that some of the conflicting results observed in vivo, such 
as its’ role in promoting inflammatory responses and cell migration (Melendez, 2008), 
were due to the activity of the different isoforms under different environmental conditions, 
as well as the level, location and source of SPHK1. To date, the exact role of SPHK1 in 
macrophages remains elusive, especially with regards to type II activated macrophages. 
As SPHK1 is expressed in type II activated macrophages as well as macrophages 
activated into the ‘novel’ state by exposure to schistosome complexes, it seems likely that 
SPHK1 contributes in some way to the anti-inflammatory outcome, and therefore warrants 
further investigation.   
These investigations also illustrated a reduction in CD40 associated with increased anti-
inflammatory functions. Supporting this notion is the reduction in LPS-induced CD40 
expression which occurred in response to both schistosome immune complexes and 
SRBC immune complexes. Studies have shown that an active component of schistosome 
egg antigen (SEA), Omega-1, significantly increases Th2 responses and reduces Th1 
development, with a reduction in CD40 expression on dendritic cells observed (Steinfelder 
et al., 2009). However, the investigators did not assess the significance of this reduction at 
the time. As with Steinfelder et al, we saw a reduction in CD40 in response to 
schistosome immune complexes as well as type II-inducing stimuli on macrophages, as 
opposed to dendritic cells. CD40 promotes the production of inflammatory cytokines such 
as IL-6, IL-12 and IL-23, all of which are associated with the induction of pathology-
inducing Th1 and Th17 subset development (Langrish et al., 2005; Perona-Wright et al., 
2009). In mice deficient in CD40, a significant inhibition of Th17 and Th1 development is 
noted, through the reduction of IL-6, IL-23 and IL-12 production, which therefore protects 
against EAE (Perona-Wright et al., 2009). The reduction in CD40 on macrophages 
exposed to type II-inducing stimuli or schistosome complexes, may therefore significantly 
impair the development of Th17 cells through the reductions in inflammatory cytokines, as 
well as reducing the infiltration of inflammatory cells through reduced chemokine 
production. Therefore, this investigation puts into focus another possible mechanism 
contributing to the protection type II activation and schistosome infection provide against 
EAE. 
Involvement of CD40 signalling in T cell biasing  
Although CD40 expression has long been associated with Th1-driven cell mediated 
responses (Alderson et al., 1993; Campbell et al., 1996), studies in 2002 by MacDonald et 
al illustrated the essential requirement of CD40 signalling for the induction of Th2 
responses by dendritic cells. Type II activation or schistosome infection protect against 
EAE (La Flamme et al., 2003; Sewell et al., 2003; Tierney et al., 2009), and as 
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demonstrated in this thesis, macrophages express reduced CD40 in the absence of 
complete inhibition upon exposure to either stimuli. Furthermore, both are capable of 
polarising Th2 responses (Gerber et al., 2001; La Flamme et al., 2006; Zheng et al., 
2008). This suggests to us that low but maintained levels of CD40 on macrophages (i.e. 
not completely abolished) have  a role in deviating T cell responses. This thesis therefore 
assessed the effect of altered levels of CD40/CD40L signalling between T cells and 
macrophages, with the aim of identifying if there was a particular low level which 
enhances Th2 cell biasing. 
Although we did not enhance type II activation through the inhibition of CD40/CD40L 
signalling, we did see significant differences in T cell responses. These differences 
depended on the level of CD40/CD40L signalling. An example was the loss of IL-10 
suppression with T cells that were exposed to classical macrophages after the signalling 
was reduced. Furthermore, low levels of CD40/CD40L inhibition had no significant effect 
on Th2 polarisation by type II activation, while Th1 development was still significantly 
impaired. An inhibitory effect on both Th2 and Th1 responses was seen in the complete 
absence of CD40/CD40L signalling however. Further studies may be required; however 
this investigation suggests that at low levels of CD40L signalling, Th1 development is 
reduced, whereas there is little effect on the responsiveness of T cells to Th2-inducing 
stimuli by type II activation. In the setting of inflammatory illnesses, macrophages which 
elicit this low level of CD40/CD40L interaction seen by type II macrophages may be 
beneficial in depressing detrimental Th1 responses while maintaining protective Th2 
development. This would somewhat explain why in some circumstances the absence of 
CD40 results in the ablation of Th2 development (MacDonald et al., 2002b), whereas in 
other situations, CD40L inhibition protects against disease by increasing Th2 
development, as seen in the prevention of graft rejection (Hancock et al., 1996). This may 
be a result of the preferential inhibition of Th1 and not Th2 responses, when there is 
incomplete blockage of CD40L. 
Major producers of IL-10 include Th2 cells (Sornasse et al., 1996) as well as Tregs (Groux 
et al., 1997). Although IL-2Rα and IL-4Rα expression are commonly associated with the 
induction of Th2 responses (Cote-Sierra et al., 2004), it is also possible that type II 
activated macrophages induce Tregs. Studies have shown IL-4 to induce Tregs from 
naive CD4 T cells, resulting in high expression of IL-2Rα (CD25) and increased IL-10 
(Skapenko et al., 2005), which are characteristics seen in our studies. Furthermore, 
McKee et al  demonstrated the role of both Tregs and Th2 cells in the suppression of Th1 
development during schistosomiasis (McKee et al., 2004), illustrating the possible effect of 
schistosome complexes or type II activation on Treg development. Further investigations 
would be required to assess this induction, however as proliferation was not inhibited by T 
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cells exposed to type II macrophages, it may be fair to assume the responses were that of 
a Th2 polarized subset.  
Our results support previous reports (MacDonald et al., 2002b), whereby the complete 
absence of CD40 results in a reduction in the development of Th2 cells, as well as 
supporting the notion that differential levels of CD40 signalling alter counter-regulatory 
responses (Mathur et al., 2004). Also provided in this thesis are some novel insights into 
the suppressive effects of CD40/CD40L signalling on IL-10 production, a mechanism 
which may be a contributing factor to the suppression of both Th1 and Th2 responses 
seen at high levels of CD40 inhibition, and may possibly be involved in the induction of 
suppressive regulatory T cells (Wan et al., 2009).  
6.2 Summary 
Further supporting previous literature (Mathur et al., 2004; Murugaiyan et al., 2006), this 
thesis illustrates the intricate balance a single co-signalling molecule can elicit. As with 
MacDonald et al, CD40 was found essential for the induction of Th2 responses, which in 
our setting was elicited via type II activation. IL-10, although suppressive of IL-12 as also 
previously reported (D'Andrea et al., 1993), was not required for the cytokine and surface 
marker profile elicited by type II activation. This supports studies by Grazia Cappiello et al, 
who saw no effect in the ability of type II macrophages to reduce IL-12, while extending 
the knowledge to the effects on other cytokines/chemokines and surface markers which 
were not previously investigated. As well as providing further insight into alterations type II 
activation induces at both the level of macrophages and T cells, we present previously 
unreported effects of schistosome complexes on macrophage activation, illustrating the 
induction of what seems to be a novel activation state exhibiting a hybrid of characteristics 
of type II and alternative activation. The findings from this thesis bring us a step closer to 
understanding mechanisms involved in promoting anti-inflammatory immune responses, 
which is essential for identifying more effective treatments for autoimmunities. 
Furthermore, although much remains to be validated, provided here are some new 
avenues of research for future investigations into understanding essential components of 
immune deviation. 
6.3 Future 
Future studies may involve investigating the roles of SPHK1, a shared marker of both type 
II activation and the ‘hybrid’ state induced by schistosome immune complexes. As both 
type II activation and schistosome infection protect against EAE, SPHK1 and RELMα may 
be important contributors to this effect (La Flamme et al., 2003; Sewell et al., 2003; 
Tierney et al., 2009; Zheng et al., 2008). Investigations may also be carried out to 
elucidate whether the activation state induced by schistosome complexes in vitro, occurs 
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in vivo, and whether it contributes to protection against EAE. As T cell proliferation in 
response to type II activation and classical activation were similar despite the reduction in 
PDL-1 on type II macrophages, further investigations are required to elucidate the role of 
PDL-1/PD-1 signalling during type II activation. This co-signalling interaction, as with 
CD40L signalling, may be required for Th2 cell biasing. Further understanding the effect of 
co-signalling molecules on T cell biasing may have important implications in the 
treatments of not only pro-inflammatory associated diseases, but also those diseases 
such as leishmaniasis which require efficient Th1 responses (Stenger et al., 1996). The 
suppressive effect of CD40/CD40L signalling on anti-inflammatory cytokines such as IL-10 
should also be further investigated, as should the effects of increasing CD40 signalling on 
T cell responses in contrast to CD40 inhibition. Although CD40 inhibition was unable to 
increase the anti-inflammatory Th2-biasing capabilities, it would still be interesting to 
investigate the outcomes of different levels of increased CD40/CD40L signalling. 
Identifying ways to enhance anti-inflammatory responses against EAE will not only benefit 
the development of treatments for MS, but will also have positive implications in the 
treatment of other inflammatory illnesses. Furthermore, the increase in knowledge about 
mechanisms involved in different macrophage phenotypes will enable us to better identify 
mechanisms involved in promoting or preventing diseases.  
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Appendix A-Supplementary Tables and figures 
TableA1  Final concentrations/dilutions of ELISA reagents  
IL-12p40 (BD Biosciences) 
Reagent  Dilution/concentration Diluent 
Capture 1:1000 0.1 M Na2HPO4, pH=9.0 
Standards 4 ng/ml 5% FCS in PBS pH=7.4 
Detection 1:1000 5% FCS in PBS pH=7.4 
SA-HRP 1:2000 5% FCS in PBS pH=7.4 
 
IL-10 (BD Biosciences) 
Reagent Dilution/concentration Diluent 
Capture 1:500 0.1 M Na2HPO4, pH=9.0 
Standards 25 ng/ml 10% FCS in PBS pH=7.4 
Detection 1:2500 10% FCS in PBS pH=7.4 
SA-HRP 1:1000 10% FCS in PBS pH=7.4 
 
IFNγ (BD Biosciences) 
Reagent Dilution/concentration Diluent 
Capture 1:1000 0.1 M Na2HPO4, pH=9.0 
Standards 4 ng/ml 5% FCS in PBS pH=7.4 
Detection 1:4000 5% FCS in PBS pH=7.4 
SA-HRP 1:2000 5% FCS in PBS pH=7.4 
 
 
 
116 
 
IL-4 (BD Biosciences) 
Reagent Dilution/concentration Diluent 
Capture 1:2000 PBS, pH=7.4 
Standards 50 U/ml 5% FCS in PBS pH=7.4 
Detection 1:4000 5% FCS in PBS pH=7.4 
SA-HRP 1:2000 5% FCS in PBS pH=7.4 
 
Table A2 Western blot antibody dilutions 
Primary Antibody Company Dilution 
Anti-tubulin-Rabbit Abcam 1:700 
Anti-SPHK1-Rabbit Abcam 1:700 
Anti-RELMα-Rabbit Abcam 1:700 
Anti-iNOS-Mouse Transduction Laboratories 1:700 
Dilutions of primary antibodies made in 1.5-2 ml of 5% blocking solution (5% non-fat skim 
milk in TTBS) 
Secondary Antibody Company Dilution 
Anti-Rabbit cy3 GE Healthcare  1:1000 
Anti-Mouse cy5 GE Healthcare 1:660 
Dilutions of secondary antibodies made in 1.5-2mls of TTBS (appendix B) 
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Kinetic graphs for type II activation, with additional controls for the absence 
of LPS 
 
b a 
**** *
*** ***
 
c 
***
***
 
FigA1 Macrophages exposed to type II-inducing stimuli exhibit reductions in co-signaling molecules 
maximally at 24 h post stimulation: Macrophages derived from C57BL/6 mice were stimulated with 
200 ng/ml LPS alone or LPS in the presence of SRBC or opsonised SRBC (SRBC:IgG). Cells were 
also left non-stimulated in media or cultured with SRBC or SRBC-IgG in the absence of LPS. After 
2, 4, 8, 24, or 30 h of culture, CD80 (a), PDL-1 (b), and CD40 (c) were assessed via flow 
cytometry. * P<0.05 ,**P<0.01 ,***P<0.001: Two way ANOVA with Bonferoni post test : 
SRBC:IgG+LPS  vs LPS. Data points represent the mean +S EM of two experiments. 
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Effects of CD40 signaling on macrophage phenotype- 24 hour time point (as 
opposed to the presented 8 hour time point). 
a b 
 
*
** *
*
Figure A2 CD40 stimulation does not effect the IL-10/IL-12 ratio between classical and type II 
macrophages at 24 h after stimulation Macrophages (106 cells/ml) were exposed to classical or 
type II activating stimuli. Stimulatory rat-anti-mouse CD40 antibody (3/23) and IgG isotype control 
(rat IgG2) (8 µg/ml) (BD Bioscience) were added to appropriate cultures at the time of primary 
stimulation. After 24 h culture IL-10 and IL-12 were assessed via ELISA. *P<0.05 two way ANOVA 
with Bonferroni post-test; Type II versus Classical. Bars represent datapoints (mean+SEM) of 
duplicate wells. 
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Graphs on CD40/CD40L alterations, with data from co-cultures with non-
activated macrophages: Supports the notion that remaining IFNγ (From 
overnight priming) in co-cultures elicited T cell responses in the absence of 
stimulants. 
a b 
 
NS 
NS 
*** *** *** ***
c 
 
Figure A3 CD40/CD40L inhibition has no effect on IL-12 or IFNγ suppression by type II 
macrophages but alters IL-10 production Macrophages (106 cells/ml) were exposed to classical or 
type II activating stimuli. CD4 T cells were isolated from OTII mice and stained with CFSE. CD4 T 
cells (2.5x106 cells/ml) plus 1 µM OVA323-339 peptide was added to macrophage cultures, along with 
varying concentrations (0.1-8 µg/ml) of anti-mouse CD40 ligand antibody (MR1) 3 h after classical 
or type II activation. After 72 h culture IL-12 (a), IL-10 (b), and IFNγ (c) were assessed via ELISA. 
*P<0.05 **P<0.01 ***P<0.001: Two way ANOVA with Bonferroni post test ; responses to Type II vs 
Classical MØ. Graphs represent datapoints (mean + SEM) from two experiments. (c) is presented 
as % of control compared to cultures with classical macrophages. 
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Kinetic graphs for schistosome egg exposure with additional controls in the 
absence of LPS 
a b 
 
 
c 
 
 
Figure A4 Schistosome egg and egg complex do not induce significant alterations in macrophage 
surface markers. Primary BMMØ (106 cells/ml) derived from C57BL/6 mice were primed with 20 
U/ml IFNγ overnight followed by stimulation with Media, LPS (200 ng/ml), Schistosome egg 
(1000/well), Egg+LPS, opsonised Egg (Egg:ser), or opsonised egg + LPS (Egg:Ser+LPS). Cells 
were also exposed to Egg of Egg:ser in the absence of LPS and incubated at 37oC in 5%CO2.  
After 0.5, 2, 4, 8 and 24 h culture CD40 (a), CD80 (b) and PDL-1 (c) were assessed via flow 
cytometry. Data represents the mean +SEM of two experiments, except for the 24 h time point 
which represents one experiment. Data is presented as % of control compared to cultures with 
LPS. 
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Graph illustrating the similar effect 1000 and 2000 schistosome eggs per 
well have on macrophage activation 
 
*
* *
 
Figure A5 Schistosome eggs at either 1000/well or 2000/well elicit similar responses Primary 
BMMØ (106 cells/ml) derived from C57BL/6 mice were primed with 20 U/ml IFNγ overnight followed 
by stimulation with Media, LPS (200 ng/ml), Schistosome egg either at 1000/well or 2000/well in 
the absence of presence of LPS, or Egg complexed to serum (Egg:Ser) in the presence or absence 
of LPS. After 8 h culture IL-12 was assessed via ELISA. *P<0.05. One way ANOVA followed by 
Bonferroni post test; treatments vs LPS. Graphs represent the mean + SEM from duplicate wells. 
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Optimisation of IFNγ concentration for priming macrophages prior to 
stimulation- identifying which concentration provides the greatest 
inflammatory response 
 
 
Figure A6 Priming macrophages with 20 U/ml IFNγ generates the most inflammatory conditions for 
further investigations.  Primary BMMØ (106 cells/ml) derived from C57BL/6 mice were primed with 
20, 50, 100 or 200 U/ml IFNγ overnight followed by stimulation with LPS (200 ng/ml), and incubated 
at 37oC in 5%CO2.  After 8 h culture, IL-12 was assessed via ELISA. 
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Appendix B-Recipes 
Isolation buffer (For CD4 T cell isolation) 
2% FCS (ICP biologicals, Auckland) 
2 mM EDTA (Merk) 
1 x dPBS (Invitrogen, Auckland,NZ) 
Phosphate buffered saline (PBS) (10x) 
For 2 L of 10 X PBS: 
170 g NaCl (Merck Ltd, Palmerston North, New Zealand) 
62.32 g Na2HPO4.12H2O (Merck) 
4.04 g NaH2pPO4.2H2O (Merck) 
2 L ddH2O 
Facs Buffer (For flow cytometry) 
0.1% sodium azide 
97.9% PBS 
2% FCS (ICP biologicals, Auckland) 
Complete T cell medium (CTCM) 
10% FCS 
1% Hepes, Penstrep, Non-essential amino acids, L-Glutamine (Invitrogen) 
0.1%  β-Mercaptoethanol (Invitrogen) 
85.9% Dulbecco’s modified eagle medium (dMEM) ( Invitrogen) 
Wash buffer 
96% Dulbecco’s modified eagle medium (dMEM) ( Invitrogen) 
3% Hepes  
1% Penstrep  
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Flow cytometry antibodies 
Antibody Company 
Anti- CD40- PE (3/23) (BD Bioscience) 
Anti-CD80- FITC (16-10A1) (BD Biosciences) 
Anti-IgG2a –PE (eBR2a)  (BD Bioscience) 
Anti- I-Ab- PE (AF6-120.1) (BD Biosciences) 
Anti-F4/80 bio (C1:A3-1) (Serotec, Oxford, UK) 
Anti- CD124-PE (mIL4-M1) (BD Biosciences) 
Anti-PDL-1- PE (M1H5) (eBioscience, CA, USA) 
Anti-PDL-2- PE (TY25) (eBiosciences) 
Anti-mouse-CD16/32 (2.4G2) (BD Biosciences) 
SaV CyC (BD Biosciences) 
Anti-CD25-FITC (3C7) (BD Biosciences) 
Anti-CD4-Cyc (RM4-5) (BD Biosciences) 
Anti-IgG2a- FITC (R35-95) (BD Biosciences) 
 
Tris buffered saline 10X (TBS) (500ml) 
(Tris 200 mM, Nacl 1.36 M, pH 7.6) 
2.1 g Tris, 40 g NaCl, 12 ml HCl to give pH7.6, ddH20 up to 500 ml 
Tween Tris buffered saline (TTBS) 
995 ml TBS (1X), 5 ml Tween-20 
Tris glycine buffer X5 
(Tris 125 mM, Glycine 950 mM) 
Glycine 72.1 g, Tris 15.1 g, ddH2O up to 1 L 
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Working transfer buffer 
(Tris 25 mM, Glycine 192 mM , methanol 10% (v/v)) 
600 ml ddH2O, 200 ml Tris Glycine buffer 5 X, 200 ml methanol 
Running buffer SDS 
(Tris 25 mM, Glycine 192 mM, SDS 0.1%) 
1.0 g SDS, 200 ml Tris Glycine buffer 5 X, ddH2O up to 1 L 
RIPA Buffer 
Tris-HCl: 1.2110 ,NaCl: 8.766 ,EDTA: 0.3722 ,TritonX-100: 10 ml ,SDS: 1.0 ,sodium 
deoxycholate: 10.0 (in g/L)  . 
Western Blott Gels: 
10% separating gel: 
ddH20 - 8ml 
1.5 M tris 8.8 - 5ml 
10% SDS - 200 µl (USB, Cleveland,Ohio) 
Acrylamide - 6.66 ml ( Biorad) 
10% ammonium persulfate (APS) - 100 µl 
TEMED - 10 µl (Amersham, England) 
4% stacking gel: 
ddH20 - 6.1 ml 
1.5 M tris pH 6.8 - 2.5 ml 
10% SDS - 100 µl 
acrylamide -  1.33 ml 
10% APS - 50 µl 
TEMED - 10 µl 
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